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Preface
Heterocyclic systems are important building blocks for new materials possessing
interesting electronic, mechanical, or biological properties. For more than a century,
many heterocycles have constituted the largest areas of research in organic chemistry.
Heterocycles play an important role in biochemical processes because the side groups
of the most typical and essential constituents of living cells, DNA and RNA, are based
on aromatic heterocycles. The presence of heteroatoms results in significant changes
in the cyclic molecular structure due to the availability of unshared pairs of electrons
and the difference in electronegativity between heteroatoms and carbon.
Many synthetic methods have been developed for the preparation of heterocycles.
The current book project covers the basics and advanced utility of heterocycles in
biochemistry, industrial chemistry, environmental sciences, pharmacy, microbiol-
ogy, biotechnology, and related disciplines. Also, it will fulfill the requirement for
new approaches in experimental skills and solving problems obtained during func-
tional group transformation. This book provides a broad range of solutions to the
problems of graded difficulties from organic reactions, rearrangements, and reagents
along with their isolation and synthetic applications. The main goal of this book is
to build on the foundation of synthesis and characterization. Special emphasis has
been placed on the synthesis and mechanism of the reactions of different classes of
heterocycles. Furthermore, it will bridge the gap between teaching, research, and
practice. Finally, this book project provides a concise and comprehensive overview of
the methods and biological importance of heterocyclic compounds synthesis.
B.P. Nandeshwarappa
Davangere University,
India
Sadashiv S.O.
Garden City University, 
India 
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Chapter 1
Introductory Chapter: Synthesis 
and Antimicrobial Activities 
of Dihydroazeto[2′,3′:4,5]
seleno[2,3-b]quinolines
B.P. Nandeshwarappa, G.K. Prakash and S.O. Sadashiv
1. Introduction
Literature survey reveals that sulfur- and selenium-containing molecules have 
attracted great importance in synthetic organic chemistry; particularly, aromatic five- 
and six-membered heterocycles fused or bridged to quinoline ring in linear fashion are 
found in many natural products due to their great pharmacological importance [1–7].
Substituted 2-azetidinone is an important class of compound for its importance 
in β-lactam antibiotic synthesis [8–10]. β-Lactam drugs in heterocycles are still the 
most widely prescribed antibiotics used in medicine [11]. The discovery of penicil-
lin 2-azetidinone-based heterocycles have been one of the main classes of drugs 
with wide therapeutic activities, viz. anticonvulsant [12], anti-inflammatory [13], 
antibacterial [14], herbicidal [15], and also functioning as enzyme inhibitor [16] 
and are effective on central nervous system.
The conversion of aryl quinolines into dihydroazeto[2′,3′:4,5]seleno[2,3-b]quino-
lines is of vital importance in synthetic organic chemistry. Seleno[2,3-b]quinolines are 
prepared via their corresponding halogenated derivatives. In the current approach, 
we have planned to synthesize title compounds by efficient methods for the synthesis 
of seleno[2,3-b]quinolines, starting from easily accessible dichloro substituents by a 
reaction with sodium hydrogen selenide in water media with quantitative yield under 
remarkably soft conditions. Also, we came to know that good results were achieved 
using sodium hydrogen selenide (NaHSe). Here, we wish to examine the feasibility 
and efficiency of an approach to synthesis of some new seleno[2,3-b]quinolines.
In continuation of our research program directed toward the studies on Sulfur 
Chemistry [17–30] and synthesis of new potentially bioactive molecules, we were in 
need of a medicinal, bioorganic, industrial, cost-effective and commercial method 
for the synthesis of quinoline-based sulfur and selenium compounds. Also, the 
extensive biological properties and pharmaceutical applications have attracted 
interests in development of such sulfur and selenium-containing analogs.
2. Results and discussions
In this contribution, we focused our attention on the fast and efficient synthesis 
of dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinolines. At first, the key intermediate 
3-formyl-2-chloroquinoline [31] and azitidones [32] have been prepared from avail-
able reported methods.
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In the current investigation very interesting result was observed in the reaction 
of 1a–e on subjected to ring cyclisation with sodium hydrogen selenide in water 
offered seleno quinolines 2a–e. As expected, the 1H NMR spectrum exhibited two 
peaks at δ 5.71 ppm and δ 4.91 ppm of two protons present in azetidinone ring, i.e., 
-N-CH-C- and -Se-CH- of newly formed thieno ring. The aromatic protons resonate 
as multiplets at δ 7.26–8.50 ppm. The structure was further confirmed by recording 
its mass spectra. It gave the molecular ion peak at m/z 351(M+) which corresponds 
to molecular formula C18H12N2OSe. Also, halogen test was used to confirm the 
absence of chlorine.
3. Experimental
IR spectra were taken on a Perkin Elmer 157 Infrared spectrophotometer. 1H 
NMR spectra (300 MHz) were recorded on a Bruker supercon FT-NMR instrument 
using TMS as internal standard and mass spectra on a Jeol JMS-D 300 mass spec-
trometer operating at 70 eV. Melting points were determined in open capillary and 
are uncorrected. Purity of the compounds was checked by TLC on silica gel and the 
compounds were purified by column chromatography.
3.1 Preparation of sodium hydrogen selenide
A mixture of 1 g of selenium powder and 25 ml of water was taken in a 500 ml 
beaker. The heat obtained was controlled by keeping this mixture at ice cold 
condition. A calculated amount of sodium borohydride of 0.026 moles was added 
in stepwise with constant stirring. During this, immediate liberation of foaming 
takes place because of the formation of hydrogen gas. Once the addition of sodium 
borohydride is over, approximately 25 ml of water was added along the side of 
the beaker and stirring was continued over 15 min. During this, a colorless, deep, 
reddish NaHSe formed and thus the obtained result was used without further any 
purification.
3.2 Preparation of dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinolines (2a: E)
About 0.01 mole of azitidone 1a, and 0.01 mole sodium hydrogen selenide, and 
50 ml of water were taken in a 500-ml round-bottom flask. The contents of the 
flask were refluxed over 10–15 min on a water bath. The crystalline solid 2a was 
precipitated in the flask. The contents of the flask was poured into a beaker contain-
ing 500 mL ice cold water, stirred, filtered, and finally, washed with ethanol. The 
compound obtained was dried, and recrystallized from ethyl acetate. In the same 
way the compounds, 2b–e were prepared (Figure 1).
2a. 1-Phenyl-2a, 7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 280°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 4.91 (1H, s, -Se-
CH-), 5.71 (1H, s, -N-CH-C), 7.26–8.50 (10H, m, Ar-H); IR (KBr) ν (cm−1): 1735.81 
(C=O azetidinone), 1653. [M+], 351. Calcd. (%) for C18H12N2OSe: C; 61.55, H; 3.44, 
N; 7.98, Se; 22.48, Found: C; 61.08, H; 3.44, N; 7.95, Se; 22.43.
2b. 1-(4-Methylphenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 272°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 2.60 (s, -CH3), 
4.87 (1H, s, -Se-CH-), 5.89 (1H, s, -N-CH-C), 7.20–8.49 (9H, m, Ar-H); IR (KBr) 
ν (cm−1): 1735.61 (C=O azetidinone), [M+], 365. Calcd. (%) for C19H14N2OSe: C; 
62.47, H; 3.86, N; 7.67, Se; 21.62, Found: C; 62.45, H; 3.83, N; 7.64, Se; 21.65.
2c. 1-(4-Methoxyphenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
5
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Solid, mp. 287°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 3.90 (s, -OCH3), 
4.92 (1H, s, -Se-CH-), 5.79 (1H, s, -N-CH-C), 7.23–8.42 (9H, m, Ar-H); [M+], 381. 
Calcd. (%) for C19H14N2O2Se: C; 59.85, H; 3.70, N; 7.35, Se; 20.71. Found: C; 59.87, H; 
3.73, N; 7.39, Se; 20.73.
2d. 1-(4-Chlorophenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 292°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 4.79 (1H, s, -Se-
CH-), 5.70 (1H, s, -N-CH-C), 7.29–8.55 (9H, m, Ar-H); [M+], 385. Calcd. (%) for 
C18H11ClN2OSe: C; 56.05, H; 2.87, N; 7.26, Se; 20.47, Found: C; 56.09, H; 2.89, N; 7.23, 
Se; 20.43.
2e. 1-(4-Nitrophenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 288°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 4.70 (1H, s, -Se-
CH-), 5.68 (1H, s, -N-CH-C), 7.34–8.60 (9H, m, Ar-H). [M+], 396. Calcd. (%) for 
C18H11N3O3Se: C; 54.56, H; 2.80, N; 10.60, Se; 19.93, Found: C; 54.52, H; 2.83, N; 
10.63, Se; 19.95.
4. Antimicrobial activity
The in vitro antimicrobial activity was carried out against 24 h old cultures 
of three bacteria by disk diffusion method [33] using ampicillin as the reference. 
Compounds 2a–e were tested against Gram-positive bacteria (Staphylococcus aureus, 
Micrococcus roseus) and Gram-negative bacteria (Escherichia coli). The compounds 
were tested at a concentration of 0.001 mol/ml in DMF against all organisms. The 
zone of inhibition was compared with the standard drug after 24 h of incubation 
at 25°C and measured in mm. Results are reported in Table 1, and it was found 
that compounds 2d and 2e were highly active against S. aureus and M. roseus 
Figure 1. 
General synthetic procedure for dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinolines.
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ν (cm−1): 1735.61 (C=O azetidinone), [M+], 365. Calcd. (%) for C19H14N2OSe: C; 
62.47, H; 3.86, N; 7.67, Se; 21.62, Found: C; 62.45, H; 3.83, N; 7.64, Se; 21.65.
2c. 1-(4-Methoxyphenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
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Solid, mp. 287°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 3.90 (s, -OCH3), 
4.92 (1H, s, -Se-CH-), 5.79 (1H, s, -N-CH-C), 7.23–8.42 (9H, m, Ar-H); [M+], 381. 
Calcd. (%) for C19H14N2O2Se: C; 59.85, H; 3.70, N; 7.35, Se; 20.71. Found: C; 59.87, H; 
3.73, N; 7.39, Se; 20.73.
2d. 1-(4-Chlorophenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 292°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 4.79 (1H, s, -Se-
CH-), 5.70 (1H, s, -N-CH-C), 7.29–8.55 (9H, m, Ar-H); [M+], 385. Calcd. (%) for 
C18H11ClN2OSe: C; 56.05, H; 2.87, N; 7.26, Se; 20.47, Found: C; 56.09, H; 2.89, N; 7.23, 
Se; 20.43.
2e. 1-(4-Nitrophenyl)-2a,7b-dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinoline
Solid, mp. 288°C; 1H NMR (300 MHz, DMSO-d6) δ (ppm): 4.70 (1H, s, -Se-
CH-), 5.68 (1H, s, -N-CH-C), 7.34–8.60 (9H, m, Ar-H). [M+], 396. Calcd. (%) for 
C18H11N3O3Se: C; 54.56, H; 2.80, N; 10.60, Se; 19.93, Found: C; 54.52, H; 2.83, N; 
10.63, Se; 19.95.
4. Antimicrobial activity
The in vitro antimicrobial activity was carried out against 24 h old cultures 
of three bacteria by disk diffusion method [33] using ampicillin as the reference. 
Compounds 2a–e were tested against Gram-positive bacteria (Staphylococcus aureus, 
Micrococcus roseus) and Gram-negative bacteria (Escherichia coli). The compounds 
were tested at a concentration of 0.001 mol/ml in DMF against all organisms. The 
zone of inhibition was compared with the standard drug after 24 h of incubation 
at 25°C and measured in mm. Results are reported in Table 1, and it was found 
that compounds 2d and 2e were highly active against S. aureus and M. roseus 
Figure 1. 
General synthetic procedure for dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinolines.
Heterocycles - Synthesis and Biological Activities
6
(Gram-positive) and moderately active against E. coli (Gram-negative), and com-
pound 2c was slightly active against M. roseus and E. coli. Compound 2e was slightly 
active against S. aureus and M. roseus, and compounds 2a and 2b were slightly active 
against M. roseus. Other compounds were all inactive against these three pathogenic 
microorganisms. Hence, further studies in these compounds are planned to obtain 
clinically useful agents.
Compound number Microorganisms
S. aureus M. roseus E. coli
Ampicillin
2a
2b
2c
2d
2e
20
5
4
4
13
14
22
7
4
5
16
15
22
5
4
4
10
9
Zone of inhibition was expressed in mm.
Highly active +++ (inhibition zone >12 mm); moderately active ++ (inhibition zone 9–12 mm); slightly active + 
(inhibition zone 6–9 mm); and inactive (inhibition zone <6 mm).
Table 1. 
Antimicrobial activity tests of dihydroazeto[2′,3′:4,5]seleno[2,3-b]quinolines (2a–e).
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Abstract
An environmentally friendly, economic synthetic protocol was advanced for 
synthesis of biologically and pharmacologically vital five- and six-membered 
heterocycles containing nitrogen, sulphur and oxygen as heteroatom. A series of 
thiazole derivatives was prepared by the reaction of substituted phenacyl halides 
and phenyl thiourea in the presence of TiO2 nanoparticles (NPs) as nanocatalyst 
in DCM. Similarly, another series of six-membered heterocyclic compounds were 
synthesized by the reaction of phenacyl halides with phenylenediamine, 2-amino-
phenol, 2-aminobenzenethiol to produce corresponding products (1,4-quinoxaline, 
benzoxazine, benzothiazine) under catalytic effect of TiO2nanocatalyst. Analytical 
and spectral (FTIR, 1H and 13C NMR and SEM) techniques were employed for the 
structural elucidation of the synthesized compounds.
Keywords: environmentally friendly, thiazole derivatives, nanocatalyst, 
1,4-quinoxaline, benzoxazine, benzothiazine
This chapter is divided into two sections:
1. Synthesis of five-membered heterocylces from phenacyl halides
2. Synthesis of six-membered heterocylces from phenacyl halides
1. Synthesis of five-membered heterocylces from phenacyl halides
1.1 Introduction
Cyclic compounds which contain one or more hetero atoms besides carbon are 
called heterocyclic compounds. Most commonly nitrogen, sulphur and oxygen are 
present as hetero atoms. Phosphorous, tin, boron, silicon, etc. are other less com-
mon hetero atoms. Numerous heterocyclic compounds have three to six atoms in the 
ring, but only those compounds which have five- or six-membered ring are by far 
most significant. Heterocyclic compounds are broadly circulated in nature and are 
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predominantly important because of the extensive variety of physiological activi-
ties related with this course of substances. Several of the important compounds 
contain heterocyclic rings, e.g. most of the members of alkaloids, vitamin B com-
plex, chlorophyll, antibiotics, other plants pigments, dyes, amino acids, enzymes, 
the genetic material, DNA, drugs, etc. These biologically active molecules always 
drawn the attention of chemist over the years specifically because of their biological 
significance.
One striking structural article characteristic to heterocycles, which continue to be 
exploited to great benefit by the drug industry, lies in their capability to manifest sub-
stituents around a core scaffolds in sharp three-dimensional representations [1]. In 
early studies of chemistry, nitrogen and sulphur containing heterocyclic compounds 
contained predominantly and they were thoroughly associated with the enlargement 
of organic chemistry which was concerned with the study of materials separated 
from living sources and are widely used as structural motif in drug discovery [2].
Heterocycles form by far the leading classical splits of organic chemistry and 
are of enormous prominence in the biological and industrial field. One of the major 
causes for the extensive use of heterocyclic compounds is their structures that can be 
precisely manipulated to attain the required alteration in function. Another impor-
tant feature embraced by heterocycles is the possibility of incorporating functional 
groups either as substituents or as the part of ring system itself. They are also the 
integral part of the wide range of drugs, most of the vitamins, biomolecules, many 
natural products, and biologically active compounds, including antifungal, antitu-
mor, antimicrobial [3], antibiotic, anti-inflammatory, antidepressant, antimalarial 
[4] antibacterial, antiviral, herbicidal, anti-HIV, antidiabetic, insecticidal and fungi-
cidal agents. Further, most of the heterocycles possess vital applications in materials 
science such as dyestuff, fluorescent sensor, plastics, information storage, brighten-
ing agents, and analytical reagents. In addition, they have applications in polymer 
and supramolecular chemistry, especially in conjugated polymers. Moreover, they 
act as organic light-emitting diodes (OLEDs), organic conductors, light harvesting 
systems, photovoltaic cells, optical data carriers [5], chemically controllable switches, 
semiconductors, molecular wires, and liquid crystalline compounds. Thus consider-
ation has been given to advanced effective new methods to synthesize heterocycles.
Now, nanotechnologies are broadly considered to have the potential to bring 
assistances in area as diverse as water contamination, drug development, informa-
tion and communication technologies and the production of lighter and strong 
materials. Nanotechnologies include the conception and manipulation of materials 
at the nanometre scale, either by refining or reducing bulk materials or by scaling 
up from single groups of atoms. Nanoparticles (1–100 nm size) have a distinctive 
place in nanoscience and nanotechnology, not only because of their specific proper-
ties subsequent from their reduced dimensions, but also because they are auspicious 
building blocks for more complex nanostructures. Nanoparticles with the diameter 
of less than 10 nm have created extreme curiosity over the past decade due to their 
developed potential application in area such as nanoscale electronics, sensors, 
optics and catalysis. Due to this importance of nanoparticles so many efforts have 
been devoted to the synthesis of nanoparticles from last few years.
Furthermore, the α-halogenation of ketones is an important conversion in 
synthetic organic chemistry [6]. Due to high reactivity of α-bromoketones, they 
react with a large number of nucleophiles which provide a range of biologically 
active compounds [7]. α-bromoacetophenone derivatives have been examined for 
their active contribution in the inhibition of protein tyrosine phosphatase such as 
PTP1B and SHP-1 [8]. Bromination of 1,3-keto compounds at the reactive posi-
tion increases bioactivity, mainly cytotoxicity against breast cancer 1A9 cells, with 
respect to the unsubstituted compound [9].
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For several conversions employed in organic and pharmaceutical synthesis, 
especially, α-bromo carbonyl compounds have become a significant structural 
motif for the development of numerous biologically active compounds for 
instancethiazolidin-4-one, quinoxalines [10], cyclohexanone derivatives, thio-
phene, pyrazolo[1,5-α][1,3,5]triazine, imidazo[1,2-a][1,3,5]triazin, pyrazolines, 
imidazo[2,1-b] benzothiazoles [11], thiadiazine and triazolo[3,4-b][1,3,4]thia-
diazine. Additionally, they are adaptable building blocks for the retro-synthesis 
of natural products. α-bromoalkanones were prepared by direct method from 
α-bromination of carbonyl compounds, which has fascinated significant con-
sideration in the synthetic organic chemistry [12]. The brominated products are 
important intermediates for the synthesis of various useful molecules such as 
pharmaceuticals, surfactants, pesticides and biologically active heterocyclic com-
pounds [13]. α-Bromination is also a crucial step for introducing a functional group 
into a molecule for further conversions. α-Halogenated carbonyl compounds are 
broadly used in organic synthesis as appreciated reaction intermediates and they 
show versatile uses in organic conversions.
Thiazole ring containing heterocyclic systems are a significant structural entity 
for several bioactive molecules [14]. Thiazole has been used in the preparation 
of imperative drugs essential for antibacterial treatment, inflammation and pos-
sesses immunosuppressant activity [15]. It also possesses inhibitor’s activity against 
antiallergies, enzyme cyclo-independent kinase, antitumor and schizophrenia [16]. 
Some of the thiazole derivatives prepared as fungicide as well as preventing in vivo 
growth of Xanthomonas and anti-arthritis. Amino-thiazoles act as an oestrogen 
receptor and as a potent class of adenosine receptor antagonists. Development of 
heterocyclic chemistry is still in advance phase where lot of scope is accessible for 
researcher. In continuation of this research, various publications on development 
of biologically active heterocycles containing nitrogen and sulfur as heteroatom in 
recent years have come into light.
Previously many synthetic methods have been used to synthesize α-halo car-
bonyl compounds and various reagents have been applied for halogenation of active 
α-hydrogen of carbonyl compounds such as bromine has been previously used as 
a elementary brominating reagent for the α-bromination of carbonyl compounds 
but bromine is very harmful chemical to use. To overcome this limitation, several 
different reagents such as copper(II) bromide [17], tribromoacetophenone [18], 
1,4-dioxane bromooxonium bromide [19], pyridium and tetrabutylammonium 
tribromide have also been employed as substitutions to bromine. The most com-
monly used reagents for a-bromination of ketones include molecular bromine [20], 
N-bromosuccinimide (NBS) [21]. Recently, various methods have been reported 
using NBS-NH4OAc [22], NBS-photochemical [23], NBS-PTSA [24], NBS-silica 
supported sodium hydrogen sulphate [25], NBS-Amberlyst-15 [26], NBS-Lewis 
acids [27], NBS-ionic liquids [28], MgBr2-(hydroxy(tosyloxy)iodo)benzene-MW 
[29], N-methylpyrrolidin-2-one hydrotribromide (MPHT) [30], (CH3)3SiBr-KNO3 
[31], BDMS, NaBr [32].
Here we are reporting a new efficient synthetic procedure for the synthesis of 
α-halo acetophenoes and thiazole derivatives using heterogeneous catalyst TiO2 
NPs. Presented route is more advanced, eco-friendly and more efficient.
1.2 Experimental details
All the required chemicals were purchased from Sigma Aldrich, Alpha Aesar 
and used without further purification. The melting points were checked in open 
capillary tubes in melting point apparatus and are uncorrected. The comple-
tion of the reaction was checked on TLC plates coated with silica gel-G in the 
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n-hexane-EtOAc (v/v = 7:3) and visualised by exposure in UV chamber. The IR 
spectra were recorded on Shimadzu IR-435 spectrophotometer (νmax in cm−1). 
1H NMR, and 13C NMR spectra were recorded using a JEOL RESONANCE 
Spectrometer at 400.0 and 100.0 MHz respectively (δ in ppm) using TMS 
(d = 0.0) as an internal standard for 1H NMR, and CDCl3 was used as internal 
standard (d = 77.0) for 13C NMR. Chemical shifts are reported in parts per 
million (ppm) as follows: chemical shift, multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, br = broad). The elemental analysis (C, H 
and N) were performed using vario-III analyser. The nanoparticles are charac-
terized by FTIR and SEM.
1.2.1 General procedure for the synthesis of TiO2 NPs
TiO2 NPs were prepared by sol-gel method [33], using titanium(IV) isopropox-
ide. For the synthesis of TiO2 NPs, [Ti{OPri}4] (1.75 g) was taken in round bottom 
flask with dry isopropanol (~35 ml). 2–3 drops of water-isopropanol mixture (1,1) 
was added to the above mentioned clear solution and magnetically stirred for 2 h 
then sol formation occurred immediately. To ensure complete hydrolysis, excess of 
water ~10 ml {stoichiometric amount (0.22 g)}, in small lots with continuous stir-
ring for ~4 h was added. The mixture was again stirred for 1 h, till a gel is formed. 
The synthesized gel was dried in an oven (100°C) and then washed properly with 
acetone then an off-white powder was obtained. This powder was sintered at 600°C 
for 4 h to yield a white powder, which was characterized by FTIR and SEM as pure 
TiO2.
1.2.2 Characterization of TiO2 NPs
The TiO2 nanocatalyst was prepared using sol-gel method and characterized 
by various techniques using FT-IR and Scanning Electron Microscopy (SEM). The 
FT-IR spectrum of TiO2 NPs is given in Figure 1. The absorbance bands at around 
3235–3550 cm−1 were proved to the adsorbed water and hydroxyl group in nano 
sized TiO2 (Figure 1). The band observed at 720 cm−1 is due to Ti-O-Ti while absor-
bance bands at 460 cm−1 show stretching vibration due to Ti-O, which is customary 
with the reported IR spectra for nano TiO2 [33]. The SEM images of this oxide are 
revealed in Figure 2. The scales that are shown in Figure 2 are of 500 nm come into 
sight to specify formation of agglomerates granular morphology, constituted by 
nano-sized crystallites.
Figure 1. 
The FT-IR spectra of TiO2 NPs.
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1.2.3 General procedure for the synthesis of substituted thiazoles (3a–e)
In a 20 ml round bottom flask phenacyl bromide (1) (0.5 mmol) and substituted 
phenyl thioureas (2) (0.5 mmol) were added in 5 mL DCM. A catalytic amount of 
TiO2 NPs (5 mol%) is added to reaction mixture. Thereafter, the reaction mixture 
was allowed to stir at magnetic stirrer at 50°C for 20–30 min. The progress of reac-
tion was monitored by TLC, the solid separated was filtered, washed with Hypo 
solution and recrystallized with ethanol (Figure 3) The detailed mechanism of the 
synthesis is shown in Figure 4 (Table 1).
1.3 Spectral data of substituted thiazole (3a–e)
1.3.1 [4-(4-Bromo-phenyl)-thiazole-2-yl]-(4-chloro-phenyl)-amine (3a)
IR (cm−1, KBr): 3315, 1611, 1462, 1370, 762, 644; 1H NMR (CDCl3, 400 MHz): 
δ 4.03 (s, NH), 7.17 (d, 2H, Ar–H), 7.34 (d, 2H, Ar–H), 7.42 (d, 2H, Ar–H), 7.55 (d, 
2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 106.2, 118.5, 119.5, 128.4, 130.5, 131.0, 
131.3, 138.6, 149.4, 175.3; HRMS; m/z 365.94 (M+); C15H10BrClN2S: calcd. C, 49.27; 
H, 2.76; N, 7.66; found C, 49.25; H, 2.75; N, 7.69.
1.3.2 [4-(4-Chloro-phenyl)-thiazole-2-yl]-phenyl-amine (3b)
IR (cm−1, KBr): 3349, 1646, 1434, 1389, 779, 667; 1H NMR (CDCl3, 400 MHz): 
δ 4.12 (s, NH), 7.18 (d, 2H, Ar–H), 7.42 (d, 2H, Ar–H), 7.45 (d, 2H, Ar–H), 7.57 
(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 107.3, 119.3, 120.7, 130.3, 131.5, 
131.9, 132.3, 140.6, 150.3, 176.9; HRMS; m/z 286.03 (M+); C15H11ClN2S: calcd. C, 
62.82; H, 3.87; N, 9.77; found C, 62.83; H, 3.89; N, 9.78.
1.3.3 [4-(4-Methoxy-phenyl)-thiazole-2-yl]-phenyl-amine (3c)
IR (cm−1, KBr): 3317, 1633, 1467, 1379, 767, 648; 1H NMR (CDCl3, 400 MHz): 
δ 4.07 (s, NH), 7.18 (d, 2H, Ar–H), 7.39 (d, 2H, Ar–H), 7.48 (d, 2H, Ar–H), 
7.56(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 109.5, 112.5, 120.6, 130.7, 
131.8, 131.9, 132.4, 140.6, 150.7, 177.5; HRMS; m/z 282.08 (M+); C16H14N2OS: 
calcd. C, 68.06; H, 5.00; N, 9.92; found C, 68.08; H, 5.02; N, 9.93.
Figure 2. 
(a and b). The SEM image of the TiO2 NPs.
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(a and b). The SEM image of the TiO2 NPs.
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1.3.4 [4-(4-Fluoro-phenyl)-thiazole-2-yl]-phenyl-amine (3d)
IR (cm−1, KBr): 3340, 1623, 1470, 1389, 766, 665; 1H NMR (CDCl3, 400 MHz): 
δ 4.09 (s, NH), 7.21 (d, 2H, Ar–H), 7.37 (d, 2H, Ar–H), 7.45 (d, 2H, Ar–H), 
7.58(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 109.8, 121.7, 123.8, 130.6, 
131.6, 131.9, 132.1, 139.7, 151.5, 179.8; HRMS; m/z 270.06 (M+); C15H11FN2S: 
calcd. C, 66.65; H, 4.10; N, 10.36; found C, 66.67; H, 4.11; N, 10.37.
1.3.5 [4-(2-Chloro-phenyl)-thiazole-2-yl]-phenyl-amine (3e)
IR (cm−1, KBr): 3325, 1632, 1472, 1379, 768, 647; 1H NMR (CDCl3, 400 MHz): 
δ 4.06 (s, NH), 7.21 (d, 2H, Ar–H), 7.39 (d, 2H, Ar–H), 7.46 (d, 2H, Ar–H), 
7.59(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 110.5, 119.5, 121.6, 131.6, 
131.9, 132.2, 132.5, 141.9, 152.7, 179.3; HRMS; m/z 286.03 (M+); C15H11ClN2S: 
calcd. C, 62.82; H, 3.87; N, 9.77; found C, 62.83; H, 3.89; N, 9.78.
Figure 4. 
Proposed mechanism for TiO2 NPs catalysed thiazole synthesis.
Figure 3. 
Synthesis of various substituted thiazole (3a-e).
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δ 4.09 (s, NH), 7.21 (d, 2H, Ar–H), 7.37 (d, 2H, Ar–H), 7.45 (d, 2H, Ar–H), 
7.58(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 109.8, 121.7, 123.8, 130.6, 
131.6, 131.9, 132.1, 139.7, 151.5, 179.8; HRMS; m/z 270.06 (M+); C15H11FN2S: 
calcd. C, 66.65; H, 4.10; N, 10.36; found C, 66.67; H, 4.11; N, 10.37.
1.3.5 [4-(2-Chloro-phenyl)-thiazole-2-yl]-phenyl-amine (3e)
IR (cm−1, KBr): 3325, 1632, 1472, 1379, 768, 647; 1H NMR (CDCl3, 400 MHz): 
δ 4.06 (s, NH), 7.21 (d, 2H, Ar–H), 7.39 (d, 2H, Ar–H), 7.46 (d, 2H, Ar–H), 
7.59(d, 2H, Ar–H); 13C NMR (CDCl3, 100.4 MHz): δ 110.5, 119.5, 121.6, 131.6, 
131.9, 132.2, 132.5, 141.9, 152.7, 179.3; HRMS; m/z 286.03 (M+); C15H11ClN2S: 
calcd. C, 62.82; H, 3.87; N, 9.77; found C, 62.83; H, 3.89; N, 9.78.
Figure 4. 
Proposed mechanism for TiO2 NPs catalysed thiazole synthesis.
Figure 3. 
Synthesis of various substituted thiazole (3a-e).
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2.  Synthesis of six-membered heterocylces from phenacyl halides: 
(1,4-quinoxaline, 1,4-benzoxazines, 1,4-benzothiazines)
2.1 Introduction
Quinoxalines are important class of nitrogen containing heterocycles, possessing 
nitrogen atom at 1,4 position. These heterocycles possess various pharmacological 
[34–38] and biological properties such as antibiotic (echinomycin, bleomycin), 
anticancer [39] anti-viral [40], anti-bacterial, antibiotic, and anti-inflammatory. The 
compounds of quinoxalines used to develop organic semiconductors [41, 42], dehy-
droannulenes [43], and also used in dyes [44]. Various methods have been reported 
in literature for the synthesis of quinoxalines, i.e. condensation of 1,2-diketone 
with phenylene diamine to yield the desired quinoxaline under reflux condition at 
ambient temperature with various solvents such as benzene, ethanol [45] with use 
of different catalyst like molecular iodine, copper(II) sulphate, indium(III) chlo-
ride, o-iodoxybenzoic acid, ceric ammonium nitrate, silica gel, gallium(III) triflate 
phosphorus oxychloride, oxidative coupling of epoxides with ene-1,2-diamines 
[46], 1,4-addition of 1,2-diamines to diazenylbutenes [47], cyclization-oxidation of 
phenacyl bromides with 1,2-diamines by HClO4-SiO2 [48] and by using solid phase 
synthesis [49, 50]. Quinoxaline has also been synthesized by the chemical reaction of 
phenylene diamine and different substituted phenacyl bromides via solid phase [49, 
50], synthesis by using different catalyst like 1,4-diazabicyclo [2,2,2]octane, trimeth-
ylsilyl chloride, perchloric acid supported on silica, KF-alumina, β-cyclodextrin.
1,4-Benzoxazines are important moiety of heterocyclic compounds having 
considerable biological [51], pharmaceutical [52] and wide range of synthetic utili-
ties. Therefore, new methods should be developed for an efficient protocol for their 
synthesis. In addition of above information these compounds also served as precur-
sors for the synthesis of many medicinally important drugs [53]. The skeleton of these 
type of structures are synthesized by the direct intramolecular reductive cyclization 
of appropriate nitroketones or by intramolecular annulation of 2-aminophenoxy 
ketones [54]. Benzoxazines are also prepared by the condensation reaction of 2-amin-
ophenols with substituted phenacyl halides [55]. Although, these reported procedures 
are not specific and general because involvement of more than one-steps, requirement 
of high temperature, give low to moderate yields and use of commercially unavailable 
starting material. Hence the discovery of new protocols which leads to an efficient 
synthetic procedure for synthesis of 1,4-benzoxazine and their derivatives.
There are many reported methods in literature for the efficient synthesis for 
multicomponent reactions (MCRs) for the natural products, these methods are of 
great advantage at atom and step economy level, and these are also environmental 
friendly. 4H-1,4-benzothiazines (having nitrogen and sulphur heteroatom at 1,4 
position) are a family of heterocycles possessing number of important biologi-
cal and pharmacological properties [56]. A compound containing thiazine ring 
namely 2-benzoyl-7-chloro-3-methyl-5-trifluoromethyl-4H-1,4-benzothiazine [57] 
possessing numerous biological activities like antiemetics, neuroleptics, antihista-
minics, antipsychotics, antibacterial, tranquilizers, sedatives, and anticarcinogen. 
This type of heterocycles has attracted considerable interest of researchers, which 
leads to the development of synthetic strategies. Therefore, the development and 
use of new MCRs have been an interesting topic in the areas of various branches of 
chemistry like synthetic organic, medicinal and pharmachemistry.
Although, these reported methods suffered from various limitations such as 
toxic nature of reagents, excess loading of catalyst, need of high temperature, 
expensive reagents and complicated work-up to complete the reaction. In pres-
ent era development of green and sustainable protocols attract the attention of 
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2.1 Introduction
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ylsilyl chloride, perchloric acid supported on silica, KF-alumina, β-cyclodextrin.
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considerable biological [51], pharmaceutical [52] and wide range of synthetic utili-
ties. Therefore, new methods should be developed for an efficient protocol for their 
synthesis. In addition of above information these compounds also served as precur-
sors for the synthesis of many medicinally important drugs [53]. The skeleton of these 
type of structures are synthesized by the direct intramolecular reductive cyclization 
of appropriate nitroketones or by intramolecular annulation of 2-aminophenoxy 
ketones [54]. Benzoxazines are also prepared by the condensation reaction of 2-amin-
ophenols with substituted phenacyl halides [55]. Although, these reported procedures 
are not specific and general because involvement of more than one-steps, requirement 
of high temperature, give low to moderate yields and use of commercially unavailable 
starting material. Hence the discovery of new protocols which leads to an efficient 
synthetic procedure for synthesis of 1,4-benzoxazine and their derivatives.
There are many reported methods in literature for the efficient synthesis for 
multicomponent reactions (MCRs) for the natural products, these methods are of 
great advantage at atom and step economy level, and these are also environmental 
friendly. 4H-1,4-benzothiazines (having nitrogen and sulphur heteroatom at 1,4 
position) are a family of heterocycles possessing number of important biologi-
cal and pharmacological properties [56]. A compound containing thiazine ring 
namely 2-benzoyl-7-chloro-3-methyl-5-trifluoromethyl-4H-1,4-benzothiazine [57] 
possessing numerous biological activities like antiemetics, neuroleptics, antihista-
minics, antipsychotics, antibacterial, tranquilizers, sedatives, and anticarcinogen. 
This type of heterocycles has attracted considerable interest of researchers, which 
leads to the development of synthetic strategies. Therefore, the development and 
use of new MCRs have been an interesting topic in the areas of various branches of 
chemistry like synthetic organic, medicinal and pharmachemistry.
Although, these reported methods suffered from various limitations such as 
toxic nature of reagents, excess loading of catalyst, need of high temperature, 
expensive reagents and complicated work-up to complete the reaction. In pres-
ent era development of green and sustainable protocols attract the attention of 
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scientists because the use of these above reagents causes many allergic diseases. In 
this connection of research, various researchers have considerable attention on use 
of non-hazardous reagents like nanoparticles as heterogeneous catalysts for organic 
transformations. So, keeping in view these facts of green technology we have tried 
our effort to develop, a new synthetic strategy for the synthesis of 1,4-quinoxaline, 
1,4-benzoxazines, 1,4-benzothiazines catalysed by TiO2 nanoparticles (NPs).
This method is considered to be environment friendly because of use of solid 
heterogeneous catalyst that provides many advantages such as, ease of handling, 
non-corrosiveness, high yield, low cost and reusability of the used nanocatalyst.
2.2 General procedure for the synthesis of six-membered heterocycles
2.2.1 General procedure for the synthesis of 1,4-quinoxaline (3a and b)
In a 50 ml round bottom flask we took 1,2-phenylenediamine (1) (1 mmol) and 
substituted phenacyl bromide (2) (1 mmol) and dissolved both in dichloromen-
thane-DCM (5 mL). Now add catalytic amount of TiO2 nanoparticles and stirring 
is continuous at 50°C for appropriate time limit. After completion of reaction, the 
whole content was filtered fir the removal of nanocatalyst and it was well washed 
with ethyl acetate (10 mL). This obtained filtrate was concentrated and purified 
by column chromatography by using hexane/ethylacetate (15% ethyl acetate in 
hexane) as an eluent to yield desired quinoxaline derivatives in appropriate yields. 
The nanocatalyst can be recovered after thoroughly washing with ethyl acetate, air 
dried, and activation at 80°C for 3 h and can reused for further cycles (Figure 5).
2.2.2 Spectral data of synthesized compounds
2.2.2.1 2-Phenylquinoxaline (3a)
Dark yellow solid; M.P: 75–78.3°C; 1H NMR (400 MHz, CDCl3, TMS = 0 PPM): 
δ = 7.50–7.58 (m, 3H, ArH), 7.70–7.82 (m, 2H, ArH), 8.14–8.28 (m, 4H, ArH), 
9.43 (s, 1H, C3-H) ppm; 13C NMR (100.4 MHz, CDCl3, TMS = 0 PPM): δ = 127.1, 
129.19, 129.26, 129.5, 129.6, 130.5, 130.8, 136.4, 141.9, 142.8, 143.6, 152.8 ppm; LCMS 
(ESI-MS): m/z calcd. for C14H10N2 (M+): 206.24; found: 207.1 (M + H).
2.2.2.2 2-(3-bromophenyl)quinoxaline (3b)
Light brown solid; M.P: 132–133.8°C;1H NMR (400 MHz, CDCl3, TMS = 0 
PPM): δ = 7.44–7.48 (t, 1H, ArH), 7.66–7.68 (dd, 1H, ArH), 7.77–7.85 (m, 2H, ArH), 
8.14–8.19 (m, 3H, ArH), 8.32–8.40 (t, 1H, ArH), 9.50 (s, 1H, C3-H) ppm; 13C NMR 
(100 MHz, CDCl3, TMS = 0 PPM): δ = 124.4, 126.8, 129.8, 130.6, 130.9, 131.5, 131.6, 
Figure 5. 
Synthesis of 1,4-quinoxaline.
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138.9, 141.8, 142.8, 143.9, 153.2 ppm; LCMS (ESI-MS): m/z calcd. for C14H9BrN2 
(M+): 285.14; found: 287.0 (M + 2H).
2.2.3 General procedure for the synthesis of 1,4-benzoxazines (3c and d)
A catalytic amount of nanoparticles (TiO2) added to the stirring mixture of 
o-aminophenol (1) (1 mmol), substituted phenacyl bromide (2) (1 mmol) and triethyl 
amine (Et3N) (1.1 mmol). After the completion of the reaction the whole content was 
extracted with Et2O (5X2, 10 mL). After extraction the organic layer was washed with 
brine (20 mL), and dried over the layer of anhydrous Na2SO4, concentrated and puri-
fied by column chromatography by using silica gel and EtOAc/hexane (1:20) (Figure 6).
2.2.3.1 2-Phenyloxazine (3c)
Brown solid; M.P:88–89.5°C; 1H NMR (400 MHz, CDCl3, TMS = 0 PPM): 
δ = 7.50–7.62 (m, 3H, ArH), 7.76–7.80 (m, 2H, ArH), 8.15–8.29 (m, 4H, ArH), 4.88 
(s, 2H, C3-H) ppm; 13C NMR (100.4 MHz, CDCl3, TMS = 77.0 PPM): δ = 127.5, 
129.0, 129.2, 129.5, 129.6, 130.1, 130.8, 136.8, 141.5, 142.8, 143.3, 151.8 ppm; LCMS 
(ESI-MS): m/z calcd for C14H10N2 (M+): 206.24; found: 207.1 (M + H).
2.2.3.2 2-(3-bromophenyl) oxazine (3d)
Light yellow solid, M.P: 142–143.8°C;1H NMR (400 MHz, CDCl3, TMS = 0 
PPM): δ = 7.51–7.58 (t, 1H, ArH), 7.66–7.70 (dd, 1H, ArH), 7.74–7.78 (m, 2H, ArH), 
8.16–8.19 (m, 3H, ArH), 8.36–8.40 (t, 1H, ArH), 4.98 (s, 2H, C3-H) ppm; 13C NMR 
(100 MHz, CDCl3, TMS = 77.0 PPM): δ = 74.5, 126.9, 128.8, 130.8, 131.2, 131.5, 131.9, 
139.9, 141.9, 142.4, 143.9, 153.2 ppm; LCMS (ESI-MS): m/z calcd for C14H10BrN2 
(M+): 285.14; found: 287.0 (M + 2H).
2.2.4 General procedure for the synthesis of 1,4-benzothiazines (4e and f)
In a round bottom flask the 2-aminobenzenethiol (1) (1 mmol), aromatic aldehyde 
(2) (1 mmol), and substituted phenacyl bromide (3) (1 mmol), were added in the stir-
ring solution of the DABCO (0.2 mmol) in (Et3N), and stirring was continued for 6 h in 
an oil bath at 65°C. After the completion of the reaction the whole reaction mixture was 
cooled and diluted with DCM (20 mL) and then washed with water. The obtained resi-
due was purified by column chromatography on silica gel (300–400 mesh) with EtOAc 
and petroleum ether (1:20, v/v) as the eluent to yield the desired product (Figure 7).
Figure 6. 
Synthesis of 1,4-benzoxazines.
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2.2.4.1  Phenyl (3-phenyl-3,4-dihydro-4H-benzo[b][1,4]thiazin-2-yl)  
methanone (4e)
Light yellow solid; M.P.: 124–126°C; 1H NMR (400 MHz, CDCl3): δ 7.86 
(d, J = 7.5 Hz, 2H), 7.52 (t, J = 7.1 Hz, 1H), 7.41–7.26 (m, 7H), 7.08 (q, J = 7.5 Hz, 2H), 
6.70 (t, J = 8.9 Hz, 2H), 5.12 (d, J = 4.8 Hz, 1H), 4.72 (d, J = 5.4 Hz, 1H), 4.45 (s, 1H) 
ppm; 13C NMR (100.4 MHz, CDCl3) δ47.6, 57.9, 113.8, 115.2, 118.4, 127.4, 127.8, 
128.2, 128.4, 128.6, 128.6, 128.7, 133.8, 135.4, 142.4, 142.6, 194.4 ppm; HRMS (ESI) 
calcd for [C21H17NOS + H] + 332.1109, found 332.1104.
2.2.4.2  (3-Phenyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-2-yl)(p-tolyl) 
methanone (4f)
Brown solid; M.P.: 118–120°C; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 7.5 Hz, 
1H), 7.56 (t, J = 7.8 Hz, 1H), 7.40 (t, J = 7.2 Hz, 2H), 7.26 (t, J = 8.0 Hz, 3H), 7.10–7.04 
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118.2, 127.4, 127.8, 128.2, 128.4, 128.5, 128.6, 128.7, 133.8, 135.2, 142.2, 142.6, 194.2, 
21.5 ppm; HRMS (ESI) calcd. for [C22H19NOS + H] + 346.1266, found 346.1260.
3. Results and discussion
In this chapter we have tried to develop an efficient protocol for the synthesis of 
five-membered disubstituted derivatives (thiazole, 3a–e, Figure 3) by using TiO2 
NPs in moderate to excellent yields from the starting materials phenacyl halides and 
thioureas. Similarly, six-membered nitrogen containing heterocycles (quinoxaline 
derivatives, 3a, b, Figure 5) from o-phenylenediamines and substituted phenacyl 
bromides in the presence of TiO2/DCM at 50°C. In the similar way, six-membered 
nitrogen and oxygen containing heterocycles (benzoxzines, 3c and d, Figure 6) was 
Figure 7. 
Synthesis of 1,4-benzothiazines.
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synthesized under the set of conditions Et3N/TiO2 at room temperature by annulation 
of o-aminophenols with substituted phenacyl bromides via one pot process. 1,4-ben-
zothiazines are prepared by the reaction of the benzaldehyde, phenacyl halides and 
2-aminothiophenols in the presence of set of conditions DABCO, TiO2, Et3N to yield 
benzothiazine (4e and f, Figure 7). The TiO2 NPs was characterised by FTIR and SEM 
images which confirmed the synthesis of TiO2 NPs in the nano range.
4. Conclusion
In conclusion, we have developed a green and economic procedure for the 
synthesis of bioactive five- and six-membered heterocycles. This synthetic meth-
odology allowed us to synthesize products in good to excellent yields, which is 
irrespective to the functional groups which are present in the starting material. 
The used protocol is mild and environmental friendly. There are many merits of 
the used protocol like, low cost of green catalyst, obtaining high yield of products, 
operational simplicity, and the catalyst can be reused without any significant loss 
in catalytic property up to four catalytic cycle. These outstanding features of this 
method make it environmentally friendliness.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Heterocycles - Synthesis and Biological Activities
20
2.2.4.1  Phenyl (3-phenyl-3,4-dihydro-4H-benzo[b][1,4]thiazin-2-yl)  
methanone (4e)
Light yellow solid; M.P.: 124–126°C; 1H NMR (400 MHz, CDCl3): δ 7.86 
(d, J = 7.5 Hz, 2H), 7.52 (t, J = 7.1 Hz, 1H), 7.41–7.26 (m, 7H), 7.08 (q, J = 7.5 Hz, 2H), 
6.70 (t, J = 8.9 Hz, 2H), 5.12 (d, J = 4.8 Hz, 1H), 4.72 (d, J = 5.4 Hz, 1H), 4.45 (s, 1H) 
ppm; 13C NMR (100.4 MHz, CDCl3) δ47.6, 57.9, 113.8, 115.2, 118.4, 127.4, 127.8, 
128.2, 128.4, 128.6, 128.6, 128.7, 133.8, 135.4, 142.4, 142.6, 194.4 ppm; HRMS (ESI) 
calcd for [C21H17NOS + H] + 332.1109, found 332.1104.
2.2.4.2  (3-Phenyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-2-yl)(p-tolyl) 
methanone (4f)
Brown solid; M.P.: 118–120°C; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 7.5 Hz, 
1H), 7.56 (t, J = 7.8 Hz, 1H), 7.40 (t, J = 7.2 Hz, 2H), 7.26 (t, J = 8.0 Hz, 3H), 7.10–7.04 
(m, 4H), 6.68–6.60 (m, 2H), 5.02 (d, J = 5.7, 1H), 4.58 (d, J = 6.3 Hz, 1H), 4.34 
(s, 1H), 2.26 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ 47.1, 57.6, 113.6, 115.0, 
118.2, 127.4, 127.8, 128.2, 128.4, 128.5, 128.6, 128.7, 133.8, 135.2, 142.2, 142.6, 194.2, 
21.5 ppm; HRMS (ESI) calcd. for [C22H19NOS + H] + 346.1266, found 346.1260.
3. Results and discussion
In this chapter we have tried to develop an efficient protocol for the synthesis of 
five-membered disubstituted derivatives (thiazole, 3a–e, Figure 3) by using TiO2 
NPs in moderate to excellent yields from the starting materials phenacyl halides and 
thioureas. Similarly, six-membered nitrogen containing heterocycles (quinoxaline 
derivatives, 3a, b, Figure 5) from o-phenylenediamines and substituted phenacyl 
bromides in the presence of TiO2/DCM at 50°C. In the similar way, six-membered 
nitrogen and oxygen containing heterocycles (benzoxzines, 3c and d, Figure 6) was 
Figure 7. 
Synthesis of 1,4-benzothiazines.
21
Phenacyl Bromide: An Organic Intermediate for Synthesis of Five- and Six-Membered Bioactive…
DOI: http://dx.doi.org/10.5772/intechopen.88243
Author details
Dinesh Kumar Jangid* and Surbhi Dhadda
Department of Chemistry, University of Rajasthan, Jaipur, Rajasthan, India
*Address all correspondence to: dinu.jangid@gmail.com
synthesized under the set of conditions Et3N/TiO2 at room temperature by annulation 
of o-aminophenols with substituted phenacyl bromides via one pot process. 1,4-ben-
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odology allowed us to synthesize products in good to excellent yields, which is 
irrespective to the functional groups which are present in the starting material. 
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Chapter 3
Amidoxime Derivatives with Local
Anesthetic, Antitubercular, and
Antidiabetic Activity
Lyudmila Kayukova, Umirzak Jussipbekov
and Kaldybay Praliyev
Abstract
Оur task in the field of new derivatives of amidoximes was the elaboration for
new medication with increased activity and lower toxicity than medications used in
practice. Here are the results of the search for new painkillers and antitubercular
and antidiabetic drugs in the class of amidoxime derivatives. Nitrous derivatives of
α-chloro-α-isonitrosoacetone, O-aroyl-β-aminopropioamidoximes, and 3-[β-(piper-
idine-1-yl)]ethyl-5-aryl-1,2,4-oxadiazoles were tested for conduction, infiltration,
and terminal anesthesia. Among them hit compounds were discovered. The search
for new anti-TB drugs is executed in the world. Salts and bases of O-aroylation
products of β-(thiomorpholin-1-yl) and β-(4-methylpiperazin-1-yl)
propioamidoximes during in vitro antitubercular screening for DS, DR, and MDR
strains of M. tuberculosis manifest themselves as highly active competitive com-
pounds. In the series of the derivatives of β-aminopropioamidoximes, a search for
new antidiabetic drugs was done. The compounds with pronounced antidiabetic
properties were revealed. The obtained data of the most promising samples with a
preliminary assessment of their average toxic dose in animals can be used in further
in vivo testing of infiltration anesthesia conditions, of antidiabetic properties, and at
the development of doses and new treatment regimens for TB.
Keywords: nitrous derivatives of α-chloro-α-isonitrosoacetone, bases and salts of
O-aroyl-β-aminopropioamidoximes, 3-(β-amino)ethyl-5-aryl-1,2,4-oxadiazoles,
local anesthetics, in vitro antitubercular, antidiabetic screening
1. Introduction
First of all, researchers’ interest in amidoximes is due to the possibility of their
synthetic modification according to the reaction groups NOH and NH2. The largest
number of derivatives was obtained as a result of acylation reactions at the O-atom
of the NOH group and subsequent transformations involving the NH2 fragment to
1,2,4-oxadiazoles [1]. In most cases, amidoxime derivatives, including heterocyclic
radicals, under standard conditions are stable, allowing their structural identifica-
tion, and withstand storage and biological screening. Arrays of data were obtained
on their diverse biological activity: antitubercular, local anesthetic, antidiabetic,
antioxidant, etc. [2, 3].
The rational use of drugs is one of the urgent problems of modern medicine.
A doctor of any profile most often faces the need to eliminate and prevent pain.
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With pain of varying intensities, adequate pain relief reduces the patient’s tension
and fear, prevents him from forming a negative attitude to medical manipulations,
and protects the nervous system of the doctor and patient, providing better medical
care. The search for new painkillers with increased activity and lower toxicity than
painkillers used in practice is one of the tasks of modern medical chemistry. We
developed new β-aminopropioamidoximes and studied their neurotropic proper-
ties. Herein we present results from a study of the local anesthetic activities of three
chemical groups of new amidoxime derivatives [4].
Tuberculosis (TB) is the leading cause of death and morbidity in more than one
third of the world’s population. Of the 56.4 million deaths worldwide due to the 10
leading causes in 2016, tuberculosis ranked 10th, from which 1.4 million people
died [5].
In May 2014, the World Health Organization (WHO) approved a new global TB
control strategy “End TB”. This strategy marks a critical shift from tuberculosis
control to ending the epidemic by 2035. The “End TB” strategy emphasizes the need
for innovation to accelerate progress by optimizing existing ones in the short term
and introducing new innovative modes in the long term [6]. In order to reduce the
duration of treatment, the rapid development of drug resistance and toxic and side
effects of existing anti-TB drugs, and to reduce the cost of extremely expensive
treatment of TB (DS, MDR, XDR), the world is searching for new anti-TB drugs.
We have synthesized the salts and bases of the O-aroylation products of
β-(thiomorpholin-1-yl) and β-(4-methylpiperazin-1-yl)propioamidoximes,
containing in the β-position pharmacophore fragments of 1-methylpiperazine and
thiomorpholine. In vitro antitubercular screening of β-aminopropioamidoxime
derivatives in the DS, DR, and MDR strains of M. tuberculosis revealed highly active
competitive compounds which are less toxic than rifampicin and isoniazid with
activity significantly exceeding the activity of the reference preparations. It is
assumed that these compounds may be the subject of subsequent trials in the
development of doses and new treatment regimens for TB [7, 8].
Diabetes is on the rise across the globe. Presently every 7 seconds someone is
estimated to die from diabetes or its complications. This is against the background
of a global diabetes prevalence of 8.8% of the world population in 2017. The prev-
alence is expected to further increase to 9.9% by the year 2045. In total numbers,
this reflects a population of 424.9 million people with diabetes worldwide in 2017
with an estimate of a 48% increase to 628.6 million people for the year 2045 [9].
Due to the urgency of the problem of diabetes in the world, a search is underway for
new antidiabetic drugs. The antidiabetic activity of amidoxime derivatives is known
[10, 11]. We conducted in vitro testing of derivatives of β-aminopropioamidoximes:
bases and pharmacologically acceptable salts of O-aroyl-β-(morpholin-1-yl)
propioamidoxime and 5-aryl-3-β-(piperidin-1-yl and morpholin-1-yl)ethyl-1,2,4-
oxadiazoles with respect to their ability to inhibit the activity of α-amylase and
α-glucosidase enzymes. Identified compounds with pronounced antidiabetic
properties must be noted; a series of 3,5-disubstituted 1,2,4-oxadiazoles is more
active than a series of O-aroyl-β-aminopropioamidoximes [12].
The data obtained can be used in further in vivo testing of the antidiabetic
properties of the most promising samples with a preliminary assessment of their
average toxic dose in animals.
2. Local anesthetic activity of new amidoxime derivatives
Herein we present results from a study of the local anesthetic activities of three
chemical groups of new amidoxime derivatives (1–10) [4].
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The first group includes derivatives of α-chloro-α-isonitrosoacetone such as 3-
acetyl-5,5-bis(hydroxymethyl)-5,6-dihydro-4H-1,2,4-oxadiazine (1) and the anti-
isomer of N-(4-methylphenyl)acetylformamidoxime thiosemicarbazone (2). The
second group includes the hydrochlorides of O-aroyl-β-aminopropioamidoximes
with piperidine (3), morpholine (4–6), and benzimidazole (7 and 8) in the β-position.
The third group consists of 3-[β-(piperidin-1-yl)]ethyl-5-p-tolyl-1,2,4-oxadiazole (9)
and 3-[β-(piperidin-1-yl)]ethyl-5-m-chlorophenyl-1,2,4-oxadiazole (10).
The local anesthetic activity of 1–10 was studied in three types of anesthesia, i.e.,
infiltration, conduction, and terminal. The reference drugs were trimecaine, lido-
caine, novocaine, and kazcaine [hydrochloride of 1-(2-ethoxyethyl)-4-ethynyl-4-
benzoyloxypiperidine] (Tables 1–3).
Compound Anesthesia index
(М  m)
Duration of complete anesthesia
(М  m), min
Total duration of anesthesia
(М  m), min
1 22.6  1.4* 10.0  2.5** 40.0  2.7*
2 28.0  2.2** 14.4  0.4*** 29.1  2.2**
3 28.8  3.7**** 15.0  0.0* 28.0  4.9***
4 31.4  1.4** 18.3  7.7 55.0  1.8****
5 30.6  1.3* 20.8  2.4**** 55.8  2.1**
6 21.0  2.4* 8.3  2.7 34.1  0.8*
7 31.0  1.2**** 20.0  2.8* 45.8  2.5****
8 34.0  1.15* 25.0  2.8** 55.8  2.1**
9 34.1  0.7** 25.0  0.3* 58.3  2.7*
10 36.0  0.0* 85.0  0.8**** 125.0  1.8**
Trimecaine 34.1  0.5 30.0  1.7 44.1  1.7
Lidocaine 32.3  2.3 25.8  0.8 54.5  2.3
Novocaine 30.0  0.2 10.0  0.0 22.0  0.1
Kazkain 31.1  1.2 25.0  2.5 75.0  0.7
*Compared to trimecaine.
**Compared with lidocaine.
***In comparison with novocaine.
****Compared to cascaine.
Table 1.
Activity and duration of action of compounds 1–10 (0.5% concentration) for infiltration anesthesia.
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The experimental results indicated that all compounds 1–10 were effective to
different degrees in infiltration anesthesia (Table 1). The most active compound
was 10, which induced the maximum deep anesthesia (anesthesia index 36.0) and
exceeded statistically that of the reference drugs with the exception of lidocaine.
Compound Anesthesia index
(М  m)
Duration of complete anesthesia
(М  m), min
Total duration of anesthesia
(М  m), min
1 329.0  20.0* 10.0  0.0*** 64.0  1.5*
2 301.0  5.3** 15.0  0.0* 72.0  4.0*
3 319.7  5.6*** 45.0  0.0** 69.3  3.0**
4 427.0  44.0* 48.0  0.0**** 80.6  2.0***
5 310.0  43.7* 20.0  0.0* 65.0  3.1*
6 242.9  4.7** 10.0  0.8* 61.2  1.2*
7 425.7  15.6* 84.0  2.6** 144.0  3.5****
8 534.0  12.0**** 88.0  0.0*** 118.0  3.1*
9 591.0  34.0* 90.0  2.4* 105.0  5.9*
10 600.0  0.0* 70.4  1.1*** 90.0  3.1**
Trimecaine 324.0  14.0 20.0  0.0 63.0  1.3
Lidocaine 366.8  94.8 10.0  0.0 68.0  2.8
Novocaine 310.0  43.7 10.0  0.0 60.0  0.0
Kazkain 600.0  0.0 208.9  7.3 280.0  0.0
*Compared to trimecaine.
**Compared with lidocaine.
***In comparison with novocaine.
****Compared to cascaine.
Table 2.
Activity and duration of action of compounds 1–10 (1% concentration) for conduction anesthesia.
Compound Regnier index
(М  m)
Duration of complete anesthesia
(М  m), min
Total duration of anesthesia
(М  m), min
1 85.6  5.0 0.0 14.4  1.5
2 242.5  16.4 0.0 33.1  1.6
3 186.3  9.7 0.0 28.0  2.4
4 150.6  16.2 0.0 27.5  1.9
5 281.6  18.5 0.0 38.0  1.9
6 13.0  0.0 0.0 0.0
7 103.0  10.5 0.0 22.0  0.9
8 373.4  37.3 0.0 43.1  4.0
9 601.5  32.7 0.0 62.0  2.3
10 430.0  14.4 0.0 48.75  2.1
Dikain 1300.0  0.0 65.0  0.0 120.0  0.0
Table 3.
Activity and duration of action of compounds 1–10 (1% concentration) for terminal anesthesia.
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This compound also turned out to be more active than the other tested com-
pounds. The anesthesia indices of 8 and 9 were almost the same as that for
trimecaine and were slightly greater than those for lidocaine, novocaine, and
kazcaine. The strength of the anesthesia induced by 4 and 7 was greater than that of
novocaine, equal to that of kazcaine, and less than that of trimecaine and lidocaine.
The anesthesia indices of 1–3 and 4 were less than those of the reference drugs.
Compound 10 had a longer duration of conduction anesthesia than the other tested
compounds (including the reference drugs).
Compounds 5 and 7–9 had longer durations of action than novocaine, shorter
than trimecaine, and essentially the same as lidocaine and kazcaine. The duration of
total anesthesia of 4was longer than that of novocaine and slightly shorter than that
of the other reference drugs. The durations of total anesthesia for 1 and 4 (10.0 and
8.3 min) were comparable with that of novocaine.
Table 2 presents results from a study of conduction anesthesia by 1–10.
Like in the preceding series of tests, 10 had the highest activity. Its anesthesia
index was greater than those of trimecaine, lidocaine, and novocaine and equal to
that of kazcaine. Compounds 1–5 and 7–9 were rather active. Their anesthesia
indices were greater than those of trimecaine, novocaine, and lidocaine. However,
they were less than that of kazcaine. Compound 6 was less active than the reference
drugs. Like in the preceding series of tests, the durations of total anesthesia of the
studied compounds were compared. Table 2 shows that all compounds 1–10 had
total anesthesia duration indices that were shorter than that of kazcaine although 3,
4, and 7–10 had durations of action longer than those of novocaine, lidocaine, and
trimecaine.
Compounds 1–10 in terminal anesthesia were weaker and shorter acting than
dicaine (Table 3). However, not one of these compounds exhibited an irritating
effect.
Thus, it was shown that amidoxime derivatives 1–10 exhibited anesthetic effects
that were greater than those of the reference drugs in conduction and infiltration
anesthesia. The 1,2,4-oxadiazoles 9 and 10 and to a lesser extent O-aroyl-
aminopropioamidoximes with a β-benzimidazole substituent 7 and 8 had longer
durations of action than the reference drugs.
3. Search for new antitubercular drugs among the salts and bases
of O-aroylation products of β-(thiomorfolin-1-yl)- and
β-(4-methylpiperazin-1-yl)propioamidoximes
A search for qualitatively new antitubercular drugs with the requirements of
reducing the duration of treatment, eliminating of the rapid drug resistance devel-
opment and toxic side effects of the existing antitubercular drugs, and reducing
the cost of extremely expensive treatment of TB (DS, MDR, XDR) is being
conducted in the world.
1,5-Diphenylpyrroles have been identified as a class of compounds with high
in vitro antitubercular activity. Replacing of the methylpiperazine substituent for
thiomorpholine and replacing the chlorine atom in position 4 of the N-phenyl
moiety with the fluorine atom, as well as varying the aromatic substituents at the
C-2 atom of the pyrrole ring during the transition from p-CH3 (BM221) to
p-CH3O (BM233) and to p-CH3S (BM579) in 1,5-(4-chlorophenyl)-2-methyl-3-
(4-methylpiperazin-1-yl)methyl-1H-pyrrole (BM212), leads to an increase in
in vitro antitubercular activity on M. tuberculosis H37Rv strains [13, 14].
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The experimental results indicated that all compounds 1–10 were effective to
different degrees in infiltration anesthesia (Table 1). The most active compound
was 10, which induced the maximum deep anesthesia (anesthesia index 36.0) and
exceeded statistically that of the reference drugs with the exception of lidocaine.
Compound Anesthesia index
(М  m)
Duration of complete anesthesia
(М  m), min
Total duration of anesthesia
(М  m), min
1 329.0  20.0* 10.0  0.0*** 64.0  1.5*
2 301.0  5.3** 15.0  0.0* 72.0  4.0*
3 319.7  5.6*** 45.0  0.0** 69.3  3.0**
4 427.0  44.0* 48.0  0.0**** 80.6  2.0***
5 310.0  43.7* 20.0  0.0* 65.0  3.1*
6 242.9  4.7** 10.0  0.8* 61.2  1.2*
7 425.7  15.6* 84.0  2.6** 144.0  3.5****
8 534.0  12.0**** 88.0  0.0*** 118.0  3.1*
9 591.0  34.0* 90.0  2.4* 105.0  5.9*
10 600.0  0.0* 70.4  1.1*** 90.0  3.1**
Trimecaine 324.0  14.0 20.0  0.0 63.0  1.3
Lidocaine 366.8  94.8 10.0  0.0 68.0  2.8
Novocaine 310.0  43.7 10.0  0.0 60.0  0.0
Kazkain 600.0  0.0 208.9  7.3 280.0  0.0
*Compared to trimecaine.
**Compared with lidocaine.
***In comparison with novocaine.
****Compared to cascaine.
Table 2.
Activity and duration of action of compounds 1–10 (1% concentration) for conduction anesthesia.
Compound Regnier index
(М  m)
Duration of complete anesthesia
(М  m), min
Total duration of anesthesia
(М  m), min
1 85.6  5.0 0.0 14.4  1.5
2 242.5  16.4 0.0 33.1  1.6
3 186.3  9.7 0.0 28.0  2.4
4 150.6  16.2 0.0 27.5  1.9
5 281.6  18.5 0.0 38.0  1.9
6 13.0  0.0 0.0 0.0
7 103.0  10.5 0.0 22.0  0.9
8 373.4  37.3 0.0 43.1  4.0
9 601.5  32.7 0.0 62.0  2.3
10 430.0  14.4 0.0 48.75  2.1
Dikain 1300.0  0.0 65.0  0.0 120.0  0.0
Table 3.
Activity and duration of action of compounds 1–10 (1% concentration) for terminal anesthesia.
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This compound also turned out to be more active than the other tested com-
pounds. The anesthesia indices of 8 and 9 were almost the same as that for
trimecaine and were slightly greater than those for lidocaine, novocaine, and
kazcaine. The strength of the anesthesia induced by 4 and 7 was greater than that of
novocaine, equal to that of kazcaine, and less than that of trimecaine and lidocaine.
The anesthesia indices of 1–3 and 4 were less than those of the reference drugs.
Compound 10 had a longer duration of conduction anesthesia than the other tested
compounds (including the reference drugs).
Compounds 5 and 7–9 had longer durations of action than novocaine, shorter
than trimecaine, and essentially the same as lidocaine and kazcaine. The duration of
total anesthesia of 4was longer than that of novocaine and slightly shorter than that
of the other reference drugs. The durations of total anesthesia for 1 and 4 (10.0 and
8.3 min) were comparable with that of novocaine.
Table 2 presents results from a study of conduction anesthesia by 1–10.
Like in the preceding series of tests, 10 had the highest activity. Its anesthesia
index was greater than those of trimecaine, lidocaine, and novocaine and equal to
that of kazcaine. Compounds 1–5 and 7–9 were rather active. Their anesthesia
indices were greater than those of trimecaine, novocaine, and lidocaine. However,
they were less than that of kazcaine. Compound 6 was less active than the reference
drugs. Like in the preceding series of tests, the durations of total anesthesia of the
studied compounds were compared. Table 2 shows that all compounds 1–10 had
total anesthesia duration indices that were shorter than that of kazcaine although 3,
4, and 7–10 had durations of action longer than those of novocaine, lidocaine, and
trimecaine.
Compounds 1–10 in terminal anesthesia were weaker and shorter acting than
dicaine (Table 3). However, not one of these compounds exhibited an irritating
effect.
Thus, it was shown that amidoxime derivatives 1–10 exhibited anesthetic effects
that were greater than those of the reference drugs in conduction and infiltration
anesthesia. The 1,2,4-oxadiazoles 9 and 10 and to a lesser extent O-aroyl-
aminopropioamidoximes with a β-benzimidazole substituent 7 and 8 had longer
durations of action than the reference drugs.
3. Search for new antitubercular drugs among the salts and bases
of O-aroylation products of β-(thiomorfolin-1-yl)- and
β-(4-methylpiperazin-1-yl)propioamidoximes
A search for qualitatively new antitubercular drugs with the requirements of
reducing the duration of treatment, eliminating of the rapid drug resistance devel-
opment and toxic side effects of the existing antitubercular drugs, and reducing
the cost of extremely expensive treatment of TB (DS, MDR, XDR) is being
conducted in the world.
1,5-Diphenylpyrroles have been identified as a class of compounds with high
in vitro antitubercular activity. Replacing of the methylpiperazine substituent for
thiomorpholine and replacing the chlorine atom in position 4 of the N-phenyl
moiety with the fluorine atom, as well as varying the aromatic substituents at the
C-2 atom of the pyrrole ring during the transition from p-CH3 (BM221) to
p-CH3O (BM233) and to p-CH3S (BM579) in 1,5-(4-chlorophenyl)-2-methyl-3-
(4-methylpiperazin-1-yl)methyl-1H-pyrrole (BM212), leads to an increase in
in vitro antitubercular activity on M. tuberculosis H37Rv strains [13, 14].
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Taking into account the above examples, we synthesized compounds of the
β-aminopropioamidoxime series containing in the β-position fragments of
1-methylpiperazine and thiomorpholine (11–21).
In vitro antitubercular screening of a series of O-aroyl-β-aminopropioa-
midoximes (11–21) on DS museum H37Rv and wild* I MTB strains and two wild DR
and MDR strains of MTB II and III on Shkolnikova liquid medium found that
compounds 11–21 in varying degrees have antitubercular activity from >100 to
0.01 μg/ml (Table 4).
Thus, on the DS strains of MTB O-benzoyl-β-(thiomorpholin-1-yl)
propioamidoxime (18) and hydrochloride, iodomethylate of O-p-toluoyl-β-
(1-methylpiperazin-1-yl)propioamidoxime (21) showed the highest activity
at 0.01 μg/ml; compound 19 had an average antitubercular activity with
MBC >20 μg/ml; the remaining compounds 11–17 and 20 had MBC from 100
to >100 μg/ml.
The highest activity in 0.1 μg/ml on DR andMDR strains of MTB II and III was
shown by hydrochloride, iodomethylate ofO-p-toluoyl-β-(1-methylpiperazin-1-yl)
propioamidoxime (21) (Table 4).
The acute toxic effect of rifampicin, isoniazid, and compounds 18 and 21 (LD50)
was determined on white mice of both sexes weighing 17–23 g when administered
subcutaneously. The toxicity of rifampicin SV is 267.6  7.2 mg/kg; of isoniazid
62.5  12.8 mg/kg; and of compounds 18 and 21, respectively, 325.0  17.8 and
1750.0  35.6 mg/kg.
Thus, hydrochloride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazin-1-yl)
propioamidoxime, is by 100 times more active against DS strains than rifampicin
SV and by 10 times more active than isoniazid; it is by 20 times more active against
DR strains than rifampicin SV and by 10 times more active than isoniazid. Hydro-
chloride, iodomethyl O-p-toluoyl-β-(4-methylpiperazin-1-yl)propioamidoxime,
is less toxic than rifampicin SV by 6.5 times and by 28 times less toxic than
isoniazid.
O-Benzoyl-β-(thiomorpholin-1-yl)propioamidoxime is by 100 times more
active against DS strains than rifampicin SV and by 10 times more than isoniazid;
it is less toxic than rifampicin SV by 1.2 times and by 5.2 times less toxic than
isoniazid. These data are protected by the patents of the Republic of Kazakhstan
[7, 8].
32
Heterocycles - Synthesis and Biological Activities
Based on the high priority requirements of increasing the effectiveness and
safety of treatment in the development of new antitubercular drugs, it can be
argued that O-benzoyl-β-(thiomorpholin-1-yl)propioamidoxime and hydrochlo-
ride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazine-1-yl)propioamidoxime,
are competitive because they are less toxic and more active than the basic
tuberculostatics used in practice: isoniazid and rifampicin.
4. Inhibition of α-amylase and α-glucosidase by new
β-aminopropioamidoxime derivatives
The urgency of discovering effective medicines to treat diabetes and information
about the antidiabetic activity of amidoxime derivatives [9–11] prompted us to test
β-aminopropionamidoxime bases and pharmacologically acceptable salts of O-
aroyl-β-(morpholin-1-yl)propionamidoximes and 5-aryl-3-β-(piperidin-1-yl- and
morpholin-1-yl)ethyl-1,2,4-oxadiazoles for in vitro inhibitory activity against the
enzymes α-amylase and α-glucosidase, which determine the supply level of glucose
from the gastrointestinal tract into the blood pool.
Herein, results from in vitro screening of new β-aminopropionamidoximes
(22–26) for antidiabetic activity are now reported. The series of β-aminopropiona-
midoximes included bases and pharmacologically acceptable salts (hydrochloride,
acetate, oxalate, citrate, and methyl iodide) of O-aroyl-β-(morpholin-1-yl)
propionamidoximes 22–24 and 5-(p-, m-substituted phenyl)-3-(β-piperidin-1-yl-
and morpholin-1-yl)-1,2,4-oxadiazoles 25 and 26.
№ соmp. MBC on the M. tuberculosis strains, μg/ml
H37Rv I II III LD50, mg/kg
11 >100 >100 100 100 —
12 100 100 100 100 —
13 100 100 100 100 —
14 >100 >100 100 100 —
15 100 100 100 100 —
16 100 100 100 100 —
17 >100 >100 >100 >100 —
18 0.01 0.01 100 100 325.0  17.8
19 >20 >20 100 100 —
20 100 100 100 100 —
21 0.01 0.01 0.1 0.1 1750.0  35.6
Rifampicin 1 1 2 2 267.6  7.2
Isoniazid 0.1 0.1 1 1 62.5  12.8
*Wild strains of M. tuberculosis I, II, and III were isolated from the patients and typed in the RSE “National Scientific
Center for Phthisiopulmonology of the Republic of Kazakhstan” of the Ministry of Health of the Republic of
Kazakhstan: I, DS (drug-sensitive) to anti-TB drugs; II, DR (drug-resistant) to rifampicin; III, MDR (multidrug-
resistant) to rifampicin, isoniazid, and ethambutol.
Table 4.
Bactericidal activity and average subcutaneous toxicity of O-aroyl-β-(thiomorpholin-1-yl)propioamidoximes
(11–20) and double salt of O-p-toluoyl-(4-methylpiperazin-1-yl)propioamidoxime (21) on DS and DR
strains of M. tuberculosis.
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Taking into account the above examples, we synthesized compounds of the
β-aminopropioamidoxime series containing in the β-position fragments of
1-methylpiperazine and thiomorpholine (11–21).
In vitro antitubercular screening of a series of O-aroyl-β-aminopropioa-
midoximes (11–21) on DS museum H37Rv and wild* I MTB strains and two wild DR
and MDR strains of MTB II and III on Shkolnikova liquid medium found that
compounds 11–21 in varying degrees have antitubercular activity from >100 to
0.01 μg/ml (Table 4).
Thus, on the DS strains of MTB O-benzoyl-β-(thiomorpholin-1-yl)
propioamidoxime (18) and hydrochloride, iodomethylate of O-p-toluoyl-β-
(1-methylpiperazin-1-yl)propioamidoxime (21) showed the highest activity
at 0.01 μg/ml; compound 19 had an average antitubercular activity with
MBC >20 μg/ml; the remaining compounds 11–17 and 20 had MBC from 100
to >100 μg/ml.
The highest activity in 0.1 μg/ml on DR andMDR strains of MTB II and III was
shown by hydrochloride, iodomethylate ofO-p-toluoyl-β-(1-methylpiperazin-1-yl)
propioamidoxime (21) (Table 4).
The acute toxic effect of rifampicin, isoniazid, and compounds 18 and 21 (LD50)
was determined on white mice of both sexes weighing 17–23 g when administered
subcutaneously. The toxicity of rifampicin SV is 267.6  7.2 mg/kg; of isoniazid
62.5  12.8 mg/kg; and of compounds 18 and 21, respectively, 325.0  17.8 and
1750.0  35.6 mg/kg.
Thus, hydrochloride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazin-1-yl)
propioamidoxime, is by 100 times more active against DS strains than rifampicin
SV and by 10 times more active than isoniazid; it is by 20 times more active against
DR strains than rifampicin SV and by 10 times more active than isoniazid. Hydro-
chloride, iodomethyl O-p-toluoyl-β-(4-methylpiperazin-1-yl)propioamidoxime,
is less toxic than rifampicin SV by 6.5 times and by 28 times less toxic than
isoniazid.
O-Benzoyl-β-(thiomorpholin-1-yl)propioamidoxime is by 100 times more
active against DS strains than rifampicin SV and by 10 times more than isoniazid;
it is less toxic than rifampicin SV by 1.2 times and by 5.2 times less toxic than
isoniazid. These data are protected by the patents of the Republic of Kazakhstan
[7, 8].
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Based on the high priority requirements of increasing the effectiveness and
safety of treatment in the development of new antitubercular drugs, it can be
argued that O-benzoyl-β-(thiomorpholin-1-yl)propioamidoxime and hydrochlo-
ride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazine-1-yl)propioamidoxime,
are competitive because they are less toxic and more active than the basic
tuberculostatics used in practice: isoniazid and rifampicin.
4. Inhibition of α-amylase and α-glucosidase by new
β-aminopropioamidoxime derivatives
The urgency of discovering effective medicines to treat diabetes and information
about the antidiabetic activity of amidoxime derivatives [9–11] prompted us to test
β-aminopropionamidoxime bases and pharmacologically acceptable salts of O-
aroyl-β-(morpholin-1-yl)propionamidoximes and 5-aryl-3-β-(piperidin-1-yl- and
morpholin-1-yl)ethyl-1,2,4-oxadiazoles for in vitro inhibitory activity against the
enzymes α-amylase and α-glucosidase, which determine the supply level of glucose
from the gastrointestinal tract into the blood pool.
Herein, results from in vitro screening of new β-aminopropionamidoximes
(22–26) for antidiabetic activity are now reported. The series of β-aminopropiona-
midoximes included bases and pharmacologically acceptable salts (hydrochloride,
acetate, oxalate, citrate, and methyl iodide) of O-aroyl-β-(morpholin-1-yl)
propionamidoximes 22–24 and 5-(p-, m-substituted phenyl)-3-(β-piperidin-1-yl-
and morpholin-1-yl)-1,2,4-oxadiazoles 25 and 26.
№ соmp. MBC on the M. tuberculosis strains, μg/ml
H37Rv I II III LD50, mg/kg
11 >100 >100 100 100 —
12 100 100 100 100 —
13 100 100 100 100 —
14 >100 >100 100 100 —
15 100 100 100 100 —
16 100 100 100 100 —
17 >100 >100 >100 >100 —
18 0.01 0.01 100 100 325.0  17.8
19 >20 >20 100 100 —
20 100 100 100 100 —
21 0.01 0.01 0.1 0.1 1750.0  35.6
Rifampicin 1 1 2 2 267.6  7.2
Isoniazid 0.1 0.1 1 1 62.5  12.8
*Wild strains of M. tuberculosis I, II, and III were isolated from the patients and typed in the RSE “National Scientific
Center for Phthisiopulmonology of the Republic of Kazakhstan” of the Ministry of Health of the Republic of
Kazakhstan: I, DS (drug-sensitive) to anti-TB drugs; II, DR (drug-resistant) to rifampicin; III, MDR (multidrug-
resistant) to rifampicin, isoniazid, and ethambutol.
Table 4.
Bactericidal activity and average subcutaneous toxicity of O-aroyl-β-(thiomorpholin-1-yl)propioamidoximes
(11–20) and double salt of O-p-toluoyl-(4-methylpiperazin-1-yl)propioamidoxime (21) on DS and DR
strains of M. tuberculosis.
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Compounds 22–24a and b, 25, and 26 were described [12, 15, 16].
Compounds 24b–f were derived from the base of O-p-toluoyl-β-(morpholin-
1-yl)propionamidoxime 24a and were prepared in one step by adding of equivalent
amounts of organic acids (acetic, oxalic, citric) and methyl iodide in various sol-
vents. Acetate 24c was prepared by reacting 24a with a twofold excess of glacial
AcOH in refluxing in EtOH.
The in vitro activity of 22–26 for inhibition of α-amylase and α-glucosidase was
tested using two series of experiments. Table 5 presents the screening results using
acarbose as the standard in both instances.
The greatest inhibitory activities (50%) for α-amylase were found for O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 48%); 5-(p-
bromophenyl)-3-[(β-piperidin-1-yl)ethyl]-1,2,4-oxadiazole (25b, 51%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 48%). Moderate
activity for α-amylase (from 27 to 43%) was found for O-m-chlorobenzoyl-β-
(morpholin-1-yl)propionamidoxime hydrochloride (23, 35%); base O-p-toluoyl-β-
(morpholin-1-yl)propionamidoxime (24a, 32.5%); citrate of O-p-toluoyl-β-
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(morpholin-1-yl)propionamidoxime (24e, 37%); and 5-(p-toluoyl)-3-[(β-piperidin-
1-yl)ethyl]-1,2,4-oxadiazole (25a, 43%).
The highest inhibitory activities against α-glucosidase were exhibited by O-p-
anisoyl-β-(morpholin-1-yl)propionamidoxime (22a, 78.7%); iodine methylate of
O-p-toluoyl-β-(morpholin-1-yl)propionamidoxime (24f, 78.1%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 61.7%).
Moderate inhibitory activity for α-glucosidase was manifested by O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 23%) and its hydro-
chloride (23, 45.1%).
The reference compound acarbose exhibited the standard inhibitory activity
against α-amylase and α-glucosidase of 71.0 and 75.5%, respectively.
In conclusion, it is noteworthy that bases and pharmacologically acceptable salts
of O-aroyl-β-aminopropionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-
yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles (22–26) showed more pronounced
inhibitory activity for α-glucosidase than for α-amylase. Both 22a and 24f had
α-glucosidase activity comparable with that of the standard acarbose.
A structure–activity relationship for two series of screening experiments found
that, as a rule, 3,5-disubstituted 1,2,4-oxadiazoles exhibited greater inhibition of
α-amylase and α-glucosidase than their chemical precursors, i.e., bases and
pharmacologically acceptable salts of O-aroyl-β-aminopropionamidoximes.
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Compound 22a 22b 23 24a 24b 24c 24d Acarbose
Inhibition,
%
α-Amylase — 48.0  5.8 35.0  0.6 32.5  0.22 27.0  5.5 25.6  0.26 — 71.0  2.7
α-Glucosidase 78.7  0.9
1**
23.0  0.84 45.1  1.99 22.8  0.09 34.7  1.36 27.4  0.15 — 75.0  1.32
Compound 24e 24f 25a 25b 25c 26 Acarbose
Inhibition, % α-Amylase 37.0  3.4 — 43.0  3.0 51.0  9.1 — 48.0  5.9 71.0  2.7
α-Glucosidase — 78.1  4.41** 67.2  0.82 68.7  1.81 67.2  1.79 61.7  2.26 75.0  1.32
*Activity absent ().
**p > 0.05 vs. acarbose.
Table 5.
Inhibitory activity of 22–26 for α-amylase and α-glucosidase, %*.
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Compounds 22–24a and b, 25, and 26 were described [12, 15, 16].
Compounds 24b–f were derived from the base of O-p-toluoyl-β-(morpholin-
1-yl)propionamidoxime 24a and were prepared in one step by adding of equivalent
amounts of organic acids (acetic, oxalic, citric) and methyl iodide in various sol-
vents. Acetate 24c was prepared by reacting 24a with a twofold excess of glacial
AcOH in refluxing in EtOH.
The in vitro activity of 22–26 for inhibition of α-amylase and α-glucosidase was
tested using two series of experiments. Table 5 presents the screening results using
acarbose as the standard in both instances.
The greatest inhibitory activities (50%) for α-amylase were found for O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 48%); 5-(p-
bromophenyl)-3-[(β-piperidin-1-yl)ethyl]-1,2,4-oxadiazole (25b, 51%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 48%). Moderate
activity for α-amylase (from 27 to 43%) was found for O-m-chlorobenzoyl-β-
(morpholin-1-yl)propionamidoxime hydrochloride (23, 35%); base O-p-toluoyl-β-
(morpholin-1-yl)propionamidoxime (24a, 32.5%); citrate of O-p-toluoyl-β-
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(morpholin-1-yl)propionamidoxime (24e, 37%); and 5-(p-toluoyl)-3-[(β-piperidin-
1-yl)ethyl]-1,2,4-oxadiazole (25a, 43%).
The highest inhibitory activities against α-glucosidase were exhibited by O-p-
anisoyl-β-(morpholin-1-yl)propionamidoxime (22a, 78.7%); iodine methylate of
O-p-toluoyl-β-(morpholin-1-yl)propionamidoxime (24f, 78.1%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 61.7%).
Moderate inhibitory activity for α-glucosidase was manifested by O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 23%) and its hydro-
chloride (23, 45.1%).
The reference compound acarbose exhibited the standard inhibitory activity
against α-amylase and α-glucosidase of 71.0 and 75.5%, respectively.
In conclusion, it is noteworthy that bases and pharmacologically acceptable salts
of O-aroyl-β-aminopropionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-
yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles (22–26) showed more pronounced
inhibitory activity for α-glucosidase than for α-amylase. Both 22a and 24f had
α-glucosidase activity comparable with that of the standard acarbose.
A structure–activity relationship for two series of screening experiments found
that, as a rule, 3,5-disubstituted 1,2,4-oxadiazoles exhibited greater inhibition of
α-amylase and α-glucosidase than their chemical precursors, i.e., bases and
pharmacologically acceptable salts of O-aroyl-β-aminopropionamidoximes.
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Abstract
Cancer is one of the major life burdens and around 18.1 million new cancer 
cases and 9.6 million deaths have been estimated in 2018 globally. Recent reports 
of the World Health Organization (WHO) stated that about one in six death cases 
globally is mainly due to cancer. Hence, the development of efficacious drugs 
with novel mechanisms is necessary for various cancer types. The chemotherapy 
drug resistance and non-selectivity toward targets have turned the current cancer 
research on to the highly emerging selective targets for the development of potential 
anticancer agents. Benzimidazole is regarded as an essential pharmacophore of the 
cancer research because of wide anticancer potentials with versatile mechanisms to 
inhibit the tumor progression and also facile synthetic strategies for an easy syn-
thesis of various benzimidazole derivatives. The selective anticancer potentials also 
depend on the substitution of the benzimidazole nucleus. Therefore, it would lead 
to providing a path for the development of novel target-specific and highly effective 
benzimidazole-based anticancer agents.
Keywords: benzimidazole, cancer, specific targets, synthetic strategies
1. Introduction to cancer
Cancer is one of the dreadful diseases in the world and mainly characterized by 
uncontrolled cell proliferation. Worldwide, one in six women and one in five men 
develop cancer during their lifetime, and one in eleven women and one in eight men 
die from the disease. Global data clearly show that nearly half of the new cases and 
more than half of the cancer deaths worldwide in 2018 are estimated to occur in 
Asian countries because the region has nearly 60% of the global population and it 
is estimated to have a rise of over 21.4 million new cases per year, with 13.2 million 
cancer deaths, by 2030. The top three cancer types viz. breast, lung, and colorectal 
are responsible for one-third of the cancer incidence and mortality burden world-
wide [1, 2]. Behavioral risk factors such as tobacco usage and smoking; physical 
risk factors such as exposure to ionizing radiations and asbestos; and genetic 
predominant factors are the main contributors to cancer. Even though utmost care 
has been taken, the disease still causes the death of millions of people globally [3]. 
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is estimated to have a rise of over 21.4 million new cases per year, with 13.2 million 
cancer deaths, by 2030. The top three cancer types viz. breast, lung, and colorectal 
are responsible for one-third of the cancer incidence and mortality burden world-
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risk factors such as exposure to ionizing radiations and asbestos; and genetic 
predominant factors are the main contributors to cancer. Even though utmost care 
has been taken, the disease still causes the death of millions of people globally [3]. 
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Although scientific advances have focused on knowing the exact pathophysiology 
of the disease and tremendous efforts have been made on early diagnosis of cancer, 
the overall mortality rate has not subsided. Moreover, the cancer survival rate tends 
to be extremely low in some developing countries. This is due to the combination of 
both late-stage detection and limited access to time and qualitative treatment [4].
Radiotherapy, surgery, and chemotherapy are the usual cancer treatment strategies 
[5]. Among these, chemotherapy is considered as one of the efficient and first-line 
strategies in suppressing tumor prognosis and eradication. Most of the chemothera-
peutic drugs target the key cellular mechanisms and inhibit the cell division and 
thereby prevent cancer cell multiplication. Current clinical anticancer drugs usually 
act on metabolically effective or fast replicating cells and show drawbacks such as poor 
selectivity between cancer cells and healthy cells [6]. Cancer cells generally disturb the 
cell signaling pathways and tissue morphogenesis for the neoplastic propagation of 
tumors. Therefore, targeting these cell pathways by cytotoxic agents has been a proven 
therapeutic approach to subside tumor growth and disease progression. Unfortunately, 
most of the cytotoxic drugs cause side effects due to the poor selectivity and specific-
ity toward cancer cells. However, the higher toxic profiles and poor tolerance of the 
present chemotherapeutic drugs are major obstacles to the effective treatment of 
cancer [7, 8]. Therefore, it is highly pertinent to design and synthesize new anticancer 
agents with improved efficiency and reduced side effects to complement the present 
DNA interacting agents
Alkylating agents Alkylation of DNA bases
Procarbazine, dacarbazine, and temozolomide
DNA cleaving agents Cause strand scission at the binding site-Bleomycin
Cross-linking agents Binding to DNA results in intra- and inter-strand cross-linking
Platinum complexes-carboplatin, cisplatin, oxaliplatin
Nitrogen mustards-cyclophosphamide, ifosfamide
Intercalating agents Stacking between DNA base pairs
Anthracyclines-doxorubicin, epirubicin
Mitoxantrone and actinomycin-D
Topoisomerase inhibitors Topoisomerase I-camptothecins
Topoisomerase II-Anthracyclines, etoposide
Anti-metabolites
Purine analogues Mercaptopurine
Pyrimidine analogues 5-Fluorouracil
DHFR inhibitors Methotrexate
Antitubulin agents
Taxol Paclitaxel, Docetaxel
Vinca alkaloids Vincristine, Vinblastine, Vinorelbine
Tyrosine kinase inhibitors
Small molecule Imatinib (Gleevec): inhibits ABL, c-Kit kinase, PDGFR
Gefitinib (Iressa): inhibits EGFR
Monoclonal antibody Trastuzumab: inhibits EGFR2, HER2
Angiogenesis/ Metastasis inhibitors
Monoclonal antibody Bevacizumab (Avastin): targets VEGF
Table 1. 
Common anticancer drugs along with their mechanisms of action.
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chemotherapeutic approaches. Identifying new drugs and drug  combinations for 
cancer treatment is essential to combat this lethal disease. Hence, further research 
that emphasizes mainly on the development of efficient chemotherapeutic agents is 
an emerging area of research in the field of medicinal chemistry. The list of various 
available chemotherapeutic agents has been shown in Table 1 [9].
2. Introduction to Benzimidazole
Benzimidazole heterocyclic nucleus can be termed as “Master Key” due to its 
overwhelming biological profile and synthetic applications in medicinal chem-
istry. It is among the top five most common five-membered aromatic nitrogen 
heterocycles in U.S. FDA-approved pharmaceutical drugs [10]. Benzimidazoles 
are structural isosteres of nucleobases due to the fused nitrogen nuclei and they 
readily interact with biomolecular targets and elicit many biological activities such 
as anticancer [11], anti-inflammatory [12], antiulcer [13], anti-hypertensive [14], 
and anthelmintic [15]. Akhtar et al. in his recent review described the therapeutic 
evolution of benzimidazole scaffolds during the last quinquennial period [16]. 
This nitrogen-containing heterocycle was present in a number of well-established 
clinical drugs with diverse therapeutic activities. For instance, drugs like rabepra-
zole (1) and omeprazole (2) are benzimidazole-containing drugs, act as proton 
pump inhibitors, and are, therefore, used in the treatment of stomach ulcers [17]. 
Albendazole (3) and thiabendazole (4) are anthelmintic drugs that act by the 
inhibition of tubulin polymerization and impair the uptake of glucose, eventually 
leading to the death of the parasites [18]. Nocodazole (5) is a well-recognized anti-
neoplastic agent that mainly acts by tubulin polymerization inhibition. Candesartan 
(6) is a benzimidazole-based orally active potent angiotensin II receptor antagonist 
that is used for the treatment of hypertension [19]. Bendamustine (7) is nitrogen 
mustard which belongs to alkylating agents, a class of chemotherapeutic agent 
and used in the treatment of chronic lymphomas [20]. Dovotininb (8) is the orally 
active benzimidazole quinolinone compound with potential antineoplastic activ-
ity (Figure 1). It strongly binds to the fibroblast growth receptor 3 (FGFR3) and 
inhibits its phosphorylation and induces tumor cell death [21].
Figure 1. 
Examples of drugs and other bioactive molecules containing benzimidazole motif.
Heterocycles - Synthesis and Biological Activities
40
Although scientific advances have focused on knowing the exact pathophysiology 
of the disease and tremendous efforts have been made on early diagnosis of cancer, 
the overall mortality rate has not subsided. Moreover, the cancer survival rate tends 
to be extremely low in some developing countries. This is due to the combination of 
both late-stage detection and limited access to time and qualitative treatment [4].
Radiotherapy, surgery, and chemotherapy are the usual cancer treatment strategies 
[5]. Among these, chemotherapy is considered as one of the efficient and first-line 
strategies in suppressing tumor prognosis and eradication. Most of the chemothera-
peutic drugs target the key cellular mechanisms and inhibit the cell division and 
thereby prevent cancer cell multiplication. Current clinical anticancer drugs usually 
act on metabolically effective or fast replicating cells and show drawbacks such as poor 
selectivity between cancer cells and healthy cells [6]. Cancer cells generally disturb the 
cell signaling pathways and tissue morphogenesis for the neoplastic propagation of 
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therapeutic approach to subside tumor growth and disease progression. Unfortunately, 
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ity toward cancer cells. However, the higher toxic profiles and poor tolerance of the 
present chemotherapeutic drugs are major obstacles to the effective treatment of 
cancer [7, 8]. Therefore, it is highly pertinent to design and synthesize new anticancer 
agents with improved efficiency and reduced side effects to complement the present 
DNA interacting agents
Alkylating agents Alkylation of DNA bases
Procarbazine, dacarbazine, and temozolomide
DNA cleaving agents Cause strand scission at the binding site-Bleomycin
Cross-linking agents Binding to DNA results in intra- and inter-strand cross-linking
Platinum complexes-carboplatin, cisplatin, oxaliplatin
Nitrogen mustards-cyclophosphamide, ifosfamide
Intercalating agents Stacking between DNA base pairs
Anthracyclines-doxorubicin, epirubicin
Mitoxantrone and actinomycin-D
Topoisomerase inhibitors Topoisomerase I-camptothecins
Topoisomerase II-Anthracyclines, etoposide
Anti-metabolites
Purine analogues Mercaptopurine
Pyrimidine analogues 5-Fluorouracil
DHFR inhibitors Methotrexate
Antitubulin agents
Taxol Paclitaxel, Docetaxel
Vinca alkaloids Vincristine, Vinblastine, Vinorelbine
Tyrosine kinase inhibitors
Small molecule Imatinib (Gleevec): inhibits ABL, c-Kit kinase, PDGFR
Gefitinib (Iressa): inhibits EGFR
Monoclonal antibody Trastuzumab: inhibits EGFR2, HER2
Angiogenesis/ Metastasis inhibitors
Monoclonal antibody Bevacizumab (Avastin): targets VEGF
Table 1. 
Common anticancer drugs along with their mechanisms of action.
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chemotherapeutic approaches. Identifying new drugs and drug  combinations for 
cancer treatment is essential to combat this lethal disease. Hence, further research 
that emphasizes mainly on the development of efficient chemotherapeutic agents is 
an emerging area of research in the field of medicinal chemistry. The list of various 
available chemotherapeutic agents has been shown in Table 1 [9].
2. Introduction to Benzimidazole
Benzimidazole heterocyclic nucleus can be termed as “Master Key” due to its 
overwhelming biological profile and synthetic applications in medicinal chem-
istry. It is among the top five most common five-membered aromatic nitrogen 
heterocycles in U.S. FDA-approved pharmaceutical drugs [10]. Benzimidazoles 
are structural isosteres of nucleobases due to the fused nitrogen nuclei and they 
readily interact with biomolecular targets and elicit many biological activities such 
as anticancer [11], anti-inflammatory [12], antiulcer [13], anti-hypertensive [14], 
and anthelmintic [15]. Akhtar et al. in his recent review described the therapeutic 
evolution of benzimidazole scaffolds during the last quinquennial period [16]. 
This nitrogen-containing heterocycle was present in a number of well-established 
clinical drugs with diverse therapeutic activities. For instance, drugs like rabepra-
zole (1) and omeprazole (2) are benzimidazole-containing drugs, act as proton 
pump inhibitors, and are, therefore, used in the treatment of stomach ulcers [17]. 
Albendazole (3) and thiabendazole (4) are anthelmintic drugs that act by the 
inhibition of tubulin polymerization and impair the uptake of glucose, eventually 
leading to the death of the parasites [18]. Nocodazole (5) is a well-recognized anti-
neoplastic agent that mainly acts by tubulin polymerization inhibition. Candesartan 
(6) is a benzimidazole-based orally active potent angiotensin II receptor antagonist 
that is used for the treatment of hypertension [19]. Bendamustine (7) is nitrogen 
mustard which belongs to alkylating agents, a class of chemotherapeutic agent 
and used in the treatment of chronic lymphomas [20]. Dovotininb (8) is the orally 
active benzimidazole quinolinone compound with potential antineoplastic activ-
ity (Figure 1). It strongly binds to the fibroblast growth receptor 3 (FGFR3) and 
inhibits its phosphorylation and induces tumor cell death [21].
Figure 1. 
Examples of drugs and other bioactive molecules containing benzimidazole motif.
Heterocycles - Synthesis and Biological Activities
42
In 1954, Tamm, Folkers, and co-workers first reported the synthesis and anti-
viral activities of halogenated benzimidazole nucleosides [22]. They found that 
5,6-dichloro-1-β-D-ribofuranosyl benzimidazole (DRB) has multiple biological 
activities including activity against RNA and DNA viruses. DRB inhibits cellular 
RNA polymerase II, thus affecting the multiple cellular processes so that it is more 
cytotoxic than antiviral. Slayden et al. found that albendazole (3) and thiaben-
dazole (4) known tubulin inhibitors interfered and delayed the Mtb cell division 
processes [23]. Later, Kumar et al. proposed that the benzimidazole core would be a 
novel FtsZ inhibitor, which will have activity against both drug-sensitive and drug-
resistant Mtb [24]. This molecular framework displays numerous biological proper-
ties and is usually present in various drug compositions. Benzimidazoles tethered to 
various bioactive pharmacophores have also displayed potent antitumor activities.
Benzimidazoles have revolutionized the drug discovery process by their diverse 
range of biological activities, which make this scaffold an indispensable anchor for 
the innovation of novel therapeutic agents. Thus, the therapeutic potential of the 
benzimidazole and related drugs has attracted researchers to design and synthesize 
more potent derivatives with a wide range of pharmacological activities. Owing to 
the immense synthetic value and extended bioactivities exhibited by benzimid-
azoles and their derivatives, efforts have been made from time to time to create 
libraries of these compounds.
3. Target-based benzimidazole derivatives
3.1 Galectin-1 inhibitors
Galectin-1 (Gal-1) is expressed in various normal and pathological conditions 
and has multiple functions with a wide range of biological activity. Gal-1, a human 
homodimeric lectin protein of 14KDa, is implicated in many signaling pathways, 
immune responses associated with cancer progression, neurological conditions, and 
immune disorders [25]. Gal-1 has a carbohydrate recognition domain (CRD), which 
is selective toward β-galactosides in the body. Inhibition of human Gal-1 has been 
regarded as one of the potential therapeutic approaches for the treatment of cancer, 
as it plays a major role in tumor development and metastasis by modulating vari-
ous biological functions viz. angiogenesis, apoptosis, migration, and cell immune 
escape [26]. The overexpression of Gal-1 has been reported in many cancer types 
like the brain, breast, osteosarcoma, lung, prostate, melanoma, etc. [27]. Gal-1 can 
mediate neoplastic transformation by interacting with oncogenes, such as H-Ras 
and promote Ras-mediated signal transduction involving RAF1 and extracellular 
signal-regulated kinase (ERK). Gal-1 multivalently mediates tumor cell-ECM adhe-
sion at the primary site by cross-linking cell surface glycoproteins, such as integrins, 
and glycosylated proteins in the ECM, such as laminin and fibronectin [28]. Hence, 
Gal-1 is regarded as a promising molecular target for the development of new 
therapeutic drugs for cancer.
Recently, a new series of 1-benzyl-1H-benzimidazole derivatives have been 
synthesized as Gal-1-mediated anticancer agents. The target compound (9) showed 
significant growth inhibition against breast cancer (MCF-7) cells with an IC50 
value of 7.01 ± 0.20 μM. The target compound also showed good cytotoxicity in 
the range of 10.69–14.04 μM against colorectal cancer (HCT-116), breast cancer 
(MDA-MB-231), prostate cancer (DU-145), and lung cancer (A-549). In addition, 
in-vitro Gal-1 expression in cell supernatant of MCF-7 cells with compound (9) was 
measured in enzymatic GAL-1 ELISA studies and found to show dose-dependent 
reduction from 10 to 300 μM. The target compound showed Gal-1-mediated 
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apoptosis, which was confirmed by morphological changes in MCF-7-treated cells 
like blebbing, cell wall deformation, and cell shrinkage, based on the apoptosis 
studies such as Acridine Orange/Ethidium Bromide (AO/EB) staining, DAPI nucleic 
acid staining, mitochondrial membrane potential, annexin V/propidium iodide dual 
staining assay, and dichlorofluorescein (DCF) fluorescence studies. In cell cycle 
analysis, the target compound selectively arrested MCF-7 cell growth at the G2/M 
phase and S phase. Further, the binding specificity of target compound toward 
Gal-1 was confirmed by surface plasmon resonance and fluorescence spectroscopy 
studies and the specific binding constant value (Ka) of 1.2 × 104 M−1 was observed 
in fluorescence spectroscopy studies, whereas the equilibrium constant (KD) value 
of 5.76 × 10−4 M was observed in surface plasmon resonance studies. The bind-
ing of the target compound to Gal-1 was also confirmed by RP-HPLC studies and 
found to show 85.44% of binding to Gal-1. The molecular docking studies were also 
supported based on the strong amino acid interactions such as ARG48, TRP68, and 
ASP125 with the target compound [29, 30].
Tsung-Chieh Shih et al. reported a novel Gal-1 inhibitor named LLS2 (10), 
which was discovered through the One-Bead-Two-Compound library. The inter-
action of target gal-1 with LLS2 was confirmed by LC-MS/MS analytical and 
pull-down assay. The binding complex of LLS2 with Gal-1 selectively decreases 
membrane-specific H-Ras, and K-Ras pathways, lead to involve in the apoptosis 
process. The LLS2 exhibited a synergistic effect in combination with paclitaxel 
against many of the human cancer cell lines such as pancreatic cancer, ovarian 
cancer, and breast cancer cells in vitro. The combination of paclitaxel with LLS2 
efficiently reduces the growth of ovarian cancer xenografts in athymic mice in vivo 
(Figure 2).
The same group recently published a more potent Gal-1 inhibitor LLS3 (11), it 
impairs castration-resistant prostate cancer progression and invasion. LLS3 targets 
Gal-1 as an allosteric inhibitor, and reduces Gal-1 binding affinity toward its bind-
ing partners and also causes suppression of Akt, and AR signaling pathways. LLS3 
showed in vivo efficacy in both androgen receptor-positive and negative xenograft 
models. In addition to potentiating the anticancer effect of docetaxel to cause sup-
pression of tumors, it also efficiently suppresses the progression of prostate cancer 
cells in vivo [31, 32].
3.2 Tubulin protein inhibitors
Tubulin is one of the members of a small family of globular proteins. Several 
isoforms are present out of which α- and β-tubulins are the most common members 
of tubulin. The cellular protein tubulin is an important protein for replication. 
Figure 2. 
The novel benzimidazole derivatives as Gal-1 mediated anticancer agents.
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apoptosis, which was confirmed by morphological changes in MCF-7-treated cells 
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in fluorescence spectroscopy studies, whereas the equilibrium constant (KD) value 
of 5.76 × 10−4 M was observed in surface plasmon resonance studies. The bind-
ing of the target compound to Gal-1 was also confirmed by RP-HPLC studies and 
found to show 85.44% of binding to Gal-1. The molecular docking studies were also 
supported based on the strong amino acid interactions such as ARG48, TRP68, and 
ASP125 with the target compound [29, 30].
Tsung-Chieh Shih et al. reported a novel Gal-1 inhibitor named LLS2 (10), 
which was discovered through the One-Bead-Two-Compound library. The inter-
action of target gal-1 with LLS2 was confirmed by LC-MS/MS analytical and 
pull-down assay. The binding complex of LLS2 with Gal-1 selectively decreases 
membrane-specific H-Ras, and K-Ras pathways, lead to involve in the apoptosis 
process. The LLS2 exhibited a synergistic effect in combination with paclitaxel 
against many of the human cancer cell lines such as pancreatic cancer, ovarian 
cancer, and breast cancer cells in vitro. The combination of paclitaxel with LLS2 
efficiently reduces the growth of ovarian cancer xenografts in athymic mice in vivo 
(Figure 2).
The same group recently published a more potent Gal-1 inhibitor LLS3 (11), it 
impairs castration-resistant prostate cancer progression and invasion. LLS3 targets 
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ing partners and also causes suppression of Akt, and AR signaling pathways. LLS3 
showed in vivo efficacy in both androgen receptor-positive and negative xenograft 
models. In addition to potentiating the anticancer effect of docetaxel to cause sup-
pression of tumors, it also efficiently suppresses the progression of prostate cancer 
cells in vivo [31, 32].
3.2 Tubulin protein inhibitors
Tubulin is one of the members of a small family of globular proteins. Several 
isoforms are present out of which α- and β-tubulins are the most common members 
of tubulin. The cellular protein tubulin is an important protein for replication. 
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The novel benzimidazole derivatives as Gal-1 mediated anticancer agents.
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Microtubules are hallowing filaments and composed of head and tail polar fashion 
arrangements of α- and β-tubulins as the constituent subunits. Microtubules con-
tain 13 active protofilaments aligned parallel with the whole axis of the microtubule 
cylinder. This may provide continuous transport of cellular materials by motor pro-
teins (dynein and kinesin) over distant places. Microtubules also form an integral 
part of the cytoskeleton and are responsible for the maintenance of cell shape, and 
motility and intracellular transport of the vesicles, mitochondria, and other com-
ponents [33, 34]. Moreover, cell division involves the duplication of DNA and the 
segregation of the replicated chromosomes into two daughter nuclei. The segrega-
tion of these chromosomes is mitotic phase is brought by the microtubules. In the 
formation of the microtubule, the plus (+) end is terminated by β-tubulin whereas 
the minus (−) end is terminated by α-tubulin. They are always either in a state of 
polymerization or depolymerization. Microtubules have the ability to shorten or 
lengthen in a scholastic fashion through loss or addition of α/β-tubulin heterodi-
mers from ends of microtubules. This property is referred to as “dynamic instabil-
ity” [35, 36]. Microtubules are blessed with a property to grow continuously as long 
as the free tubulin amount is above a critical level. The critical concentration at the 
minus end is somewhat higher than at the plus end and the minus end tends to stop 
growing first. Even above the critical tubulin concentration, its end may suddenly 
stop growing and begin to shrink. The change from growth to shrinkage has been 
termed as “catastrophe.” After some time, a shrinking microtubule end may “pause” 
and/or begin to grow again; the latter process is known as “rescue.” During mitotic 
cell division, the chromosomes are segregated by the mitotic spindle, which is 
formed from tubulin microtubules. Therefore, tubulin dynamics have a distinct role 
in cell division. Some of the drugs affect the microtubulin dynamics and thus cause 
either polymerization or depolymerization and thereby alter cellular replication. 
So at the mechanistic level, tubulin is one of the most attractive and challenging 
approaches for designing new anticancer compounds.
Zhang et al. have synthesized a series of 1,2-diarylbenzimidazole derivatives 
and reported as potential anticancer agents. Among all, the target molecule (12) 
has been found to show significant cytotoxicity against human cancer cells such 
as A549, HepG2, HeLa, and MCF-7 cells in the range of GI50 = 0.71–2.41 μM and 
also found to show normal cytotoxicity toward normal cells. The apoptosis process 
by the target compound was confirmed by morphological changes on HepG2 and 
HeLa-treated cells like cell wall deformation, blebbing, and cell shrinkage, based on 
apoptosis studies such as mitochondrial membrane potential, annexin V/propidium 
iodide dual staining assay, and dichlorofluorescein (DCF) fluorescence studies. 
In cell cycle analysis, the target compound selectively arrested tumor growth at 
the G2/M phase. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 value of 8.47 μM. The molecular docking 
simulation studies were performed to confirm the binding of the target compound 
with microtubule protein and found that the target compound has made strong 
interactions with protein [37].
Miao et al. reported a novel series of 2-aryl-benzimidazole-based dehydroabietic 
acid derivatives as potential cytotoxic agents via targeting tubulin polymeriza-
tion. The synthesized molecules were characterized by elemental and analytical 
techniques. The target compound (13) showed significant growth inhibition 
against hepatocarcinoma cancer (SMMC-7721) cells with an IC50 value of 
0.08 ± 0.01 μM. The target compound also showed good cytotoxicity in the range 
of 0.04–0.07 μM against breast cancer (MDA-MB-231), cervical cancer (HeLa), 
and colon cancer (CT-26). The apoptosis studies such as ROS levels measurements, 
loss of mitochondrial membrane potential, and cell cycle analysis were performed 
to confirm the induction of apoptosis in hepatocarcinoma cancer (SMMC-7721) 
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cells. In cell cycle analysis, the target compound selectively arrested tumor growth 
at the G2/M phase. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 of 5 μM. The molecular docking studies 
supported the selectivity of the target compound to tubulin protein based on strong 
electronic interactions between the target compounds and tubulin [38].
Wang et al. reported a new series of benzimidazole containing benzsulfamide-
pyrazole ring derivatives as potential tubulin polymerization inhibitors. The 
target compound (14) showed significant growth inhibition against lung cancer 
(A549) cells with an IC50 value of 0.15 ± 0.05 μM and also showed good growth 
inhibition against Hela, HepG2, and MCF-7 cell lines in the range of 0.17–0.33 μM 
concentration. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 value of 1.52 μM. In cell cycle analysis, 
the target compound selectively arrested A549 cell growth at the G2/M phase. The 
target compound showed A549 cell apoptosis based on the studies of annexin V/
propidium iodide dual staining assay and cell cycle analysis. The molecular docking 
studies were also supported based on the strong amino acid interactions such as LYS 
352, LYS 254, ASN 258, and CYS 241 with the target compound [39] (Figure 3).
Baig et al. have reported a series of imidazo [2,1-b] thiazole-benzimidazole 
derivatives as antiproliferative agents via tubulin polymerization inhibition. The 
target molecule (15) has shown significant cytotoxicity against human lung (A549) 
cancer with an IC50 value of 1.08 μM. It also showed good cytotoxicity toward 
DU-145 (prostate), MCF-7 (breast cancer), A549 (lung cancer), and HeLa (cervi-
cal cancer) in the range of 1.65–7.55 μM. In cell cycle analysis, the target compound 
selectively arrested A549 cell growth at the G2/M phase. The target compound 
showed apoptosis, which was confirmed by morphological changes in A549-treated 
cells like blebbing, cell wall deformation, and cell shrinkage, based on the apoptosis 
studies such as Hoechst staining, mitochondrial membrane potential, annexin V/
propidium iodide dual staining assay. Further, the target compound exhibits a 
significant inhibition of microtubule assembly with an IC50 of 1.68 μM. The com-
putational studies revealed that the target compound can easily be occupied in the 
colchicine binding site of the protein [40].
3.3 Carbonic anhydrase inhibitors
The human carbonic anhydrases (hCAs) are an α-family of carbonic anhydrases 
class and exist in 16 different isoforms [41]. Based on their location in the body, 
Figure 3. 
The target benzimidazole derivatives as selective anticancer agents via targeting tubulin polymerization.
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they are classified into cytosolic hCAs such as CA I, CA II, CA III, CA VII, and CA 
XIII; transmembrane hCAs such as CA IV, CA IX, CA XII, CA XIV, and CA XV; 
mitochondrial-bound hCAs such as CA Va and Vb; secretory hCAs such as CA VI; 
and catalytically inactive isoforms like CA VIII, CA X, and CA XI, which are consid-
ered as CA-related proteins (CARPs) [42]. Among all, the hCA isoforms IX and XII 
are overexpressed in many of cancer types as these are tumor-associated transmem-
brane bound enzymes, mainly hypoxic tumors, which are regarded as emerging 
potential targets for various tumor types [43]. The overexpression of hCA isoforms 
IX and XII further contributes to the tumor progression, angiogenesis, metastasis, 
and proliferation of a variety of tumor cells [44]. In order to exhibit potential 
cytotoxicity without adverse effects, an anticancer agent should selectively inhibit 
tumor-associated hCAs IX and XII over other hCAs. Therefore, current cancer 
research focuses on the development of various heterocycles that selectively target 
tumor-linked hCA isoforms IX and XII for effective treatment strategies in cancer 
therapy [45]. Another hCA isoform II is also found to overexpress in some forms of 
cancer and other conditions like edema, glaucoma, and epilepsy.
Recently, a new series of 2-substituted-benzimidazole-6-sulfonamides have been 
reported as anticancer potentials by testing against four physiologically relevant 
hCAs such as CA I, CA II, CA IX, and CA XII. The analysis of hCA inhibition results 
showed that the new series of benzimidazole-based sulfonamide derivatives exhib-
ited selective inhibition toward tumor-associated isoforms such as CA IX and CA 
XII. The target molecule (16) of this series had shown a promising inhibition at low 
μM range against hCA IX and XII isoform, with an inhibitory constant (Ki) value of 
2.2 and 22.3 μM. Another potent compound (17) also exhibited good inhibition at 
low μM range against hCA IX and XII, with an inhibitory constant (Ki) value of 5.9 
and 7.9 μM respectively. Hence, it is concluded that these benzimidazole derivatives 
might be potential anticancer agents exhibiting a novel mechanism through inhibi-
tion of hCA isoforms IX and XII [46]. Asta Zubriene et al. have reported a series 
of novel benzenesulfonamides with benzimidazole derivatives as selective human 
carbonic anhydrase I, II, VII, XII, and XIII inhibitors. The target molecules were 
synthesized from the precursor benzimidazole derivative with different phenacyl 
bromides. The target molecules (18, 19) were evaluated against five physiologi-
cal relevant hCA isoforms (hCA, EC 4.2.1.1) CA I, CA II, CA VII, CA XII, and 
CA XIII. The target compound exhibited a promising inhibitory action at a lower 
nanomolar level against selected hCAs with an inhibitory constant (Ki) value range 
of 1.67–66.7 μM. Another target molecule has shown significant inhibition at lower 
nanomolar level against selected hCAs with an inhibitory constant (Ki) value range 
of 2.86–62.5 μM [47] (Figure 4).
3.4 Epidermal growth factor receptor (EGFR) inhibitors
The Epidermal Growth Factor Receptor is a subfamily transmembrane glyco-
protein (ErbB-1) of ErbB class of tyrosine kinase receptors and, other subfamilies 
include HER2/neu (ErbB-2), Her 3 (ErbB-3) and, Her 4 (ErbB-4) [48]. The inter-
nal ligands like EGF and TGF𝛼𝛼 facilitate the growth-promoting signal to cells by 
interacting with EGFR receptors and regulate epithelial tissue development and 
homeostasis [49, 50]. In cancer, especially epithelial malignancies, due to overpro-
duction of EGFR ligands in the tumor micro environment causes continual activa-
tion (or) mutations of EGFR receptors, result in enhances epithelial tumor growth, 
metastasis and invasion [51, 52].
In a recent study, a new series of benzimidazole-based triazole and thiadiazole 
derivatives were synthesized and evaluated as selective EGFR inhibitors. The single-
crystal X-ray crystallographic analysis has been performed to confirm the molecular 
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structure of the target compound. The synthesized compounds were evaluated for 
their EGFR kinase inhibitory potencies with erlotinib as the reference standard and, 
most of the compounds showed promising activities. The cell inhibition studies 
were also performed and the target compound (20) exhibited a significant inhibi-
tion and exhibited EGFR kinase inhibitory activity (over ≥30%) against MCF7 
cells. The molecular docking studies indicated that the target compound showed 
two-hydrogen bonding interactions with residues of LYS721 and THR830 at the 
binding site of EGFR tyrosine kinase [53]. Akhtar et al. reported the benzimid-
azole-oxadiazole hybrids as selective EGFR and erbB2 receptor inhibitors. In in vitro 
cell inhibition studies, the target compound (21) exhibited a significant inhibition 
with an IC50 of 5.0 μM against breast cancer (MCF-7) cells. The target compound 
was found to show significant inhibition of EGFR and erbB2 receptor at 0.081 
and 0.098 μM respectively. Most of the synthesized compounds exhibited a good 
cytotoxic activity against selected human cancer cell lines. In cell cycle analysis, the 
target compound selectively arrested MCF-7 cell growth at the G2/M phase. The 
computational and 3D-QSAR studies indicated that the target compound exhibited 
strong interactions with Asp831, Met769, and Thr830 of the EGFR enzyme [54].
Akhtar et al. have synthesized benzimidazole-based pyrazole derivatives 
through a one-pot multicomponent reaction and evaluated them for their poten-
tial anticancer activities. The synthesized compounds were screened against 
selected human cancer cell lines such as MCF-7, MDA-MB231, A549, HepG2, and 
HaCaT. The evaluation of EGFR inhibitory activities was performed for all the syn-
thesized compounds. The target compound (22) exhibited promising cytotoxicity 
against the lung (A549) cancer cell lines with an IC50 value of 2.2 mM and the EGFR 
receptor inhibition value with an IC50 of 0.97 mM. In cell cycle analysis, the target 
compound selectively arrested A549 cell growth at the G2/M phase. In addition, 
it suppressed the growth of lung cancer cells by inducing apoptosis. In molecular 
docking studies, the target compound showed strong electronic interactions with 
Met769, Thr830, Lys721, and Phe699 of the active pocket of the EGFR receptor [55]. 
Yuan et al. have synthesized a library of 6-amide-2-aryl benzoxazole/benzimid-
azole derivatives and evaluated them for their selective inhibitory activities against 
VEGFR-2. The library of compounds exhibited selective anticancer activity against 
the liver hepatocellular carcinoma (HepG2), and human umbilical vein endothelial 
cells (HUVECs) over the lung cancer (A549) and breast (MDA-MB-231) cancer 
Figure 4. 
The benzimidazole derivatives as human carbonic anhydrase enzyme mediated anticancer agents.
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structure of the target compound. The synthesized compounds were evaluated for 
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binding site of EGFR tyrosine kinase [53]. Akhtar et al. reported the benzimid-
azole-oxadiazole hybrids as selective EGFR and erbB2 receptor inhibitors. In in vitro 
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and 0.098 μM respectively. Most of the synthesized compounds exhibited a good 
cytotoxic activity against selected human cancer cell lines. In cell cycle analysis, the 
target compound selectively arrested MCF-7 cell growth at the G2/M phase. The 
computational and 3D-QSAR studies indicated that the target compound exhibited 
strong interactions with Asp831, Met769, and Thr830 of the EGFR enzyme [54].
Akhtar et al. have synthesized benzimidazole-based pyrazole derivatives 
through a one-pot multicomponent reaction and evaluated them for their poten-
tial anticancer activities. The synthesized compounds were screened against 
selected human cancer cell lines such as MCF-7, MDA-MB231, A549, HepG2, and 
HaCaT. The evaluation of EGFR inhibitory activities was performed for all the syn-
thesized compounds. The target compound (22) exhibited promising cytotoxicity 
against the lung (A549) cancer cell lines with an IC50 value of 2.2 mM and the EGFR 
receptor inhibition value with an IC50 of 0.97 mM. In cell cycle analysis, the target 
compound selectively arrested A549 cell growth at the G2/M phase. In addition, 
it suppressed the growth of lung cancer cells by inducing apoptosis. In molecular 
docking studies, the target compound showed strong electronic interactions with 
Met769, Thr830, Lys721, and Phe699 of the active pocket of the EGFR receptor [55]. 
Yuan et al. have synthesized a library of 6-amide-2-aryl benzoxazole/benzimid-
azole derivatives and evaluated them for their selective inhibitory activities against 
VEGFR-2. The library of compounds exhibited selective anticancer activity against 
the liver hepatocellular carcinoma (HepG2), and human umbilical vein endothelial 
cells (HUVECs) over the lung cancer (A549) and breast (MDA-MB-231) cancer 
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cell lines. The target compound exhibited a significant growth inhibition against 
HepG2 and HUVEC with IC50 values of 1.47 and 2.57 mM, respectively. The target 
compound (23) showed anti-angiogenesis ability (79% inhibition at 10 nM/eggs) 
by chick chorioallantoic membrane (CAM) assay and exhibited excellent VEGFR-2 
kinase inhibition with an IC50 of 0.051 mM. The computational analysis showed 
that the target compound made strong interactions with the active site of VEGFR-2 
kinase. It is concluded that the 6-amide-2-arylbenzoxazole/benzimidazole deriva-
tives are essential inhibitors of VEGFR-2 kinase for the treatment of anti-angiogen-
esis [56] (Figure 5).
4. Miscellaneous agents
Wu et al. synthesized a series of novel benzimidazole-2-substituted phenyl or 
pyridine propyl ketene derivatives and two representative compounds (24) and 
(25) showed significant inhibitory activity against colorectal (HCT116), breast 
(MCF-7), and liver (HepG2) cell lines, and effective inhibition of tumor growth in 
BALB/c mice with colon carcinoma HCT116 cells [57]. Reddy et al. reported a series 
of pyrazole-containing benzimidazole hybrids and evaluated them for their poten-
tial anti-proliferative activity against lung (A549), breast (MCF-7), and cervical 
(HeLa) cell lines. The compounds (26) and (27) showed potent growth inhibition 
against all the cell lines tested, with IC50 values in the range of 0.83–1.81 μM [58]. 
Gowda et al. synthesized a series of novel 1-(4-methoxyphenethyl)-1H-benzimid-
azole-5-carboxylic acid derivatives and the compound (28) induced maximum cell 
death in leukemic cells (K562 and CEM cell lines), through inducing apoptosis via 
S/G2 cell cycle arrest; down regulation of CDK2, Cyclin B1 and PCNA; cleavage of 
PARP; and elevated levels of DNA strand breaks [59]. Akhtar et al. reported a series 
of benzimidazole-linked oxadizole hybrids and the compounds were screened for 
their anticancer and in vitro EGFR and erbB2 receptor inhibition assay. Two of the 
compounds (29) and (30) displayed promising activity. The compound 70a showed 
EGFR inhibition and induced apoptosis by G2/M cell cycle arrest [54] (Figure 6).
5. Synthetic strategies
The first benzimidazole (2,5-dimethylbenzimidazole) (3) or 2,6-dimethyl-
benzimidazole (4) was prepared in 1872 by Hoebrecker through reduction of 
Figure 5. 
The benzimidazole derivatives as selective anticancer agents via targeting EGFR.
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2-nitro-4-methylacetanilide [60] (1) (Figure 7). Several years later, the synthesis of 
benzimidazole was reported by refluxing 3,4-diamino toluene (2) with acetic acid 
[61]. Many synthetic ways toward the construction of benzimidazole ring started 
Figure 6. 
The novel benzimidazole derivatives as potential anticancer agents.
Figure 7. 
General syntheses of benzimidazoles from aniline derivatives.
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from commercially available benzene derivatives containing nitrogen functional-
ities, especially ortho derivatives. Hence, a number of methods have been reported 
for the synthesis of bioactive benzimidazoles and their derivatives. The majority of 
these involve the condensation of O-phenylene diamines (5) and its derivatives with 
carboxylic acids (6), esters, alcohols, or aldehydes [62].
Synthesis of benzimidazoles in the presence of various catalysts involves the 
condensation of O-phenylene diamines with ortho esters in the presence of Lewis 
acids like ZrCl4, SnCl4, TiCl4, HFCl4, etc. The most commonly used method for syn-
thesis of benzimidazoles (7) is Phillip’s method, which involves the condensation of 
O-phenylene diamines (5) with carboxylic acids (6) or its derivatives by heating the 
reagents in the presence of concentrated hydrochloric acid [62] (Figure 8).
The benzimidazole derivatives (14) were synthesized under mild conditions 
with inherently low cost by many researchers using (8), (9), (10), (11), (12), 
and (13), as reactants (Figure 9). Suheyla et al. demonstrated the synthesis of 
benzimidazoles by condensation of O-phenylene diamine with an appropriate 
aldehyde (8) in the presence of sodium metabisulfite. They proposed the reac-
tion that depends on forming the bisulfite adduct of the aryl aldehyde to prepare 
benzimidazole.
Hanan et al. have reported one-pot conversion of aromatic and heteroaromatic 
2-nitroamines (9) into bicyclic 2H-benzimidazoles employs formic acid, iron 
Figure 9. 
Synthetic strategies of benzimidazoles.
Figure 8. 
Phillip’s condensation for the synthesis of benzimidazoles.
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powder, and NH4Cl as an additive to reduce the nitro group and effect the imidazole 
cyclization with high-yields [63]. Nale et al. developed a method for the synthesis 
of benzimidazole derivatives in the presence of zinc catalysts from N-substituted 
formamides and various o-phenylenediamines [64] (10). Mahesh et al. developed a 
method of one-pot, multicomponent reaction, which enables the transformation of 
commercial aryl amines, aldehydes, and azides (11) into various benzimidazoles via 
an efficient copper-catalyzed amination of N-aryl imines [64]. Lin et al. developed 
a method for solvent/oxidant-switchable synthesis of multisubstituted benzimid-
azoles via metal-free selective oxidative annulation of arylamidines [65] (12). Wray 
et al. synthesized various N-aryl-1H-indazoles and benzimidazoles from common 
arylamino oximes (13) in good to excellent yields [66].
6. Conclusion
There are numerous benzimidazole derivatives for various cancer types involv-
ing unique types of mechanism. Although it is a widely used pharmacophore, still 
very few target-specific benzimidazoles are available. Therefore, researchers across 
the world need to develop new benzimidazole derivatives that are more target 
specific and help in the cancer treatment to overcome non-selective toxicity and 
adverse effects. This chapter mainly focused on target-based benzimidazole deriva-
tives and synthetic strategies. Hence, it would give more ideas to young medicinal 
researchers to develop target-specific benzimidazole derivatives as potential 
cytotoxic agents.
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Abstract
Currently, cancer is one of the major health problems of the human population 
and prominent cause of death. Thiazole ring has demonstrated many pharmaco-
logical activities including anticancer. This scaffold has been found alone or incor-
porated into the diversity of therapeutic active agents such as tiazofurin, dasatinib, 
and bleomycin, which are well-known antineoplastic drugs. Recently, most of 
the compounds isolated from natural sources containing thiazole moiety exhibit 
notable cytotoxicities and present antitumor potential. In this context, several 
structural changes have been made in the original structure, such as the incorpora-
tion of different substituents or the fusion with other carbo- and heterocycles, in 
order to increase the antitumoral potency. Related to mechanism of action of these 
derivatives, some of them act through kinase modulation, polymerization inhibi-
tion of microtubule, pro-matrix metalloproteinase activation, signal transducer 
activation of transcription 3, histone deacetylase inhibition, etc.
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1. Introduction
Cancer is a generic term, which encompasses a wide group of diseases character-
ized essentially by an uncontrolled growth and propagation of cells with errors in 
the division mechanisms known as cell cycle. Cancer constitutes a major public 
health problem worldwide, since it is the second leading cause of death globally, 
with 9.6 million deaths estimated in 2018 [1]. Due to the limitations and side effects 
associated with available cancer treatments nowadays, it is an urgent challenge for 
medicinal researchers to develop more safe and selective anticancer drugs.
Among the design strategies in drug discovery, special attention has been paid 
to molecules containing sulfur heterocycles in their structures. Several studies have 
been carried out with plenty of sulfur heterocycles, including thiophene, thione, 
benzothiophene, and thiazine, towards different pathologies.
Thiazole ring is present in several anticancer drugs, such as bleomycin, sulfathi-
azole, thiazofurine, and dasatinib, and its derivatives present excellent pharmaco-
logical profiles, making this skeleton an ideal candidate to develop more potent and 
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safer drugs, especially in cancer. Herein, an extensive revision of the most relevant 
research published in the past 5 years is gathered.
2. Thiazole rings decorated with different fragments
2.1 Thiazole derivatives with in vitro efficacy
Aminothiazoles: Aminothiazoles have been widely used in drug discovery research 
due to its biological properties. Commercial drugs, such as famotidine, sudoxicam, or 
cefdinir, contain an aminothiazole core in their structures (Figure 1) [2].
Aminothiazole scaffold can be modified by derivatization of the amino group at 
position 2 of the thiazole ring. Rostom et al. [3] reported a study based on structural 
modifications including azomethine, N-formyl, N-acyl, sulfonamide, ureido, and 
thioureido functionalities. Nine derivatives were evaluated by the NCI in vitro 
screening panel assay, displaying most of them a promising antitumor activity 
against particular cell lines.
Sun et al. [4] synthesized a series of N,4-diaryl-1,3-thiazole-2-amines containing 
three aromatic rings with an amino linker. Compound 1 (Figure 2) was the most 
cytotoxic agent with IC50 values at the submicromolar level. A further biological 
evaluation showed that this compound inhibited polymerization and disrupted 
tubulin microtubule dynamics in a similar way to the natural product combretastatin 
A-4, besides effectively inducing SGC-7901 cell cycle arrest at the G2/M phase.
In other study, a series of tri-substituted aminothiazoles were designed by 
Lu et al. [5] in order to obtain new antitumoral agents. Compound 2 (Figure 2) 
displayed a EC50 value of 0.11 μM in hepatocellular carcinoma along with a selectiv-
ity towards nontumoral cells greater than 450 times.
A dysregulation of sirtuin 2 (Sirt2) plays an important role in the pathogenesis 
of cancer, among other diseases. Schiedel et al. [6] designed a series of novel 
aminothiazole derivatives with the aim of establishing a well-defined SAR model 
of sirtuin ligands. These thiazole-bearing compounds behaved as selective human 
sirtuins (hSirt2) inhibitors.
Chalcones: Chalcones are naturally biarylpropenones, which are classified as 
a subgroup of flavonoids with a broad spectrum of biological activities, including 
antimicrobial, anti-inflammatory, and anticancer properties [7].
A series of 4-amino-5-cinnamoylthiazoles as chalcone-like structures were 
synthesized and evaluated as antitumor agents, showing most of them significant 
cytotoxic activity against MCF-7, HepG2, and SW480 cell lines [8]. The most prom-
ising analog, compound 3 (Figure 2), revealed that it could prevent the prolifera-
tion of HepG2 cells by blocking cell cycle at the G2 phase and by inducing apoptosis.
Coumarins: Another strategy of design is the incorporation of a coumarin 
moiety in molecules containing thiazole. Many coumarin-bearing compounds are 
reported to have significant therapeutic potential, including anticancer activity 
Figure 1. 
Some aminothiazole as commercial drugs.
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through different mechanisms. Jashari et al. [9] reported the synthesis of new 
derivatives by combining this coumarin core with different heterocycles. The results 
showed that the compounds containing thiazoles in the structure had the most 
promising activity against the cancer cell lines tested.
This strategy can be complementary with the inclusion of other structures with 
recognized biological activities. A series of indole-incorporated thiazolylcouma-
rins were synthesized and evaluated against a wide range of tumor cell lines [10]. 
Among the tested compounds, structure 4 (Figure 2) exhibited a broad spectrum 
of growth inhibition activity with average GI50 values of 1.18–2.44 μM against nine 
cell lines.
Ayati et al. [11] also reported the synthesis of a series of new coumarin-containing 
compounds developed from the chalcone-like cinnamoylthiazoles mentioned above. 
Biological evaluations on the most cytotoxic compound 5 (Figure 2) against MCF-7 
cells revealed the induction of apoptosis and blockage of the cell cycle distribution at 
the G1-phase.
2.2 Thiazole derivatives with in vivo efficacy
For the past 5 years, few examples of scaffolds bearing a thiazole ring have been 
reported with potent efficacy in xenograft models of various types of cancer. Figure 3 
encompasses the most relevant examples gathered in the literature that are going to be 
discussed herein.
Attending to their structure, the thiazole analogs can be grouped as follows.
Diaminothiazoles: In 2015, several diaminothiazole derivatives were evaluated 
in vitro against wild-type and resistant colon, breast, and uterine cancer cells lines. 
All of them showed potent activity in all cell lines with IC50 values in the nanomolar 
range. Among them, DAT1 (4-amino-5-benzoyl-2-(4-methoxyphenylamino)thia-
zole) (Figure 3) also demonstrated in vivo tumor growth inhibition of around 60% 
in a taxol-resistant colon cancer model at a dose of 20 mg/kg [12]. More recently, 
DAT1 has also demonstrated its capacity to induce apoptosis both in vitro and in vivo 
against colon cancer models with mutated p53 through ERK-mediated upregulation 
of death receptor 5 (DR5) [13]. All these findings have placed DAT1 as a candidate 
to be tested in clinical trials.
(Thiazole-2-yl)hydrazones: Di Martile et al. reported that a novel pCAF and 
GCN5 histone deacetylase inhibitor, named CPTH6 (3-methylcyclopentylidene- 
[4-(4′-chlorophenyl)thiazol-2-yl] hydrazone) (Figure 3), was able to reduce tumor 
growth in a spheroid patient-derived lung cancer stem cells (LCSCs) xenograft model 
Figure 2. 
Thiazole derivatives as potential antitumor agents.
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Thiazole derivatives as potential antitumor agents.
Heterocycles - Synthesis and Biological Activities
60
accompanied by apoptosis induction and inhibition of α-tubulin acetylation [14]. 
Likewise, two 2-pyridyl-2,3-thiazole derivatives, TP-07 and TAP-07 (Figure 3), pos-
sess cytotoxic activity towards several cancer cell lines without antiproliferative effects 
to normal cells (IC50 > 30 μM) along with in vivo efficacy against a hepatocellular 
xenograft cancer model [15]. Thus, both compounds achieved 47% and 73% tumor 
mass reduction, respectively [15].
Spiroimidazothiazolidines: This class of compounds has demonstrated to be 
potent inhibitors of the Murine Double Minute-2 (MDM2)-p53 interaction, which 
ultimately leads to induction of apoptosis. Two analogs withstand in this class of 
compounds: a) ISA27 (Figure 3), which not only presented tumor growth inhibi-
tion in vivo alone in a glioblastoma xenograft model but also a synergistic effect 
with temozolomide, a first-line treatment drug against brain cancers [16], and  
b) SM13 (Figure 3), an analog that reduced tumor growth in a human thyroid 
cancer xenograft model in the absence of p53 transcriptional activity [17].
Piperidinone analogs: Based on previous morpholine and piperidone MDM2 
inhibitors, Gonzalez et al. introduced a thiazole ring decorated with a carboxylic 
acid over the piperidone scaffold. The resulting hit compound, termed AM-6761 
(Figure 3), maintained the MDM2 inhibition efficacy and presented an ED50 value 
of 11 mg/kg in SJSA-1 osteosarcoma xenograft model [18].
Oridonin derivatives: Oridonin is a complex ent-kaurane diterpenoid 
isolated from the traditional Chinese herb Isodon rubescens, with well-known 
cytotoxic activity against various human cancers. In 2013, Ding et al. designed 
a series of novel nitrogen-enriched oridonin derivatives with thiazole-fused 
A-ring. The hit compound, CYD0618 (Figure 3), induced a threefold shrinkage 
of the tumor volume in a triple-negative breast cancer MDA-MB-231 xenograft 
model at a dose of 5 mg/kg, showing much higher efficacy than parent oridonin 
[19]. Later, Zhou et al. reported another oridonin analog, CYD-6-17 (Figure 3),  
which significantly inhibited renal cell carcinoma tumor growth in vivo by 
targeting 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and its 
downstream pathways [20].
Figure 3. 
Representative scaffolds containing thiazole ring with proven in vivo efficacy towards several cancer xenograft 
models.
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3. Fused thiazole rings decorated with different fragments
Benzothiazoles: In the last few years, benzothiazoles have attracted consider-
able interest due to their broad spectrum of pharmacological activities, such as 
antitubercular, antimicrobial, analgesic, and antitumor properties [21].
This moiety can be functionalized with several structural modifications. Novel 
methylsulfonyl benzothiazoles were synthetized and evaluated against HeLA cell line, 
with compounds 6 and 7 (Figure 4) showing GI50 values of 0.1 μM or below [22].
Xie et al. [23] reported a new series of benzothiazole derivatives, with in vitro 
efficacy against HCT116, MCF-7, U87 MG, and A549 cell lines. Compound 8 
(Figure 4) was proved to retain the antiproliferative activity and the inhibitory 
activity against PI3K (phosphoinositide 3-kinase) and mTORC1 (mammalian target 
of rapamycin), which are abnormally active in many tumor cells.
Benzothiazole derivatives bearing pyrimidine moiety were synthetized and 
evaluated for anticancer activity against MCF-7, A549, and A375 cancer cell lines, 
with significant antitumor activity. A further study of the most promising com-
pounds indicated an effect on the expression of proteins that cause abnormal cell 
proliferation, such as ERK1/2, NF-kB, and survivin [24].
This moiety can also be used in the design of new molecules with a chalcone-
like structure, as it has been mentioned before. Imidazole bearing benzothiazoles 
were synthetized by Sultana et al. [25] and evaluated against several cancer cell 
lines. Compounds 9 and 10 (Figure 4) exhibited good cytotoxicity against human 
breast cancer (MDA MB-231) with IC50 values of 1.3 and 1.2 μM, respectively. These 
compounds were revealed to induce cell cycle arrest in G2/M phase and to inhibit 
microtubule assembly.
Imidazoles: Imidazole-based compounds have achieved great progress in medici-
nal chemistry, since they have showed anticancer, antifungal, antibacterial, and anti-
parasitic activities, among others [26]. Their use as heterocycles merged with thiazole 
has attracted great attention in the last years [27, 28] due to its therapeutic properties.
A series of imidazo[2,1-b]thiazole derivatives were evaluated against different 
tumor cell lines, showing that compounds 11 and 12 (Figure 4) had a significant 
cytotoxic activity against A549 with IC50 values of 0.92 and 0.78 μM, respectively. 
These derivatives had proven to induce cell cycle arrest in G2/M phase and apopto-
sis in this cell line [29]. Ali et al. [30] synthesized a series of imidazo[2,1-b]thiazoles 
decorated with pyrazoles that turned out to be promising leads to further develop.
Figure 4. 
Some thiazole-fused compounds with antitumor activity.
Heterocycles - Synthesis and Biological Activities
60
accompanied by apoptosis induction and inhibition of α-tubulin acetylation [14]. 
Likewise, two 2-pyridyl-2,3-thiazole derivatives, TP-07 and TAP-07 (Figure 3), pos-
sess cytotoxic activity towards several cancer cell lines without antiproliferative effects 
to normal cells (IC50 > 30 μM) along with in vivo efficacy against a hepatocellular 
xenograft cancer model [15]. Thus, both compounds achieved 47% and 73% tumor 
mass reduction, respectively [15].
Spiroimidazothiazolidines: This class of compounds has demonstrated to be 
potent inhibitors of the Murine Double Minute-2 (MDM2)-p53 interaction, which 
ultimately leads to induction of apoptosis. Two analogs withstand in this class of 
compounds: a) ISA27 (Figure 3), which not only presented tumor growth inhibi-
tion in vivo alone in a glioblastoma xenograft model but also a synergistic effect 
with temozolomide, a first-line treatment drug against brain cancers [16], and  
b) SM13 (Figure 3), an analog that reduced tumor growth in a human thyroid 
cancer xenograft model in the absence of p53 transcriptional activity [17].
Piperidinone analogs: Based on previous morpholine and piperidone MDM2 
inhibitors, Gonzalez et al. introduced a thiazole ring decorated with a carboxylic 
acid over the piperidone scaffold. The resulting hit compound, termed AM-6761 
(Figure 3), maintained the MDM2 inhibition efficacy and presented an ED50 value 
of 11 mg/kg in SJSA-1 osteosarcoma xenograft model [18].
Oridonin derivatives: Oridonin is a complex ent-kaurane diterpenoid 
isolated from the traditional Chinese herb Isodon rubescens, with well-known 
cytotoxic activity against various human cancers. In 2013, Ding et al. designed 
a series of novel nitrogen-enriched oridonin derivatives with thiazole-fused 
A-ring. The hit compound, CYD0618 (Figure 3), induced a threefold shrinkage 
of the tumor volume in a triple-negative breast cancer MDA-MB-231 xenograft 
model at a dose of 5 mg/kg, showing much higher efficacy than parent oridonin 
[19]. Later, Zhou et al. reported another oridonin analog, CYD-6-17 (Figure 3),  
which significantly inhibited renal cell carcinoma tumor growth in vivo by 
targeting 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and its 
downstream pathways [20].
Figure 3. 
Representative scaffolds containing thiazole ring with proven in vivo efficacy towards several cancer xenograft 
models.
61
Thiazole Moiety: An Interesting Scaffold for Developing New Antitumoral Compounds
DOI: http://dx.doi.org/10.5772/intechopen.82741
3. Fused thiazole rings decorated with different fragments
Benzothiazoles: In the last few years, benzothiazoles have attracted consider-
able interest due to their broad spectrum of pharmacological activities, such as 
antitubercular, antimicrobial, analgesic, and antitumor properties [21].
This moiety can be functionalized with several structural modifications. Novel 
methylsulfonyl benzothiazoles were synthetized and evaluated against HeLA cell line, 
with compounds 6 and 7 (Figure 4) showing GI50 values of 0.1 μM or below [22].
Xie et al. [23] reported a new series of benzothiazole derivatives, with in vitro 
efficacy against HCT116, MCF-7, U87 MG, and A549 cell lines. Compound 8 
(Figure 4) was proved to retain the antiproliferative activity and the inhibitory 
activity against PI3K (phosphoinositide 3-kinase) and mTORC1 (mammalian target 
of rapamycin), which are abnormally active in many tumor cells.
Benzothiazole derivatives bearing pyrimidine moiety were synthetized and 
evaluated for anticancer activity against MCF-7, A549, and A375 cancer cell lines, 
with significant antitumor activity. A further study of the most promising com-
pounds indicated an effect on the expression of proteins that cause abnormal cell 
proliferation, such as ERK1/2, NF-kB, and survivin [24].
This moiety can also be used in the design of new molecules with a chalcone-
like structure, as it has been mentioned before. Imidazole bearing benzothiazoles 
were synthetized by Sultana et al. [25] and evaluated against several cancer cell 
lines. Compounds 9 and 10 (Figure 4) exhibited good cytotoxicity against human 
breast cancer (MDA MB-231) with IC50 values of 1.3 and 1.2 μM, respectively. These 
compounds were revealed to induce cell cycle arrest in G2/M phase and to inhibit 
microtubule assembly.
Imidazoles: Imidazole-based compounds have achieved great progress in medici-
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parasitic activities, among others [26]. Their use as heterocycles merged with thiazole 
has attracted great attention in the last years [27, 28] due to its therapeutic properties.
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decorated with pyrazoles that turned out to be promising leads to further develop.
Figure 4. 
Some thiazole-fused compounds with antitumor activity.
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Due to the pharmacological properties of the imidazo[2,1-b]thiazole derivatives 
and coumarin compounds already mentioned, it has been reported a design that 
embodied both the active pharmacophores in a single molecule in order to evaluate 
their synergic activity against a series of tumor cell lines [31], showing some of 
them prominent cytotoxic activity.
Kamal et al. [32] also designed a novel series of imidazole merged with thiazole 
as chalcone-like derivatives and evaluated their cytotoxic activity against MCF-7, 
A549, HeLA, DU-145, and HT-29 cell lines. Among the compounds tested, struc-
ture 13 (Figure 4) with a pyridyl ring was the most active. This compound also 
disrupted microtubule dynamics, induced cell cycle arrest in G2/M phase and 
ultimately trigger apoptosis.
Pyrimidines: Compounds with fused rings can also be formed by merging other 
heterocyclic moieties with thiazole core. Li et al. [33] reported a novel series of 
thiazolo[5,4-d]pyrimidine derivatives, which were evaluated against three cancer 
cell lines. Compound 14 (Figure 4) showed the most potent antiproliferative activ-
ity with good selectivity when compared to normal cells (IC50 values of 1.03 μM 
against MGC803 and 38.95 μM against GES-1). Biological studies indicated that 
this compound could inhibit the cell colony formation and migration by inducing 
apoptosis on MGC803 cells.
A series of thiazolo[3,2-a]pyrimidines were synthetized and evaluated in the 
NCI-60 cell lines panel assay, achieving significant cytotoxicity against some of the 
cell lines tested [34].
4. Miscellaneous structures bearing thiazole ring
Diazepines: Heterocyclic compounds 1,4-diazepines are considered an interest-
ing moiety in drug research due to their broad range of pharmacological activities, 
including antibacterial, anti-HIV, anticonvulsant, and anticancer [35]. Ramírez 
et al. designed a series of novel thiazole-based compounds by fusing this structure 
with pyrimidine, which has also showed biological properties. The results indicated 
that some compounds showed promising antitumoral activity, with GI50 values 
below 2 μM against NCI’s in vitro cell line screening [35].
Pyrazoline: Another heterocyclic structure used in combination with thiazole 
moiety is the pyrazoline ring. New thiazolyl-pyrazoline derivatives were synthe-
tized, and their cytotoxicity was evaluated against A549 human lung adenocarci-
noma and NIH/3 T3 mouse embryonic fibroblast cells, presenting in some cases 
similar IC50 values to cisplatin [36].
Curcumins: Bayomi et al. [37] synthetized and evaluated a series of new 
curcumin analogs bearing thiazole as antitumoral and antioxidant agents, showing 
similar behavior than that of cisplatin and ascorbic acid, respectively.
Thiazolines: Thiazolines are the reduced form of thiazole and also have 
attracted interest in drug research due to its biological activity. Altintop et al. [38] 
evaluated a series of new thiazoline-based derivatives bearing a hydrazone moiety. 
The results showed that some of the compounds were potent inhibitors of DNA 
synthesis against C6 tumor cells.
5. Thiazole and metal complexes
There is a great variability of transition metals that in combination with dif-
ferent ligands have been reported as antitumoral agents acting through different 
mechanisms. The literature revealed the considerable interest in the thiazole 
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pharmacophore alone [39], fused to other rings [40], or incorporated into different 
structures [41] for cancer therapy.
On the other hand, among the most effective and well-studied class of chemo-
therapeutic agents are the platinum-based drugs, which comprise cisplatin, carbopla-
tin, and oxaliplatin. Given the clinical success of the platinum-based drugs, extensive 
research efforts have been made to develop alternative metal ions, that is, ruthenium, 
copper, zinc, and nickel, with antitumor activity.
Copper complexes: Copper complexes have attracted a vast interest due to 
their bioavailability, increased uptake in cancerous tissues, role in angiogenesis 
and photophysical properties, among others. The most common types of copper 
complexes are those incorporating 1,10-phenanthroline (phen) ligands. Planarity of 
the intercalative ligand is crucial in the binding of these complexes with DNA. The 
complexes containing nonplanar ligands favored groove binding [42].
Besides, Shakir et al. [43] have reported several Cu (II) complexes derived from 
benzothiazole and thiazole, which showed greater antioxidant and anticancer 
activities than the corresponding free ligands in various cell lines.
Studies carried out with several Cu (II) complexes with 2,2,6′,2′′-terpyridines 
revealed that these complexes are able to promote the generation of reactive oxy-
gen species (ROS) in the presence of mild reducing agents. This feature has been 
exploited to oxidatively break the DNA strands, hence inhibiting the prolifera-
tion of tumor cells. In this context, the replacement of two pyridine rings by two 
thiazole nuclei (compound 15 in Figure 5) also achieved efficient DNA cleavage in 
several tumor cell lines [44]. Later, Czerwinska et al. corroborated an increase in 
the antiproliferative effect of these complexes against ovarian carcinoma cells by 
apoptosis [45].
In addition, the copper complexes have been recognized as promising drugs for 
metastatic tumors. For example, copper complexes of pyrrolidine dithiocarbamate 
(Cu(PDTC)2) possessed potent anticancer activity on cisplatin-resistant neuroblas-
toma cells. Additionally, two copper thiosemicarbazone complexes showed similar 
effect on cisplatin-resistant neuroblastoma cells and prostate cancer. Xie et al. [46] 
reported the synthesis and antitumoral activity of two copper complexes of (4R)-
2-thioxo-4-thiazolidinecarboxylic acid (TTDC) and 3-rhodaninepropionic acid 
(RDPA) against prostate cancer, presenting both of them variable potency, likely 
Figure 5. 
Some thiazole-metal complexes with antitumor activity.
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related to different functional groups on TTDC and RDPA ligands. Owing to the 
presence of sulfur and amino groups in CuTTDC and CuRDPA, these complexes 
had emerged as ligands to attach to delivery vehicles, such as peptides or monoclo-
nal antibodies for targeted delivery.
It is notably that a number of copper (II) complexes have been shown to pres-
ent antitumor activity, through inhibition of human topoisomerase IIα. Recently, 
Sandhaus et al. [47] have identified a new complex (compound 16 in Figure 5) with 
potent antiproliferative activity towards colon cancer cell lines (HTC-116, Caco-2, 
and HT-29) and aggressive breast cancer cell lines (HCC 1500, HCC 70, HCC 1806, 
and HCC 1395).
Ruthenium complexes: Currently, ruthenium complexes are found to be a 
promising alternative for platinum because of favorable properties as anticancer 
drugs. Among the ligands, 2,6-di(thiazol-2-yl)pyridine combined with phenantro-
lines have demonstrated to act as DNA intercalative agents along with topoisom-
erase I and IIα inhibitors (compound 17 in Figure 5) [48]. The assays with other 
ligands, such as 1,3-thiazolidine-2-thione, with 1,4-bis(diphenylphosphino)butane 
or 2,2′-bipyridine, displayed strong cytotoxicity against breast and prostate cancer 
cell lines [49].
Platinum and palladium complexes: Platinum and palladium have similar 
chemical properties and modes of coordination, but the palladium compounds 
are more labile from a thermodynamic and a kinetic point of view with relation to 
platinum derivatives.
Rubino and co-workers [50] have reported two new mono-Pt(II) and binuclear 
chloro-bridged Pd(II) complexes with 2,2′-dithiobis(benzothiazole) as ligand. Only 
platinum derivative has emerged as an effective inductor of apoptotic death on 
HepG2 and MCF-7 cells and caused cell cycle arrest at G0/G1 phase while palladium 
was inactive. On the other hand, the inclusion of 2-(4-substituted)benzothiazoles 
(compound 18 in Figure 5) as ligands resulted in potent cytotoxic agents through 
tubulin polymerization in A549 and HeLa cell lines [51].
In addition, thiazolidinone-derived complexes, specifically with (Z)-2-((E)-(1-
(pyridin-2-yl)ethylidene)hydrazono)thiazolidin-4-one, were markedly cytotoxic 
to MCF-7, HepG2, and NCI-H460 and presented better profile than cisplatin [52]. 
Other relevant strategy is the combination with scaffold with proven anticancer 
activity. In this context, the coumarin-thiazole analogs complexed with platinum 
or palladium showed that the Pd complex had higher antitumor effects than its Pt 
analogs in several cancer cell lines [53].
Other metal complexes and applications: Manganese is a metal that plays a 
critical role in cell development, and it is required for mitochondrial function. As 
novelty, Islam et al. [54] have described a new Mn-EDTA complex (compound 19 
in Figure 5) incorporating a benzothiazole that has been investigated as potential 
agents for diagnosis of liver cancer by magnetic resonance.
Cobalt (II) complexes are one of the most studied, and they have been reported 
as cytotoxic agents in vitro against breast cancer cell lines [55]. However, the cobalt 
(III) complexes are less known, although a new Co(III)sulfathiazole complex have 
been reported as cytotoxic compound without genotoxic effects [56].
In recent years, lanthanum (III) complexes are emerging as promising agents 
due to their more physiological activities and lower toxicities after coordination 
with ligands. The main mechanism of action associated is the interaction with DNA 
by intercalation mode. Likewise, these compounds are useful as clinical biomark-
ers for early diagnosis of the presence of prostate cancer. One of the most relevant 
lanthanum (III) derivative is 2,3-dihydro-1H-indolo[2,3-b]phenazin-4-(5H)-
ylidene)benzothiazole-2-amine (compound 20 in Figure 5) that showed excellent 
anticancer activity in PC-3 cells [57].
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Another relevant option is the gold(I) compounds that can act as prodrugs. 
Thus, 2-mercapto thiazoline as ligand by reaction with K[Au(CN)2] resulted in the 
nitrogen-coordinated complex [NCAu(N-mtz)]. On the other hand, reaction with 
[(Ph3P)AuCl] yielded the sulfur-coordinated complex [(Ph3P)Au(S-mtz)]. Both 
of them inhibited the growth of tumorigenic cell lines such as the human ovarian 
carcinoma (A2780), human colon carcinoma (HCT116), and human breast adeno-
carcinoma (MCF7) [58].
Finally, another strategy to design new complexes as antitumoral agents is the 
combination of anti-inflammatory derivatives with metals. In this approach, the 
1,2-benzothiazines nuclei, which are present in meloxicam and piroxicam, were 
complexed with ruthenium and osmium to obtain new derivatives with potent 
activity against cancer cell lines [59].
6. Peptidic thiazoles
Thiazoles and thiazolines are quite common motifs present in peptides isolated 
from natural sources, many of them known for having biological activity, typi-
cally antibacterial. These peptides are biosynthesized from nonribosomal peptide 
synthase (NRPS) or ribosomally produced and post-translationally modified. Both 
processes involve cyclodehydrations of cysteine residues to yield thiazolines and 
subsequent dehydrogenations to give thiazoles [60]. In this context, marine organ-
ism (cyanobacteria, fungi, sponges, tunicates, ascidians, etc.) provide an endless 
source of new structures with biological potential, cancer included [61]. Many 
isolated thiazole-containing peptides from nature have anticancer properties per se, 
but more efforts are continuously needed by scientific community to enhance and 
modulate its anticancer activity through structure modifications. Recent develop-
ments in this area are included here and listed by its cyclic/acyclic nature.
6.1 Linear peptides
Cyanobacteria-derived bisebromoamide was isolated and tested against HeLa S3 
cells, showing a very low IC50 [62]. It was also shown to induce apoptosis through 
ERK and mTOR inhibition in renal carcinoma cell lines [63]. A modification of cen-
tral thiazoline of bisebromoamide by a thiazole and alanine scanning [64] provided 
new analogs, getting insights in the structural dependence of the cytotoxicity. Four 
analogs showed nanomolar cytotoxicity activity against human colon tumor cell 
line HCT116.
P-glycoprotein (P-gp, multidrug resistance protein 1) is overexpressed in 
patients suffering from chemotherapy resistance. In this sense, cyclic and acyclic 
(S)-valine-derived thiazole peptide dimers, trimers, and tetramers were found to 
be potent P-gp efflux transport inhibitors [65]. Based on this hit, further derivatiza-
tion led to peptidomimetic TTT-28 (Figure 6), which was found to be a potent 
P-gp transport inhibitor and superior to parent compound in reversal of resistance 
to placitaxel in SW620/Ad300 and HEK/ABCB1 cell lines [66]. In vivo study [67] 
showed TTT-28 enhanced intratumoral concentration of placitaxel, inhibiting the 
growth of ABCB1 overexpressing tumors. Additional extensive derivatizations of 
TTT-28 in terminal groups and central thiazole building block side chain helped to 
understand the drug/substrate interactions with P-gp [68]. Modifications on these 
sites led to divergent effects in ATPase efflux pump, from initial stimulation in 
TTT-28 to inhibition.
Polyamides based on 2 and 3 repeating units of 2-aminothiazole-4-carboxylic 
acid were synthetized [69] and proved to bind selectively to c-MYC quadruplex 
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over other G-quadruplex and duplex DNA and therefore inhibiting c-MYC onco-
gene transcription. Antiproliferative activity of the tripeptide was found in HeLa 
cells, caused by apoptotic pathway.
Thiazole scaffold is also present in short peptides known for inhibiting tubulin 
polymerization. Dolastatin 10 was firstly isolated from Dolabella auricularia and is 
composed of five unnatural amino acids with a thiazole ring in C-terminal (Figure 6). 
It was demonstrated as very potent in cell proliferation assays (IC50 < 5.0 nM), but 
due to its high toxicity at maximum tolerated dose, new analogs have been devel-
oped. N-Terminal modified dolastatin analog (PF-06380101) bearing a quaternary 
amino acid was found to have improved potency and suitable ADME properties for 
antibody-drug conjugates [70]. Modified dolastatins at thiazole moiety by addition 
of new functionalities as alcohols, amines, and thiols have also been reported [71]. 
These analogs also showed low IC50 for several cancerous cell lines.
Another thiazole-containing peptides targeting to tubulin polymerization 
are the tubulysins (Figure 6), isolated first from myxobacteria. Great number of 
modifications have been attempted to date, and numerous SAR studies have shed 
light into tubulysin mode of action (for a review, see ref. [72]).
In this context, a pretubulysin (tubulysin biosynthetic precursors) lacking of C11 
acetate and bearing a methyl group at N14 showed efficacy against various in vivo 
metastatic bladder, breast, and lung cancer models [73]. New tubulysin derivative 
KEMTUB10 with a N14-benzyl-Tuv and 4-fluorophenyl moiety in Tup exhibited 
activity in the picomolar range in the main breast cancer cell lines [74]. It blocks 
cells in G2/M phase of the cell cycle and stimulates apoptosis. In line with these 
results, attachment of alkyl groups at mentioned Tuv N14 as benzyl, 4- 
fluorobenzyl, and cyclopropylmethyl in tubulysins also led to superpotent cytotoxic 
activity [75]. More Tuv modifications have been reported, like the incorporation 
of tetrahydropyranyl ring by Diels-Alder reaction for conformational restriction 
of tubulysin [76], but rigidification seemed to affect negatively to polymerization 
inhibition. Systematic derivatization by substitution of each subunit of tubulysin 
by diverse moieties, including three-dimensional structural motifs such as cubane 
and [1.1.1]-bicyclopentane, was reported [77]. A profound structure-activity study 
indicated that thiazole in Tuv unit cannot be substituted by 3D motifs but can be 
replaced by aromatics such as pyridine without significant loss of activity.
Figure 6. 
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One objective for researchers working with tubulysins is the improvement of 
their therapeutic efficacy by the targeted cancer therapy as antibody-drug conjuga-
tion (ADC) or small molecule drug conjugates (SMDC), acting the tubulysins as 
payloads. This represents a very powerful tool, which is already being applied to 
all class of tubulin inhibitors [78]. Tubulysin warheads are therefore being used 
in ADC; one of them (AZ13599185) is in phase I clinical trials targeting HER2 
receptors, involved in breast cancer development [79]. Following this trend, the 
modifications of tubulysins for an easier linking to conjugates is a new goal. New 
derivatizations at C-terminal Tup showed broad tolerance with no loss of activity, 
enabling more opportunities to conjugate to biomolecules and receptor ligands 
[80]. Another issue that arose during ADC conjugation of tubulysins to trastu-
zumab is the metabolism of C11 acetate in vivo, inactivating the payload [81, 82]. 
The problem was solved replacing the acetate ester by a more inert functionality to 
esterases like carbamates, retaining the activity. Tubulysin warheads have also been 
applied in a SMDC strategy in conjugation with folic acid to address folate receptor 
(FR), expressed in many cancers [83]. The EC1456 conjugate was tested in mice 
bearing FR-positive xenografts leading to curation of 100%. Results against human 
vintafolide-resistant xenografts were also positive.
6.2 Cyclic peptides
Cyclic depsipeptide largazole was discovered from cyanobacteria Symploca sp. 
[84], and its distinctive structural feature is the presence of a thiazole fused linearly 
to a 4-methylthiazoline and a labile thioester (Figure 6). Largazole possesses great 
activity as inhibitor of class I histone deacetylase (HDAC) metalloenzymes [85], 
a promising target for chemotherapy. Many largazole structure-activity relation-
ship studies have been reported. Among multiple sites of modification performed, 
thiazole-thiazoline fragment located in the macrocycle seems to be the most 
promising to achieve more potent and selective analogues. Substitution of thiazole 
by pyridyl residues and depsipeptide framework alteration to peptide isostere led to 
equipotent largazole analogues but with improved selectivity for different HDACs 
[86]. The replacement of thiazole and thiazoline by bipyridyl fragments led to 
derivatives with a similar activity of largazole, but with an improved selectivity for 
class I HDAC [87].
Largazole inhibition of HDAC is actually attained by largazole thiol derived 
from thioester hydrolysis. The thiol forms a thiolate-Zn2+ complex [88], a critical 
binding for the activity, since substitution by other poorer Zn-binding groups 
correlated to less HDAC inhibition and lower cytotoxicity [89]. The octanoyl side 
chain on the thioester allows good cell permeability. Thus, modifications can be 
made for a better membrane permeability and thiol liberation inside the cell. In 
this sense, controlled release of largazole thiol from an isobutylene-caged largazole 
thiol derivative, which possesses a high permeability, has been achieved by UV light 
photoactivation of a thiol-ene triggering reaction [90].
Cyclic thiazole- and oxazoline-containing octapeptides and patellamides, 
isolated from marine tunicates, have also been an object of modification. It has been 
shown that changes in the position of thiazoles and oxazolines in ascidiacyclamide 
can influence their cytotoxic activity, obtaining inactive derivatives and 10 times 
more active compounds depending on the conformations attained [91].
Apratoxin- and thiazoline-containing depsipeptides are known potent cyto-
toxins isolated from marine cyanobacteria. Apratoxins are known for being potent 
anticancer agents and co-translational translocation inhibitors. Different deriva-
tives have been synthetized, involving thiazoline stereogenic configuration change 
at C30 and substitution in C34 [92] (Figure 6). A new derivative, apratoxin S10 with 
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over other G-quadruplex and duplex DNA and therefore inhibiting c-MYC onco-
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metastatic bladder, breast, and lung cancer models [73]. New tubulysin derivative 
KEMTUB10 with a N14-benzyl-Tuv and 4-fluorophenyl moiety in Tup exhibited 
activity in the picomolar range in the main breast cancer cell lines [74]. It blocks 
cells in G2/M phase of the cell cycle and stimulates apoptosis. In line with these 
results, attachment of alkyl groups at mentioned Tuv N14 as benzyl, 4- 
fluorobenzyl, and cyclopropylmethyl in tubulysins also led to superpotent cytotoxic 
activity [75]. More Tuv modifications have been reported, like the incorporation 
of tetrahydropyranyl ring by Diels-Alder reaction for conformational restriction 
of tubulysin [76], but rigidification seemed to affect negatively to polymerization 
inhibition. Systematic derivatization by substitution of each subunit of tubulysin 
by diverse moieties, including three-dimensional structural motifs such as cubane 
and [1.1.1]-bicyclopentane, was reported [77]. A profound structure-activity study 
indicated that thiazole in Tuv unit cannot be substituted by 3D motifs but can be 
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(R)-C30 thiazoline and the addition of a methyl group at C34, shows potent in vitro 
angiogenesis and vascularized tumor cell growth inhibition [93]. It showed antipan-
creatic cancer activity, including in orthotopic pancreatic patient-derived xenograft 
mouse model [94]. Other derivatizations consisting of thiazoline substitution 
by piperidinecarboxylic acid moiety have been developed [95]. Apratoxins M16 
showed comparable cytotoxicity to apratoxin A in HCT116 cancerous cells.
7. Conclusion
Incorporation of thiazole ring into different molecules have demonstrated to be 
a novel and promising approach to design more potent and safer antitumor drugs. 
The results of this chapter might help to enlighten other researchers to better design 
bioactive molecules. This thiazole ring can be incorporated as part of mono- or 
fused-cycles, metal complexes, or as a part of peptides. In many of these cases, 
the deletion of thiazole ring entails the loss of the bioactivity pointing out the 
importance of this ring for the anticancer activity. Thus, we consider this class of 
compounds and excellent starting point to achieve future drug candidates to treat 
cancer.
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of Heterocyclic Amine, 
1,3-Diketone and Aldehydes Using 
In Situ Generated Superoxide Ion: 
A Rapid Synthesis of Structurally 
Diverse Drug-Like Complex 
Heterocycles
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Abstract
A novel, convenient one-pot multicomponent synthesis of tetraheterocy-
clicbenzimidazolo/benzothiazolo quinazolin-1-one derivatives has been reported 
in the presence of tetraethylammonium superoxide under non-aqueous condition. 
The superoxide induced three-component reaction of various aromatic aldehydes, 
2-aminobenzimadazole/2-aminobenzothiazole and dimedone/1,3- cyclohexane-
dione produced tetraheterocyclicbenzimidazolo/benzothiazolo quinazolin-1-one 
derivatives at room temperature under the mild reaction conditions. The tetraethyl-
ammonium superoxide has been generated by phase transfer reaction of potassium 
superoxide and tetraethylammonium bromide in dry DMF at room temperature. 
The present study extended the applicability of tetraethylammonium bromide as a 
phase transfer catalyst for the efficient use of superoxide ion in multi-component 
synthesis of structurally diverse drug-like complex heterocycles (quinazolines).
Keywords: superoxide ion, multicomponent reaction, Tetraethylammonium bromide, 
 phase transfer catalyst, KO2
1. Introduction
The importance of oxygen in sustaining life is unquestionable but the aerobic 
life-style is fraught with danger. However, some recent reports about oxygen toxic-
ity have caused much concern among the whole scientific community. The oxygen 
toxicity is due to various reactive oxygen species (ROS) such as hydroxyl radical 
(HO•), superoxide anion radical O2• −, and perhydroxyl radical. Hypochlorous acid 
(HOCl), hydrogen peroxide (H2O2), singlet oxygen and ozone are also included in 
this category, although they are not free radicals but can lead to free radical reac-
tion. Out of all the reactive oxygen species, superoxide anion radical is probably 
the most important ROS, which has come to the forefront of current chemical and 
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biochemical research for the two reasons [1–4]. First superoxide ion as a biochemi-
cal species which causes many diseases such as cancer, ageing, inflammation, heart 
attack and lung injury, etc. More recently, it has been implicated to play a key role 
in both aging and cancer. Second superoxide ion as a novel reagent. Further from its 
elementary reactivity pattern, this anion radical has been recognized as a multi-
potent reagent, which acts as a base, nucleophile, oxidant and reductant. In view 
of these two points, superoxide research has become an area of interdisciplinary 
investigation [5–13].
Multi-component reactions (MCRs), in which multiple reactions are combined 
into one synthetic operation, have been used extensively to form carbon-carbon 
bonds in synthetic chemistry. Such reactions offer greater possibilities for molecular 
diversity per step with minimum reaction time, labor, cost, and waste production. 
The rapid assembly of molecular diversity utilizing MCRs has gained a great deal of 
attention, most notably for the construction of ‘drug-like’ libraries [14–20].
Quinazolines are very interesting heterocycles [21–25] as they serve as building 
blocks in numerous natural and synthetic products [26]. They exhibit a wide spec-
trum of biological and pharmacological activities such as propyl hydroxylase inhibi-
tor [27], antidiabetics [28], anti-inflammatory [29], antiviral [30], antimicrobial 
[31], antineoplastic [32] and potent immunosuppressive agents [33]. Moreover, benz-
imidazolo quinazolines have also been an important class of heterocyclic compounds 
in drug research, as they are formed from both biodynamic heterosystems, benz-
imidazole and quinazoline, which have shown significant anticancer activities. Many 
useful methods, have been reported for synthesis of tetrahydrobenzoimidazo [2,1-b] 
quinazolin-1(2H)-ones ring system skeletons, such as the condensation of aminoaz-
oles with benzylidene compounds, or three-component condensation of 2-amino-
benzothiazole or 2-aminobenzimidazole and an aldehyde with cyclic 1,3-diketone.
These reported methodologies produce good results in many cases [34, 35]. However, 
some of them suffer with certain limitations such as expensive catalysts, low yields of 
products, long reaction times, tedious procedures for preparations of catalysts, and 
tedious workup conditions [36–40]. Thus, there is enough room for further investiga-
tion in this direction. With a view to investigate the behavior of the superoxide ion 
in multicomponent organic synthesis, which is of importance in itself and further to 
assess its synthetic scope, the reaction of this novel reagent was studied.
2. Results and discussion
In continuation of our ongoing program on superoxide research and the 
synthesis of biologically active compounds, it is our current endeavor to extent 
the applicability of Et4NO2 for the synthesis of tetraheterocyclicBenzimidazolo/
benzothiazolo quinazolin-1-one ring systems 4 by a one-pot three-component 
condensation reaction of various aromatic aldehydes 2 and 1,3-diketones 3 with 
2-aminobenzimidazole/2-aminobenzothiazole 1 using tetraethylammonium super-
oxide under non aqueous conditions (Figure 1).
In order to achieve the optimum yield of the product, the effect of various param-
eters such as effect of solvents (DMF, DMSO, and CH3CN) and molar proportion 
of the reactants were investigated in detail using benzaldehyde 2, dimedone 3 with 
2-aminobenzimidazole 1 as a model reaction.
To investigate the effect of solvents, the model reaction was carried out in dif-
ferent aprotic solvents. The results obtained clearly indicate that DMF was the best 
solvent among all investigated solvents in terms of product yield and the reaction 
time (Table 1).
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In order to establish the reactants molar ratio on the yield of product the model 
reaction was carried out in different concentration of reactants (Table 2).
A perusal of the table clearly indicates the profound effect of the concentra-
tion of KO2 and Et4NBr on the yield of the product 4a. As regards the ratio of 
KO2 and Et4NBr, it is evident from the entries 1, 2 and 3 that with the diminution 
of the concentration of Et4NBr, the yield of product 4a decreases. But as may 
be seen only a little difference in the yield of the product in the case of entries 
1 and 2, the ratio of KO2 and Et4NBr was further kept to be 2:1. Therefore, in 
subsequent studies, the concentration of KO2 has been increased manifold but 
the ratio of KO2 and Et4NBr was all along maintained to be 2:1. Furthermore, in 
case of entries 5 and 6, there is just a 2% increase in the yield of the product and 
for that 2% increase, the concentration of KO2 and Et4NBr have been increased 
Figure 1. 
One-pot synthesis of compounds 4 by the three-component condensation reaction of various aldehydes and 
1,3-diketones with 2-aminobenzimidazole/2-aminobenzothiazole under superoxide ion at room temperature.
Entry Solvents Time %Yield
1 Dichloromethane 12 h Trace
2 Acetonitrile 8 h 70
3 Tetrahydrofuran 14 h 42
4 Dimethylsulfoxide 20 h Trace
5 Dimethylformamide 6 h 88
Table 1. 
Effect of solvents on the yield of the product 4a.
Entry Reactants molar ratio Product yield* (%)
Benzaldehydes:dimidone:2-aminobezimidazole:KO2:Et4NBr
1 1.0 1.0 1.0 1.0 1.0 40
2 1.0 1.0 1.0 1.0 0.5 38
3 1.0 1.0 1.0 1.0 0.25 28
4 1.0 1.0 1.0 2.5 1.25 69
5 1.0 1.0 1.0 4.0 2.00 88
6 1.0 1.0 1.0 6.0 3.00 90
*Isolated yield based on aldehyde.
Optimized condition has been shown by bold letter (entry 5).
Table 2. 
Effect of reactants molar ratio on the yield of product 4a.
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substantially (6 fold and 3 fold respectively). As a result, considering the high 
cost of KO2 and Et4NBr, the entry 5, with the reactants ratio 1:1:1:4:2, has been 
selected as the optimum ratio.
The scope and limitations of this reaction were fully illustrated with various 
ortho-, meta- and para-substituted benzaldehydes in the presence of 2-aminobenz-
imidazole and 2-aminobenzothiazole.
As indicated in Table 3, the reaction proceeded efficiently with both 
electron-withdrawing and electron releasing ortho-, meta- and para-substituted 
benzaldehydes.
The products were identified by their physical and spectral data, which were in 
full agreement with the reported values.
Table 3. 
Synthesis of tetraheterocyclicbenzimidazolo/benzothiazolo quinazolin-1-ones.
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2.1  Mechanism for the synthesis of tetraheterocyclicbenzimidazolo/
benzothiazolo quinazolin-1-ones
The proposed mechanism for the formation of tetraheterocyclicbenzimidazolo/
benzothiazolo quinazolin-1-ones ring system is given in Figure 2. The reaction was 
initiated by the abstraction of proton from 1,3-diketones 3 by tetraethylammonium 
superoxide which was in situ generated by the phase transfer reaction of potassium 
superoxide with tetraethylammonium bromide. Now, Knoevenagel condensa-
tion takes place between benzaldehyde 2 and subsequently, by dehydration, olefin 
3-benzylidene-2,4-hexanedione 5 is produced. Then 2-aminobenzimidazole/2-ami-
nobenzothiazole1 is reacted with compound 5 through a Michael addition to produce 
a product of type 6 and after cyclisation to afford tetraheterocyclicbenzimidazolo/
benzothiazolo quinazolin-1-one ring systems 4.
Potassium superoxide (1.42 g, 0.02 mol) and tetraethylammonium bromide 
(2.10 g, 0.01 mol) were weighed under nitrogen atmosphere using an atmosbag 
and were transferred into a three-necked R. B. flask, dry DMF (20 mL) was added 
to it and the mixture was agitated magnetically for 15 min to facilitate the forma-
tion of tetraethylammoniumsuperoxide. To the stirred reaction mixture, dime-
done (0.70 g, 0.005 mol) 3 were added. After 10 min, benzaldehyde (0.53 g, 0.005 
mol) 2 and 2-aminobenzimidazole (0.665 g, 0.005 mmol) 1 were introduced, 
and the stirring was continued 6 h. After the reaction was over as indicated by 
TLC, mixture was treated with cold brine solution (2 mL) followed by saturated 
sodium hydrogen carbonate solution (2 mL) to decompose the unreacted KO2. The 
mixture was then extracted with dichloromethane (3 × 15 mL) and the combined 
organic phase was dried over anhydrous Na2SO4, filtered, and evaporated to give 
the products 4a, which were purified by column chromatography.
Figure 2. 
Plausible mechanism for the formation of tetraheterocyclicbenzimidazolo/benzothiazolo quinazolin-1-one 
derivatives (4a-o).
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All the products were characterized by IR and 1H NMR (because of low solubil-
ity of compounds 4a-o, 13C NMR was not obtained).
3,3–Dimethyl–12–phenyl–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]
quinazolin–1(2H)–one (4a): M.p. > 300°C; IR (KBr, υ = cm−1) 3445, 2885, 1640, 1618, 
1610, 1565 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.16 (br. s, 1H, NH), 7.39–7.30  
(m, 6H), 7.23 (d, J = 8.0 Hz, 1H), 7.07–7.04 (m, 1H), 6.98–6.95 (m, 1H), 6.44  
(s, 1H), 2.26 (d, J = 16.0 Hz, 2H), 2.06 (d, J = 16.0 Hz, 2H), 1.06 (s, 3H), 0.92 (s, 3H). 
Anal. Calcd for C22H21N3O: C, 76.94; H, 6.16; N, 12.24; O, 4.66. Found: C, 76.90; H, 
6.20; N, 12.26; O, 4.64.
12–(4–Methoxyphenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4b): M.p. > 300°C; IR (KBr, υ = cm−1) 
3391, 2850, 1670, 1644, 1610, 1590 cm−1;1H NMR (500 MHz, DMSO–d6): δ = 11.06 
(br. s, 1H, NH), 7.36 (d, J = 8.0 Hz, 1H), 7.26–7.24 (m, 3H), 7.04 (t, J = 7.5 Hz, 1H), 
6.95 (t, J = 7.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 2H), 6.36 (s, 1H), 3.65 (s, 3H), 2.64–2.52 
(m, 2H), 2.25 (d, J = 16.0 Hz, 1H), 2.05 (d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.94  
(s, 3H). Anal Calcd for C23H23N3O2: C, 73.97; H, 6.21; N, 11.25; O, 8.57. Found: C, 
73.92; H, 6.26; N, 11.23; O, 8.59.
12–(4–Chlorophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4c): M.p. > 300°C; IR (KBr, υ = cm−1) 
3440, 2934, 1655, 1650, 1613, 1580 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.10  
(br. s, 1H, NH), 7.36 (d, J = 7.5 Hz, 1H), 7.33 (d, J = 6.5 Hz, 2H), 7.24 (s, 2H), 7.15  
(s, 1H), 7.04 (s, 1H), 6.95 (s, 1H), 6.41 (s, 1H), 2.63 (d, J = 16.0 Hz, 2H), 2.26 (d, J = 16.0 Hz, 2H), 
1.06 (s, 3H), 0.93 (s, 3H). Anal. Calcd for C22H20ClN3O: C, 69.93; H, 5.34; Cl, 9.38;  
N, 11.12; O, 4.23. Found: C, 69.90; H, 5.37; Cl, 9.34; N, 11.15; O, 4.24.
12–(4–Bromophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4d): M.p. >300°C; IR (KBr, υ = cm−1) 
3441, 2956, 1645, 1614, 1590, 1566 cm−1; 1H-NMR (500 MHz, DMSO-d6): δ = 10.01 
(br. s, 1H, NH), 6.99–7.89 (m, Ar–H), 6.43 (s, 1H), 2.59–2.67 (m, 2H), 2.20 (d, 
J = 16.00 Hz, 1H), 2.00 (d, J = 16.01 Hz, 1H) 1.05 (s, 3H), 0.94 (s, 3H). Anal. Calcd 
for C22H20BrN3O: C, 62.57; H, 4.77; Br, 18.92; N, 9.95; O, 3.79. Found: C, 62.67; H, 
4.86; Br, 18.80; N, 9.83; O, 3.90.
12–(4–Hydroxyphenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4e): M.p. > 300°C; IR (KBr, υ = cm−1) 
3449, 2891, 1642, 1613, 1587, 1566 cm−1; 1H-NMR (500 MHz, DMSO-d6) δ = 11.02 
(br. s, 1H, NH), 9.33 (s, 1H, OH), 6.61–7.36 (m, 8H, Ar–H), 6.18 (s, 1H), 2.51–2.74 
(m, 2H), 2.25 (d, J = 9.24 Hz, 1H), 2.05(d, J = 8.94 Hz, 1H), 1.07 (s, 3H), 0.96 (s, 
3H), Anal. Calcd for C22H21N3O2: C, 73.52; H, 5.89; N, 11.69; O, 8.90. Found: C, 
73.63; H, 5.97; N, 11.80; O, 8.71.
12–(3–Chlorophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4f ) M.p. > 300°C; IR (KBr, υ = cm−1) 
3400, 2891, 1660, 1652, 1613, 1575 cm−1; 1H NMR (500 MHz, DMSO−d6): δ = 11.18 
(br. s, 1H, NH), 7.46 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.30–7.21 (m, 5H), 7.06 (s, 1H), 
6.98 (s, 1H), 6.46 (s, 1H), 2.58 (d, J = 16.0 Hz, 1H), 2.26 (d, J = 16.0 Hz, 1H), 2.08 
(d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.93 (s, 3H). Anal. Calcd for C22H20ClN3O:  
C, 69.93; H, 5.34; Cl, 9.38; N, 11.12; O, 4.23. Found: C, 69.90; H, 5.37; Cl, 9.35; N, 
11.14; O, 4.24.
3,3–Dimethyl–12–(2–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4 g): M.p. > 300°C; IR (KBr, υ = cm−1) 
3398, 2972, 1664, 1645, 1618, 1594 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.18 
(br. s, 1H, NH), 7.46 (s, 1H), 7.31–7.19 (m, 5H), 7.06 (t, J = 7.5 Hz, 1H), 6.98 
(t, J = 7.5 Hz, 1H), 6.46 (s, 1H), 2.62 (d, J = 16.0 Hz, 1H), 2.55 (s, 1H), 2.26 (d, 
J = 16.0 Hz, 1H), 2.08 (d, J = 16.0 Hz, 1H), 1.06 (s, 2H), 0.93 (s, 2H). Anal. Calcd 
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for C22H20N4O3: C, 68.03; H, 5.19; N, 14.42; O, 12.36. Found: C, 68.07; H, 5.15; N, 
14.46; O, 12.32.
3,3–Dimethyl–12–(3–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4 h): M.p. > 300°C; IR (KBr, υ = cm−1) 
3394, 2970, 1660, 1648, 1615, 1598 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.26 
(br. s, 1H, NH), 8.27 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 
7.56 (t, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.07 (t, 
J = 7.5 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.65 (s, 1H), 2.27 (d, J = 16.0 Hz, 2H), 2.07 
(d, J = 16.0 Hz, 2H), 1.06 (s, 3H), 0.91 (s, 3H). Anal. Calcd for C22H20N4O3: C, 68.03; 
H, 5.19; N, 14.42; O, 12.36. Found: C, 68.08; H, 5.14; N, 14.44; O, 12.34.
3,3–Dimethyl–12–(4–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4i): M.p. > 300°C; IR (KBr, υ = cm−1) 
3396, 2980, 1662, 1641, 1612, 1594 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.27 
(br. s, 1H, NH), 8.12 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.40 (d, J = 7.5 Hz, 
1H), 7.23 (d, J = 8.0 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.60 
(s, 1H), 2.65 (d, J = 16.0 Hz, 1H), 2.54 (d, J = 16.0 Hz, 1H), 2.27  
(d, J = 16.0 Hz, 1H), 2.06 (d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.91 (s, 3H). Anal. 
Calcd for C22H20N4O3: C, 68.03; H, 5.19; N, 14.42; O, 12.36. Found: C, 68.04; H, 
5.18; N, 14.40; O, 12.38.
12–(4–Methoxyphenyl)–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]
quinazolin–1(2H)–one (4j): M.p. = 238–240°C; IR (KBr, υ = cm−1) 3398, 2976, 
1666, 1642, 1616, 1575 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.07 (br. s, 1H, 
NH), 7.36 (d, J = 8.0 Hz, 1H), 7.26–7.22 (m, 3H), 7.06–7.01 (m, 1H), 6.95  
(t, J = 7.2 Hz, 1H), 6.78 (d, J = 8.0 Hz, 2H), 6.37 (s, 1H), 3.65 (s, 3H), 2.68 (d, 
J = 5.0 Hz, 2H), 2.29 (dd, J = 10.5, 5.0 Hz, 1H), 2.22 (dd, J = 16.0, 5.0 Hz, 1H), 
2.02–1.93 (m, 1H), 1.88–1.80 (m, 1H). Anal. Calcd for C21H19N3O2: C, 73.03; H, 5.54; 
N, 12.17; O, 9.26. Found: C, 73.01; H, 5.56; N, 12.14; O, 9.29.
12–(3–Nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]quin-
azolin–1(2H)–one(4 k): M.p. > 300°C; IR (KBr, υ = cm−1) 3412, 2872, 2855, 1670, 
1640, 1617, 1601 cm−1;1H NMR (500 MHz, DMSO–d6): δ = 11.28 (br. s, 1H, NH), 
8.26 (s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.54 (t, J = 8.0  
Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.06 (t, J = 7.4 Hz, 1H), 
6.96 (t, J = 7.5 Hz, 1H), 6.66 (s, 1H), 2.40–2.18 (m, 2H), 1.93 (dd, J = 16.0, 2H);. 
Anal. Calcd for C20H16N4O3: C, 66.66; H, 4.48; N, 15.55; O, 13.32. Found: C,  
66.64; H, 4.50; N, 15.53; O, 13.34.
3,3–Dimethyl–12–phenyl–2,3,4,12–tetrahydro–1H–benzo[4,5]thiazolo[2,3–b] 
quinazolin–1–one (4 l): M.p. = 208–210°C; IR (KBr, υ = cm−1) 3428, 2965, 1680, 
1655, 1589, 1516, 1370 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 7.79 (d, J = 10.0  
Hz, 1H), 7.43 (dd, J = 17.5, 7.7 Hz, 3H), 7.28 (dd, J = 16.0, 3H), 7.20 (dd, J = 16.0,  
8.0 Hz, 2H), 6.51 (s, 1H), 2.47–2.36 (m, 2H), 2.24 (d, J = 16.0 Hz, 1H), 2.05  
(d, J = 16.0 Hz, 1H), 1.02 (s, 3H), 0.86 (s, 3H). Anal. Calcd for C22H20N2OS: C, 73.30; 
H, 5.59; N, 7.77; O, 4.44; S, 8.89. Found: C, 73.33; H, 5.56; N, 7.79; O, 4.41; S, 8.88.
3,3–Dimethyl–12–(4-methylphenyl)–2,3,4,12–tetrahydro–1H–benzo[4,5]
thiazolo[2,3–b]quinazolin–1–one(4 m):
M.p. = 203–205°C. 1H NMR (500 MHz, DMSO–d6): δ = 7.49–7.47 (m, 1H), 7.34 
(d, J = 8 Hz, 2H), 7.28–7.22 (m, 1H), 7.18–7.15 (m, 2H), 7.06 (d, J = 8 Hz, 2H), 6.47 
(s, 1H), 2.49 (s, 2H), 2.28–2.17 (m, 5H), 1.09 (s, 3H), 0.97 (s, 3H). Anal. Calcd for 
C23H22N2OS: C, 73.77; H, 5.92; N, 7.48; O, 4.27; S, 8.56. Found: C, 73.68; H, 5.71; N, 
7.60; O, 4.35; S, 8.70.
3,3–Dimethyl–12–(4-bromophenyl)–2,3,4,12–tetrahydro–1H–benzo[4,5]
thiazolo[2,3–b]quinazolin–1–one (4n): M.p. 182–184°C. 1H NMR (500 MHz, 
DMSO–d6): δ = 7.47 (d, J = 8 Hz, 1H), 7.37–7.28 (m, 5H), 7.19 (d, J = 8 Hz, 1H), 7.06 
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All the products were characterized by IR and 1H NMR (because of low solubil-
ity of compounds 4a-o, 13C NMR was not obtained).
3,3–Dimethyl–12–phenyl–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]
quinazolin–1(2H)–one (4a): M.p. > 300°C; IR (KBr, υ = cm−1) 3445, 2885, 1640, 1618, 
1610, 1565 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.16 (br. s, 1H, NH), 7.39–7.30  
(m, 6H), 7.23 (d, J = 8.0 Hz, 1H), 7.07–7.04 (m, 1H), 6.98–6.95 (m, 1H), 6.44  
(s, 1H), 2.26 (d, J = 16.0 Hz, 2H), 2.06 (d, J = 16.0 Hz, 2H), 1.06 (s, 3H), 0.92 (s, 3H). 
Anal. Calcd for C22H21N3O: C, 76.94; H, 6.16; N, 12.24; O, 4.66. Found: C, 76.90; H, 
6.20; N, 12.26; O, 4.64.
12–(4–Methoxyphenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4b): M.p. > 300°C; IR (KBr, υ = cm−1) 
3391, 2850, 1670, 1644, 1610, 1590 cm−1;1H NMR (500 MHz, DMSO–d6): δ = 11.06 
(br. s, 1H, NH), 7.36 (d, J = 8.0 Hz, 1H), 7.26–7.24 (m, 3H), 7.04 (t, J = 7.5 Hz, 1H), 
6.95 (t, J = 7.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 2H), 6.36 (s, 1H), 3.65 (s, 3H), 2.64–2.52 
(m, 2H), 2.25 (d, J = 16.0 Hz, 1H), 2.05 (d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.94  
(s, 3H). Anal Calcd for C23H23N3O2: C, 73.97; H, 6.21; N, 11.25; O, 8.57. Found: C, 
73.92; H, 6.26; N, 11.23; O, 8.59.
12–(4–Chlorophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4c): M.p. > 300°C; IR (KBr, υ = cm−1) 
3440, 2934, 1655, 1650, 1613, 1580 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.10  
(br. s, 1H, NH), 7.36 (d, J = 7.5 Hz, 1H), 7.33 (d, J = 6.5 Hz, 2H), 7.24 (s, 2H), 7.15  
(s, 1H), 7.04 (s, 1H), 6.95 (s, 1H), 6.41 (s, 1H), 2.63 (d, J = 16.0 Hz, 2H), 2.26 (d, J = 16.0 Hz, 2H), 
1.06 (s, 3H), 0.93 (s, 3H). Anal. Calcd for C22H20ClN3O: C, 69.93; H, 5.34; Cl, 9.38;  
N, 11.12; O, 4.23. Found: C, 69.90; H, 5.37; Cl, 9.34; N, 11.15; O, 4.24.
12–(4–Bromophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4d): M.p. >300°C; IR (KBr, υ = cm−1) 
3441, 2956, 1645, 1614, 1590, 1566 cm−1; 1H-NMR (500 MHz, DMSO-d6): δ = 10.01 
(br. s, 1H, NH), 6.99–7.89 (m, Ar–H), 6.43 (s, 1H), 2.59–2.67 (m, 2H), 2.20 (d, 
J = 16.00 Hz, 1H), 2.00 (d, J = 16.01 Hz, 1H) 1.05 (s, 3H), 0.94 (s, 3H). Anal. Calcd 
for C22H20BrN3O: C, 62.57; H, 4.77; Br, 18.92; N, 9.95; O, 3.79. Found: C, 62.67; H, 
4.86; Br, 18.80; N, 9.83; O, 3.90.
12–(4–Hydroxyphenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4e): M.p. > 300°C; IR (KBr, υ = cm−1) 
3449, 2891, 1642, 1613, 1587, 1566 cm−1; 1H-NMR (500 MHz, DMSO-d6) δ = 11.02 
(br. s, 1H, NH), 9.33 (s, 1H, OH), 6.61–7.36 (m, 8H, Ar–H), 6.18 (s, 1H), 2.51–2.74 
(m, 2H), 2.25 (d, J = 9.24 Hz, 1H), 2.05(d, J = 8.94 Hz, 1H), 1.07 (s, 3H), 0.96 (s, 
3H), Anal. Calcd for C22H21N3O2: C, 73.52; H, 5.89; N, 11.69; O, 8.90. Found: C, 
73.63; H, 5.97; N, 11.80; O, 8.71.
12–(3–Chlorophenyl)–3,3–dimethyl–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b] quinazolin–1(2H)–one (4f ) M.p. > 300°C; IR (KBr, υ = cm−1) 
3400, 2891, 1660, 1652, 1613, 1575 cm−1; 1H NMR (500 MHz, DMSO−d6): δ = 11.18 
(br. s, 1H, NH), 7.46 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.30–7.21 (m, 5H), 7.06 (s, 1H), 
6.98 (s, 1H), 6.46 (s, 1H), 2.58 (d, J = 16.0 Hz, 1H), 2.26 (d, J = 16.0 Hz, 1H), 2.08 
(d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.93 (s, 3H). Anal. Calcd for C22H20ClN3O:  
C, 69.93; H, 5.34; Cl, 9.38; N, 11.12; O, 4.23. Found: C, 69.90; H, 5.37; Cl, 9.35; N, 
11.14; O, 4.24.
3,3–Dimethyl–12–(2–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4 g): M.p. > 300°C; IR (KBr, υ = cm−1) 
3398, 2972, 1664, 1645, 1618, 1594 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.18 
(br. s, 1H, NH), 7.46 (s, 1H), 7.31–7.19 (m, 5H), 7.06 (t, J = 7.5 Hz, 1H), 6.98 
(t, J = 7.5 Hz, 1H), 6.46 (s, 1H), 2.62 (d, J = 16.0 Hz, 1H), 2.55 (s, 1H), 2.26 (d, 
J = 16.0 Hz, 1H), 2.08 (d, J = 16.0 Hz, 1H), 1.06 (s, 2H), 0.93 (s, 2H). Anal. Calcd 
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for C22H20N4O3: C, 68.03; H, 5.19; N, 14.42; O, 12.36. Found: C, 68.07; H, 5.15; N, 
14.46; O, 12.32.
3,3–Dimethyl–12–(3–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4 h): M.p. > 300°C; IR (KBr, υ = cm−1) 
3394, 2970, 1660, 1648, 1615, 1598 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.26 
(br. s, 1H, NH), 8.27 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 
7.56 (t, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.07 (t, 
J = 7.5 Hz, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.65 (s, 1H), 2.27 (d, J = 16.0 Hz, 2H), 2.07 
(d, J = 16.0 Hz, 2H), 1.06 (s, 3H), 0.91 (s, 3H). Anal. Calcd for C22H20N4O3: C, 68.03; 
H, 5.19; N, 14.42; O, 12.36. Found: C, 68.08; H, 5.14; N, 14.44; O, 12.34.
3,3–Dimethyl–12–(4–nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]
imidazo[2,1-b]quinazolin–1(2H)–one (4i): M.p. > 300°C; IR (KBr, υ = cm−1) 
3396, 2980, 1662, 1641, 1612, 1594 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.27 
(br. s, 1H, NH), 8.12 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.40 (d, J = 7.5 Hz, 
1H), 7.23 (d, J = 8.0 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.60 
(s, 1H), 2.65 (d, J = 16.0 Hz, 1H), 2.54 (d, J = 16.0 Hz, 1H), 2.27  
(d, J = 16.0 Hz, 1H), 2.06 (d, J = 16.0 Hz, 1H), 1.06 (s, 3H), 0.91 (s, 3H). Anal. 
Calcd for C22H20N4O3: C, 68.03; H, 5.19; N, 14.42; O, 12.36. Found: C, 68.04; H, 
5.18; N, 14.40; O, 12.38.
12–(4–Methoxyphenyl)–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]
quinazolin–1(2H)–one (4j): M.p. = 238–240°C; IR (KBr, υ = cm−1) 3398, 2976, 
1666, 1642, 1616, 1575 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 11.07 (br. s, 1H, 
NH), 7.36 (d, J = 8.0 Hz, 1H), 7.26–7.22 (m, 3H), 7.06–7.01 (m, 1H), 6.95  
(t, J = 7.2 Hz, 1H), 6.78 (d, J = 8.0 Hz, 2H), 6.37 (s, 1H), 3.65 (s, 3H), 2.68 (d, 
J = 5.0 Hz, 2H), 2.29 (dd, J = 10.5, 5.0 Hz, 1H), 2.22 (dd, J = 16.0, 5.0 Hz, 1H), 
2.02–1.93 (m, 1H), 1.88–1.80 (m, 1H). Anal. Calcd for C21H19N3O2: C, 73.03; H, 5.54; 
N, 12.17; O, 9.26. Found: C, 73.01; H, 5.56; N, 12.14; O, 9.29.
12–(3–Nitrophenyl)–3,4,6,12–tetrahydrobenzo[4,5]imidazo[2,1-b]quin-
azolin–1(2H)–one(4 k): M.p. > 300°C; IR (KBr, υ = cm−1) 3412, 2872, 2855, 1670, 
1640, 1617, 1601 cm−1;1H NMR (500 MHz, DMSO–d6): δ = 11.28 (br. s, 1H, NH), 
8.26 (s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.54 (t, J = 8.0  
Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.06 (t, J = 7.4 Hz, 1H), 
6.96 (t, J = 7.5 Hz, 1H), 6.66 (s, 1H), 2.40–2.18 (m, 2H), 1.93 (dd, J = 16.0, 2H);. 
Anal. Calcd for C20H16N4O3: C, 66.66; H, 4.48; N, 15.55; O, 13.32. Found: C,  
66.64; H, 4.50; N, 15.53; O, 13.34.
3,3–Dimethyl–12–phenyl–2,3,4,12–tetrahydro–1H–benzo[4,5]thiazolo[2,3–b] 
quinazolin–1–one (4 l): M.p. = 208–210°C; IR (KBr, υ = cm−1) 3428, 2965, 1680, 
1655, 1589, 1516, 1370 cm−1; 1H NMR (500 MHz, DMSO–d6): δ = 7.79 (d, J = 10.0  
Hz, 1H), 7.43 (dd, J = 17.5, 7.7 Hz, 3H), 7.28 (dd, J = 16.0, 3H), 7.20 (dd, J = 16.0,  
8.0 Hz, 2H), 6.51 (s, 1H), 2.47–2.36 (m, 2H), 2.24 (d, J = 16.0 Hz, 1H), 2.05  
(d, J = 16.0 Hz, 1H), 1.02 (s, 3H), 0.86 (s, 3H). Anal. Calcd for C22H20N2OS: C, 73.30; 
H, 5.59; N, 7.77; O, 4.44; S, 8.89. Found: C, 73.33; H, 5.56; N, 7.79; O, 4.41; S, 8.88.
3,3–Dimethyl–12–(4-methylphenyl)–2,3,4,12–tetrahydro–1H–benzo[4,5]
thiazolo[2,3–b]quinazolin–1–one(4 m):
M.p. = 203–205°C. 1H NMR (500 MHz, DMSO–d6): δ = 7.49–7.47 (m, 1H), 7.34 
(d, J = 8 Hz, 2H), 7.28–7.22 (m, 1H), 7.18–7.15 (m, 2H), 7.06 (d, J = 8 Hz, 2H), 6.47 
(s, 1H), 2.49 (s, 2H), 2.28–2.17 (m, 5H), 1.09 (s, 3H), 0.97 (s, 3H). Anal. Calcd for 
C23H22N2OS: C, 73.77; H, 5.92; N, 7.48; O, 4.27; S, 8.56. Found: C, 73.68; H, 5.71; N, 
7.60; O, 4.35; S, 8.70.
3,3–Dimethyl–12–(4-bromophenyl)–2,3,4,12–tetrahydro–1H–benzo[4,5]
thiazolo[2,3–b]quinazolin–1–one (4n): M.p. 182–184°C. 1H NMR (500 MHz, 
DMSO–d6): δ = 7.47 (d, J = 8 Hz, 1H), 7.37–7.28 (m, 5H), 7.19 (d, J = 8 Hz, 1H), 7.06 
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(d, J = 8 Hz, 1H), 6.45 (s, 1H), 2.47 (s, 2H), 2.29–2.20 (m, 2H), 1.07 (s, 3H), 0.91  
(s, 3H), Anal. Calcd for C22H19BrN2OS: C, 60.14; H, 4.36; Br, 18.19; N, 6.38; O, 3.64; 
S, 7.30. Found: C, 60.35; H, 4.49; Br, 18.37; N, 6.50; O, 3.80; S, 7.45.
3,3–Dimethyl–12–(4-methoxyphenyl)–2,3,4,12–tetrahydro–1H–benzo[4,5]
thiazolo[2,3–b]quinazolin–1–one (4o): M.p. 87–88°C. 1H NMR (500 MHz, 
DMSO–d6): δ = 7.49–7.46 (m, 2H), 7.38 (d, J = 8 Hz, 2H), 7.23–7.07 (m, 2H), 6.74  
(d, J = 8 Hz, 2H), 6.44 (s, 1H), 3.62 (s, 3H), 2.48 (s, 2H), 2.31–2.17 (m, 2H), 1.06  
(s, 3H), 0.93 (s, 3H). Anal. Calcd for C23H22N2O2S: C, 70.74; H, 5.68; N, 7.17; O, 8.19; 
S, 8.21. Found: C, 70.89; H, 5.80; N, 7.35; O, 8.39; S, 8.40.
3. Conclusion
In conclusion, the reaction of in situ generated O2•− with imidazoles is able to 
mimic the in vivo biochemical reactions involved and corroborate the role of O2•− in 
living cells. Since the investigation has been performed at an ambient temperature in 
the presence of in situ generated O2•−, the results may be easily correlated with those 
occurring at physiological temperatures in more complex biological counterparts.
A novel synthetic route has been developed for the synthesis of tetraheterocyclic 
benzimidazolo/benzothiazolo quinazolin-1-one ring systems using tetraethylam-
monium superoxide under non aqueous condition at room temperature (mild 
reaction condition) within 6 h. The yield of the products was obtained up to 88% 
without using any tedious purification process. The applicability of tetraethylam-
monium bromide as an inexpensive alternative to 18-crown-6 for superoxide ion 
generation has been extended in present report.
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The Oxygen-Containing Fused 
Heterocyclic Compounds
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Abstract
The oxygen-containing heterocycles are an important class of compounds 
in organic chemistry. These compounds are used as drugs (coumarin and oxa-
zole), solvent (tetrahydrofuran), flavors, and fragrances (lactones). The fusion 
of aromatic ring to the oxygen-heterocycle will change the electron density; 
thereby, the physical/chemical/biological properties will alter. Also, the prepara-
tion of these fused molecules will require a different strategy/method/reaction 
condition. The topics covered in this chapter are the general synthetic methods 
and uses of fused heterocyclic compounds containing oxygen as a heteroatom. 
The derivatization of the primary scaffold is excluded from this chapter. 
Some of the fused compounds are coumarin (benzopyrans) and piclozotan 
(benzoxazepines).
Keywords: heterocycles, oxygen heteroatom, fused molecules, coumarin, a flavonoid
1. Introduction
The oxygen-containing heterocycles are an important class of compounds in 
organic chemistry mainly because of their natural abundance and diverse biologi-
cal functions. Natural and semi-synthetic oxygen heterocyclic compounds such 
as Taxol [1] (anticancer), Digoxin (CHF treatment), Cyclosporine-A (immuno-
suppressant) and Lovastatin (hypolipidemic) are well known used as promising 
therapeutic compounds [2]. Kaur et al. reviewed the oxygen heterocycles wherein 
saturated and unsaturated compounds are considered. They discussed the clas-
sification and chemistry of each of those compounds [1]. Reports are available 
wherein the synthesis of natural products containing oxygen as heteroatom is 
reviewed by Cossy and Guérinot [2]. Also, Rowlands and Farley chaptered the 
book on the anion radicals from oxygen-containing heterocycles [3]. None of these 
reports target the oxygen-containing heterocyclic compounds where fused rings 
are taken into consideration.
2. Classification of oxygen heterocycles
The oxygen-containing heterocycles can be classified in several ways like the 
classification based on (a) the number of oxygen atoms, (b) saturation level,  
(c) aromaticity or (d) abundance. For the clarity of the concept, the classification 
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cal functions. Natural and semi-synthetic oxygen heterocyclic compounds such 
as Taxol [1] (anticancer), Digoxin (CHF treatment), Cyclosporine-A (immuno-
suppressant) and Lovastatin (hypolipidemic) are well known used as promising 
therapeutic compounds [2]. Kaur et al. reviewed the oxygen heterocycles wherein 
saturated and unsaturated compounds are considered. They discussed the clas-
sification and chemistry of each of those compounds [1]. Reports are available 
wherein the synthesis of natural products containing oxygen as heteroatom is 
reviewed by Cossy and Guérinot [2]. Also, Rowlands and Farley chaptered the 
book on the anion radicals from oxygen-containing heterocycles [3]. None of these 
reports target the oxygen-containing heterocyclic compounds where fused rings 
are taken into consideration.
2. Classification of oxygen heterocycles
The oxygen-containing heterocycles can be classified in several ways like the 
classification based on (a) the number of oxygen atoms, (b) saturation level,  
(c) aromaticity or (d) abundance. For the clarity of the concept, the classification 
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Figure 2. 
Di-oxygen containing fused heterocyclic compounds.
based on a number of oxygen atoms is used. The benzene fused furan and pyrans 
are listed in Figure 1, whereas Figure 2 represents the compounds with two oxygen 
atoms in the ring system.
3. Synthesis of benzofurans
3.1 Mono-substituted benzofurans
3.1.1 Substitution on furan ring
The ortho-hydroxystilbenes are cyclized in 70–90% yield in a metal-free environ-
ment using hypervalent iodine and 1 eq. of (diacetoxyiodo) benzene to get 2-substituted 
benzofurans [4]. The acids are converted to 2,4,6- trichloro-1,3,5-triazine esters, which 
are subsequently added to toluene, 2-hydroxybenzyl triphenylphosphonium bromide 
(1 eq.), and NEt3 and irradiated at 110°C for two cycles of 30 min to get the 2-substituted 
benzofurans having a chiral stereocenter adjacent to the heterocycle in 60–80% yield [5]. 
Pd-catalyzed cyclisation of 2-chloroaryl alkynes using KOH at 100°C for 8 h resulted in 
the formation of benzofurans [6]. All three reactions are as shown in Figure 3.
3.1.2 Substitution on the benzene ring
Also, the substituted 1-allyl-2-allyloxybenzenes cyclizes to give substituted 
benzofurans by isomerization followed by ring-closure metathesis reaction using 
5 mol.% catalyst [7]. The homologous members of benzofurans can be prepared 
by 0.1 eq. of Ru-catalyzed cycloisomerization of homo- and bis-homopropargylic 
alcohols in presence of pyridine at 90°C for 1–6 h [8] as shown in Figure 4.
Figure 1. 
Mono-oxygen containing fused heterocyclic compounds.
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3.2 Di-substituted benzofurans
3.2.1 Substitution on furan and benzene ring of benzofuran
The reaction between 1 eq. of 2-(2-hydroxyphenyl)acetonitriles with 2 eq of 
aryl boronic acids along with Pd(OAc)2 (5 mol.%), bpy (10 mol.%), TFA (10 eq.), 
with TFA as solvent heated to 80°C for 36 h resulted in benzofuran derivatives with 
more than 80% yield [9]. Sonogashira cross-coupling reaction of halide with  
terminal alkynes followed by cyclization of the resulting 2-alkynylphenols in 
one-pot method results in benzofuran. The method employs the t-BuOH, PdCl2-
(CH3CN)2 (2 mol.%), t-BuOLi (3.6 eq.) and 2-chlorophenol (1 eq.), alkyne 
(1.5 eq.) were taken in a sealed tube and heated to 110°C for 22 h to get benzofuran 
[10]. Reaction of N-tosylhydrazones and terminal alkyne in a ligand free environ-
ment, using 10 mol.% of CuBr and 3 eq. of Cs2CO3 at 100°C for 4 h resulted in 
the formation of benzofurans with 38–91% yield [11]. Reductive cyclization of 
1-(2-hydroxyphenyl)-propargyl alcohols in presence of Pd(OAc)2 (5 mol.%), 
t-BuNC (1.2 eq.), Cs2CO3 (1.2 eq.) and MeCN as solvent gives benzofurans [12]. 
These reaction schemes are as shown in Figure 5.
Figure 3. 
Preparation of mono-substituted benzofuran.
Figure 4. 
Benzene ring substituted benzofuran.
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3.2.2 2,3-Substituted benzofuran
Ring closure of 2-haloaromatic ketones (1 eq.) in presence of K3PO4 (1.5 eq.), 
CuI (10 mol.%) and DMF at 105°C for 12–16 h results in di-substituted benzofurans 
[13]. The good yield coupled with atom economy was achieved, when o-alkynyl 
Figure 6. 
Preparation of di-substituted benzofuran.
Figure 5. 
Di-substituted benzofurans.
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phenyl acetals are cyclized using PtCl2 (2 mol.%), olefin (8 mol.%) in tolene at 30°C 
[14]. Cyclization of o-iodoanisoles and terminal alkynes under mild conditions 
using an electrophile (EX like PhSeCl or p-O2NC6H4SCl) (1.5 eq.), DCM at room 
temperature for 2–6 h yields 2,3-disubstituted benzofurans [15]. These reaction 
schemes are as shown in Figure 6.
Selective dehydrative C—H alkylation reaction of alkenes with alcohols using 
[(C6H6)(PCy3)(CO)RuH]BF4, cyclopentene, toluene at 100°C for 6–12 h results in 
2,3-substituted benzofurans [16]. O-Arylhydroxylamine hydrochloride (1 eq.) with 
cyclic or acyclic ketones (1 eq.) in the presence of methanesulfonic acid (2 eq.), THF 
at 60°C for 2–24 h yields benzofurans in 40–90% yield [17]. Ketones (1 eq.) on treat-
ment with Grignard reagents (3 eq.), benzofurans are formed, in a regioselective 
manner via [1,2]-aryl migration [18]. These reactions are depicted in Figure 7.
Figure 7. 
Substituted benzofurans.
Figure 8. 
Substituted benzofuran carbaldehydes.
Heterocycles - Synthesis and Biological Activities
94
3.2.2 2,3-Substituted benzofuran
Ring closure of 2-haloaromatic ketones (1 eq.) in presence of K3PO4 (1.5 eq.), 
CuI (10 mol.%) and DMF at 105°C for 12–16 h results in di-substituted benzofurans 
[13]. The good yield coupled with atom economy was achieved, when o-alkynyl 
Figure 6. 
Preparation of di-substituted benzofuran.
Figure 5. 
Di-substituted benzofurans.
95
The Oxygen-Containing Fused Heterocyclic Compounds
DOI: http://dx.doi.org/10.5772/intechopen.88026
phenyl acetals are cyclized using PtCl2 (2 mol.%), olefin (8 mol.%) in tolene at 30°C 
[14]. Cyclization of o-iodoanisoles and terminal alkynes under mild conditions 
using an electrophile (EX like PhSeCl or p-O2NC6H4SCl) (1.5 eq.), DCM at room 
temperature for 2–6 h yields 2,3-disubstituted benzofurans [15]. These reaction 
schemes are as shown in Figure 6.
Selective dehydrative C—H alkylation reaction of alkenes with alcohols using 
[(C6H6)(PCy3)(CO)RuH]BF4, cyclopentene, toluene at 100°C for 6–12 h results in 
2,3-substituted benzofurans [16]. O-Arylhydroxylamine hydrochloride (1 eq.) with 
cyclic or acyclic ketones (1 eq.) in the presence of methanesulfonic acid (2 eq.), THF 
at 60°C for 2–24 h yields benzofurans in 40–90% yield [17]. Ketones (1 eq.) on treat-
ment with Grignard reagents (3 eq.), benzofurans are formed, in a regioselective 
manner via [1,2]-aryl migration [18]. These reactions are depicted in Figure 7.
Figure 7. 
Substituted benzofurans.
Figure 8. 
Substituted benzofuran carbaldehydes.
Heterocycles - Synthesis and Biological Activities
96
Figure 10. 
Mono substituted dibenzofurans.
Base-catalyzed, the condensation of o-hydroxyphenones with 1,1-dichloroethylene, 
gives substituted benzofuran carbaldehydes [19].
Similarly, o-cinnamyl phenols, on oxidative cyclisation, results in 2-benzyl benzofu-
rans [20], while o-alkylphenols, on annulative reaction, gives 3-aminobenzofurans  
[21] (Figure 8).
4. Synthesis of benzofuranones
Alkenylphenols and phenyl formate reacts to give benzofuranones [22], while 
phenylacetic acids undergo cyclisation to give benzofuranones [23] (Figure 9).
5. Synthesis of dibenzofurans
Iododiaryl ether cyclizes under mild conditions to yield dibenzofurans [24]. 
Ortho-diazonium slats of diaryl ethers undergo intramolecular cyclisation, 
Figure 9. 
Synthesis of benzofuranones.
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resulting in dibenzofurans [25]. Cross-coupling of 6-diazo-2-cyclohexenones and 
ortho-haloiodobenzenes gives substituted dibenzofuran [26] (Figure 10).
6. Synthesis of coumarins
Phenols react with beta-keto esters to give coumarins [27]. If phenolic acetates 
are used, then, acrylates are used [28]. Aromatic alkynoate undergoes cyclisation 
with aldehydes to form 3-acyl-4-arylcoumarins [29] (Figure 11).
Substituted 2-hydroxybenzaldehydes react with phenylacetic acids resulting in sub-
stituted 3-aryl coumarins [30]. With dialkyl acetylenedicarboxylate, 2-hydroxybenzal-
dehydes gives 4-carboxyalkyl-8-formyl coumarins [31]. 2-Hydroxybenzaldehydes (or 
2-hydroxybenzaldehydes) cyclizes with aryl acetic acids to give 3-aryl coumarins (or 
3-aryl-4-methyl-coumarins) [32] (Figure 12).
Figure 11. 
Coumarin synthesis using phenol derivatives.
Figure 12. 
Coumarin synthesis using benzaldehyde derivatives.
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7. Synthesis of isocoumarins
Bromoalkynes reacts with benzoic acid and produces 3-substituted isocoumarins 
[33]. o-Halobenzoic acids and 1,3-diketones reacts to give 3-substituted isocoumarins 
[34]. 2-Halobenzoates and ketones react to give the same product [35]. o-Halobenzoic 
acids add to alkynes resulting in isocoumarin derivatives [36] (Figure 13).
8. Synthesis of flavones and flavonols
8.1 Baker-Venkataraman rearrangement
The chemical reaction between 2-hydroxyacetophenone and acid chloride in 
the presence of base yields 1,3-diketone which undergo rearrangement and 
Figure 13. 
Synthesis of isocoumarins.
Figure 14. 
Synthesis of flavone (from 1,3-diketone).
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concomitant cyclisation to produce flavone [37]. This reaction is often used to 
synthesize chromones and flavones (Figure 14).
8.2 Algar-Flynn-Oyamada synthesis
In this method, chalcone (1,3-diaryl-2-propen-1-one) is produced by condens-
ing 2-hydroxyacetophenone with an aryl aldehyde in alkaline medium (Claisen-
Schmidt condensation) followed by oxidative cyclisation of chalcone to get 
flavone [38] (Figure 15).
A mixture of acetophenone and aromatic aldehyde when exposed to Microwave 
irradiation, 2-phenyl γ-benzopyrones are obtained [39]. The same compound can 
be prepared by cyclizing 1,3-diaryl propanediones (Figure 16).
9. Conclusions
In this chapter, the synthesis of fused heterocyclic compounds having oxy-
gen as heteroatom is considered. The care is taken not to consider the reactions, 
where the reactions of the compounds leading to derivatizations are not included. 
Figure 15. 
Synthesis of flavone (from chalcone).
Figure 16. 
Preparation of 2-phenyl γ-benzopyrones.
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Benzofurans, benzofuranones, dibenzofurans, coumarins, isocoumarins, chro-
mones, and flavones are the fused heterocyclic compounds considered in this 
chapter. Also, the reactions are indicative and not the detailed reaction conditions, 
and appropriate reagents are not included in this chapter.
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Chapter 8
Synthesis and Anticancer 
Evaluation of Benzenesulfonamide 
Derivatives
Dattatraya Navnath Pansare and Rohini Narayan Shelke
Abstract
A highly efficient protocol was developed for the synthesis of 3-(indoline-1-
carbonyl)-N-(substituted) benzene sulfonamide analogs with excellent yields. The 
new 3-(indoline-1-carbonyl)-N-(substituted) benzene sulfonamide derivatives 
(4a-g and 5a-g) were evaluated in vitro anticancer activity against a series of differ-
ent cell lines like A549 (lung cancer cell), HeLa (cervical), MCF-7 (breast cancer 
cell) and Du-145 (prostate cancer cell) respectively. The results of the anticancer 
activity data revealed that most of the tested compounds showed IC50 values from 
1.98 to 9.12 μM in different cell lines. Compounds 4b, 4d, 5d, and 5g were the most 
potent, with IC50 values ranging from 1.98 to 2.72 μM in different cell lines.
Keywords: indoline, sulfonamide, anticancer
1. Introduction
Antibiotic resistant bacteria are rapidly emerging worldwide [1]. The various biolog-
ical active heterocyclic compounds, the indole derivatives are the key structural feature 
commonly found in natural products [2, 3] and bioactive molecules, such as tryptophan 
[4], tryptamine [5], and auxin [6]. Furthermore, it has been reported that sharing of 
the indole 3-carbon in the formation of spiroindoline derivatives highly enhances bio-
logical activity [7]. Moreover, some of the compounds containing benzenesulfonamide 
moiety also show broad spectrum biological properties such as elastase inhibitors [8], 
carbonic anhydrase inhibitors [9], clostridium histolyticum collogenase inhibitors [10] 
as well as herbicides and plant growth regulators [11]. Sulfonamides are common motifs 
in many drugs and medicinal compounds and play an important role in their bioactiv-
ity since the development of sulfa antibiotics in the 1930s [12]. Common drugs such as 
glibenclamide [13], sultiame [14], and COX-II inhibitors Piroxicam [15], Ampiroxicam 
[16], and Celecoxib [17] containing a sulfonyl moiety, which displays potential activity 
across a variety of biological targets. The sulfonamides are organic sulfur compounds 
which have attracted the attention for their better pharmacological activity [18–20]. 
It is interesting to note that the sulfonamide containing moiety is known to have some 
biological and pharmaceutical properties, such as, antitumor, antibacterial, thrombin 
inhibition, and antifungal activities [21–23].
In view of the above considerations, in continuation of our previous work on 
triazoles, pyrimidine, thiazoles and thiazolidinones of pharmaceutical interest 
[24–30] we report here on the synthesis and anticancer activity of new 3-(indoline-
1-carbonyl)-N-(substituted) benzene sulfonamide analogs.
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2. Results and discussion
2.1 Chemistry
The aim of this work was to design and synthesize a novel series of benzenesulfon-
amide incorporating biologically active indoline moieties to evaluate their anticancer 
activity. We have synthesized new derivatives containing sulfonamide linkage in 
frame work. The synthetic methods adopted for the preparation of the N-(substituted 
phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide derivatives (5a-g) in  
Figure 1. We herein report the synthesis of new substituted sulfonamide derivatives 
with the aim of investigating their anticancer activity (Table 2). The synthetic meth-
ods adopted for the preparation of the title compounds (5a-g) are presented below. 
We have tried to develop simplified reaction conditions for all the steps by avoiding 
costly reagents, tedious purifications and longer reactions times, we have screened 
peptide coupling condition in Table 1 to obtain better yield, good purity, shorter reac-
tion time, avoiding costly reagents and mainly reproducibility of yields.
For synthesis of compound 2 was done by using 1 treated with sulfonyl chloride 
at 0°C in DCM for 30 min and at room temperature for 1 h. The reaction mixture 
was evaporated under reduced pressure and the obtained gummy material was 
washed with excess of n-hexane. The material was crystallized using 20% ethyl 
acetate: n-hexane mixture, no purification was required and the pure compound is 
obtained as yellow solid. This was used further used for sulfonamide reaction.
Figure 1. 
Synthesis of N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide. Reagents and conditions: 
(a) sulfonyl chloride, dichloromethane (DCM) 0°C-rt; (b) substituted amine, pyridine, DCM, 0°C-rt; 
(c) lithium hydroxide (LiOH), tetrahydrofuran (THF), water (H2O), rt.; (d) indoline, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI), diisopropylethylamine (DIPEA), DCM, rt.
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For the synthesis of compounds from 3a-g by sulfonamide coupling, different 
substituted amines were coupled with 2 in presence of pyridine as base and DCM 
as solvent at room temperature for 4 h. The reaction mass was treated with cold 2N 
aqueous HCl and stirred for 30 min., the solid precipitates out in most of cases which 
was filtered and washed with cold diethyl ether and cold pentane, all the intermediates 
obtained were white solids. For intermediates 3a-g the reaction yield was 85–95%.
For synthesis of 4a-4g requires hydrolysis of 3a-g using lithium hydroxide, 
tetrahydrofuran and water at room temperature for 10 h. Work up of reactions were 
modified, and wash in basic conditions and later acidifying it to get desired product 
as white solids with required purity. The acids obtained were in pure state so that it 
can be directly used for next amide coupling with indoline. All reaction intermedi-
ates 4a-g yield up to 80–85%.
For synthesis of 5a-g we have done series of screenings by varying different 
coupling reagents, different bases, solvents and time. We have varied the equivalents 
of reagents and bases used to get better yield and purity by avoiding column purifica-
tions. The results of screenings are explained in Table 1. In entry 1 and 2 we have 
used 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) as coupling reagent and DMF as solvent we have varied 
bases triethylamine and diisopropylethylamine after 14 h we got product 57 and 55% 
respectively. In entries 3 and 4 we have used benzotriazol-1-yl-oxytripyrrolidinophos-
phonium hexafluorophosphate (PyBOP) as coupling reagent and THF as solvent and 
TEA and DIPEA as base to obtain yields 45 and 50% respectively. In entries 5, 6, 7, and 
8 we have used the EDCI and hydroxybenzotriazole (HOBt) as coupling reagents with 
DMF as solvent along with TEA and DIPEA as base in entries 5 and 6 we have used 
2.5 equiv. of base and in entries 7 and 8 we have increased base as 4 equiv. for 14 h. The 
yields obtained are 62, 72, 78, and 67% respectively. Same results like entry 1 and 2 
are obtained in entry 9 and 10 when we used propylphosphonic anhydride (T3P) as 
coupling reagent and TEA and DIPEA as bases in DCM to get 50 and 60% yield respec-
tively. In entry 11 it was observed that when EDCI (1.5 equiv.) when used along with 
DIPEA (2.5 equiv.) in DCM the yields was 95%, highlighted bold in Table 1. Work up 
requires extraction, and later on washing with 2N aqueous hydrochloric acid (HCl) to 
Sr. no. Coupling reagent Base Solvent Time 
(h)
Yield 
(%)
1. HATU (1.1 equiv.) TEA (1.2 equiv.) DMF 14 57
2. HATU (1.1 equiv.) DIPEA (1.2 equiv.) DMF 14 55
3. PyBOP (1.1 equiv.) TEA (1.2 equiv.) THF 14 45
4. PyBOP (1.1 equiv.) DIPEA (1.2 equiv.) THF 14 50
5. EDCI (1.5 equiv.) TEA (2.5 equiv.) DMF 14 62
HOBt (1.5 equiv.)
6. EDCI (1.5 equiv.) DIPEA (2.5 equiv.) DMF 14 72
HOBt (1.5 equiv.)
7. EDCI (1.5 equiv.) TEA (4 equiv.) DMF 14 78
8. HOBt (1.5 equiv.) DIPEA (4 equiv.) DMF 14 67
9. T3P (1.2 equiv.) TEA (2.5 equiv.) DCM 10 50
10. T3P (1.2 equiv.) DIPEA (2.5 equiv.) DCM 10 60
11. EDCI (1.5 equiv.) DIPEA (2.5 equiv.) DCM 10 95
Acid (1 equiv.) and indoline (1.2 equiv.)
Table 1. 
Optimization of peptide coupling reaction (5a-g).
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Table 1. 
Optimization of peptide coupling reaction (5a-g).
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obtain solid compounds. Which was washed with 5% DCM: hexane, cold diethyl ether 
and cold pentane gives the desired compounds in yield highest yields and with 95% and 
above purity for 5a-g. We have not used HOBt in entry 11 and 90% yield obtain after 
10 h only. The advantage of peptide coupling screenings are no need of column chro-
matography, no costly reagents required, no prep purification required. All obtained 
compounds are with 95% and above purity and are directly used for anticancer testing.
2.2 Biological evaluation: anticancer activity
The synthesized compounds were evaluated for their in vitro anticancer activity 
against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, breast 
cancer cell line (MCF-7) and prostate cell line (DU-145) using 5-fluorouracil as 
reference drug [31].
5-Flourouracil is used for anal, breast, colorectal, esophageal, stomach, 
pancreatic and skin cancers mainly. The response parameter calculated was the 
IC50 value, which corresponds to the concentration required for 50% inhibi-
tion of cell viability. The results are presented in Table 2, where all compounds 
exhibit moderate to good activity compared to 5-fluorouracil as positive control. 
In the case of the human lung cancer cell line (A549) compounds 4a, 4b, 4d, 
4f, 5d, and 5g were the most potent, with IC50 values ranging from 1.98 to 
2.82 μM. On the HeLa cell line the compounds which showed potent activity 
were 4b, 4d, 5d, and 5g (IC50 = 1.99–2.92 μM). In case of the MCF-7 breast 
cancer cell line, the potent compounds were 4d, 5d, and 5g with IC50 activity 
of 2.12–2.52 μM. Lower activity was observed for the synthesized compounds 
on the Du-145 prostate cancer cell line, where the most potent candidates were 
compounds 5g with IC50 activity in the range of 2.12 μM. Generally, the lung 
Compound A549 (lung 
cancer cell)
HeLa (cervical 
cancer cell)
MCF-7 (breast 
cancer cell)
Du-145 (prostate 
cancer cell)
4a 1.98 ± 0.12 3.83 ± 0.16 3.52 ± 0.06 3.86 ± 0.16
4b 2.81 ± 0.13 2.92 ± 0.08 2.32 ± 0.22 3.82 ± 0.12
4c 4.81 ± 0.12 6.32 ± 0.04 4.32 ± 0.06 3.73 ± 0.12
4d 2.82 ± 0.11 1.99 ± 0.22 2.36 ± 0.12 3.52 ± 0.11
4e 3.86 ± 0.08 4.38 ± 0.06 3.63 ± 0.12 6.52 ± 0.22
4f 2.72 ± 0.11 3.87 ± 0.08 4.12 ± 0.06 3.86 ± 0.22
4g 3.14 ± 0.14 3.98 ± 0.12 4.86 ± 0.11 4.57 ± 0.11
5a 8.48 ± 0.14 9.12 ± 0.08 7.82 ± 0.08 9.12 ± 0.06
5b 3.82 ± 0.08 4.13 ± 0.12 3.13 ± 0.11 3.52 ± 0.08
5c 4.13 ± 0.12 5.16 ± 0.08 6.12 ± 0.12 4.52 ± 0.11
5d 2.06 ± 0.12 2.12 ± 0.08 2.52 ± 0.16 5.12 ± 0.08
5e 2.52 ± 0.11 3.52 ± 0.11 4.48 ± 0.08 4.08 ± 0.11
5f 4.48 ± 0.08 4.98 ± 0.11 5.17 ± 0.22 5.18 ± 0.18
5g 2.73 ± 0.08 2.12 ± 0.12 2.12 ± 0.08 2.12 ± 0.04
5-FU 1.61 ± 0.12 1.72 ± 0.18 1.81 ± 0.10 1.89 ± 0.12
Table 2. 
In vitro anticancer screening of the synthesized compounds against four cell lines, data are expressed as IC50 
(μM) SD (n = 3).
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(A549) and cervical (HeLa) cancer cell lines were the most sensitive to the 
synthesized compounds. With regard to broad spectrum anticancer activity, 
close examination of the data presented in Table 2, reveals that compounds 
4b, 4d, and 5g were the most active, showing effectiveness toward the four cell 
lines. The structure activity relationship (SAR) can be explained on the basis of 
substitutions on both the aromatic rings less hindered substitution like methyl 
and ethyl on ortho and para position of rings increases the anticancer activity 
in all four cell lines, interestingly ortho triflouromethyl and indoline group 
decreases the anticancer activity and despite steric hindrance 4b, 4d, 5d, and 
5g shows promising activity because of electron donating tendency. Most of the 
compounds show promising anticancer activity with electron donating groups 
on the ring than electron withdrawing groups.
2.3  General experimental procedure for the synthesis of N-(substituted 
phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g)
2.3.1 Step-1: preparation of ethyl 3-(chlorosulfonyl)benzoate (2)
To a stirred solution of ethyl benzoate (10 g, 67 mmol) in DCM (25 mL). RM 
was cooled to 0°C and chloro sulfonic acid (9 g, 73 mmol) was added drop wise and 
stirred for 1 h at same temperature followed by stirring at room temperature for 1 h. 
After completion of reaction, evaporate reaction mixture under reduced pressure 
and obtained gummy material is washed with excess of hexane and it is crystalized 
from 20% ethyl acetate: hexane mixture to obtain white solid as ethyl 3-(chlorosul-
fonyl)benzoate (2) which is used further for sulfonamide coupling reaction. Yield 
54 g (81%).
2.3.2 Step-2: preparation of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g)
To a stirred solution of ethyl 3-(chlorosulfonyl)benzoate (2) (3 g, 10.1 mmol) in 
DCM (5 ml) was added pyridine (5 ml) the mixture was stirred at room tempera-
ture for 10 min. RM was cooled to 0°C and 2-methyl aniline (1.6 g, 15.16 mmol) was 
added drop wise followed by stirring at room temperature for 3 h. The reaction was 
monitored by TLC and LCMS, after completion of reaction poured reaction mass 
on cold 2N aqueous HCl (10 ml) and stirred RM it for 30 min. Precipitation formed 
in RM. Filtered the obtained solid and wash it with excess of water and cold diethyl 
ether (10 ml) and cold pentane (10 ml) to obtain ethyl 3-(N-(o-tolyl)sulfamoyl)
benzoate 2 as white solid. Yield 2.8 g (90%).
2.3.3 Step-3: preparation of 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a-g)
To a stirred solution of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g) (2 g, 
5.40 mmol) in THF (10 ml) added water (2 ml), and lithium hydroxide (0.377 g, 
18.2 mmol) and stirred reaction mixture for 4 h. Progress reaction was monitored 
by TLC and LCMS. After the completion of reaction evaporate reaction mixture 
under reduced pressure to obtain gummy material. Added 10 ml of water in it and 
extracted it with diethyl ether (10 ml). Collected aqueous layer and adjust its pH to 
4 by using 6N aqueous HCl. Precipitation occurs stirred it for 30 min. Filtered the 
obtained solid and wash it with excess of water, cold diethyl ether (10 ml) and cold 
pentane (10 ml) to obtain desired 3-(N-(o-tolyl)sulfamoyl)benzoic acid 4a as white 
solids. Yield 1.6 g (90%).
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obtain solid compounds. Which was washed with 5% DCM: hexane, cold diethyl ether 
and cold pentane gives the desired compounds in yield highest yields and with 95% and 
above purity for 5a-g. We have not used HOBt in entry 11 and 90% yield obtain after 
10 h only. The advantage of peptide coupling screenings are no need of column chro-
matography, no costly reagents required, no prep purification required. All obtained 
compounds are with 95% and above purity and are directly used for anticancer testing.
2.2 Biological evaluation: anticancer activity
The synthesized compounds were evaluated for their in vitro anticancer activity 
against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, breast 
cancer cell line (MCF-7) and prostate cell line (DU-145) using 5-fluorouracil as 
reference drug [31].
5-Flourouracil is used for anal, breast, colorectal, esophageal, stomach, 
pancreatic and skin cancers mainly. The response parameter calculated was the 
IC50 value, which corresponds to the concentration required for 50% inhibi-
tion of cell viability. The results are presented in Table 2, where all compounds 
exhibit moderate to good activity compared to 5-fluorouracil as positive control. 
In the case of the human lung cancer cell line (A549) compounds 4a, 4b, 4d, 
4f, 5d, and 5g were the most potent, with IC50 values ranging from 1.98 to 
2.82 μM. On the HeLa cell line the compounds which showed potent activity 
were 4b, 4d, 5d, and 5g (IC50 = 1.99–2.92 μM). In case of the MCF-7 breast 
cancer cell line, the potent compounds were 4d, 5d, and 5g with IC50 activity 
of 2.12–2.52 μM. Lower activity was observed for the synthesized compounds 
on the Du-145 prostate cancer cell line, where the most potent candidates were 
compounds 5g with IC50 activity in the range of 2.12 μM. Generally, the lung 
Compound A549 (lung 
cancer cell)
HeLa (cervical 
cancer cell)
MCF-7 (breast 
cancer cell)
Du-145 (prostate 
cancer cell)
4a 1.98 ± 0.12 3.83 ± 0.16 3.52 ± 0.06 3.86 ± 0.16
4b 2.81 ± 0.13 2.92 ± 0.08 2.32 ± 0.22 3.82 ± 0.12
4c 4.81 ± 0.12 6.32 ± 0.04 4.32 ± 0.06 3.73 ± 0.12
4d 2.82 ± 0.11 1.99 ± 0.22 2.36 ± 0.12 3.52 ± 0.11
4e 3.86 ± 0.08 4.38 ± 0.06 3.63 ± 0.12 6.52 ± 0.22
4f 2.72 ± 0.11 3.87 ± 0.08 4.12 ± 0.06 3.86 ± 0.22
4g 3.14 ± 0.14 3.98 ± 0.12 4.86 ± 0.11 4.57 ± 0.11
5a 8.48 ± 0.14 9.12 ± 0.08 7.82 ± 0.08 9.12 ± 0.06
5b 3.82 ± 0.08 4.13 ± 0.12 3.13 ± 0.11 3.52 ± 0.08
5c 4.13 ± 0.12 5.16 ± 0.08 6.12 ± 0.12 4.52 ± 0.11
5d 2.06 ± 0.12 2.12 ± 0.08 2.52 ± 0.16 5.12 ± 0.08
5e 2.52 ± 0.11 3.52 ± 0.11 4.48 ± 0.08 4.08 ± 0.11
5f 4.48 ± 0.08 4.98 ± 0.11 5.17 ± 0.22 5.18 ± 0.18
5g 2.73 ± 0.08 2.12 ± 0.12 2.12 ± 0.08 2.12 ± 0.04
5-FU 1.61 ± 0.12 1.72 ± 0.18 1.81 ± 0.10 1.89 ± 0.12
Table 2. 
In vitro anticancer screening of the synthesized compounds against four cell lines, data are expressed as IC50 
(μM) SD (n = 3).
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(A549) and cervical (HeLa) cancer cell lines were the most sensitive to the 
synthesized compounds. With regard to broad spectrum anticancer activity, 
close examination of the data presented in Table 2, reveals that compounds 
4b, 4d, and 5g were the most active, showing effectiveness toward the four cell 
lines. The structure activity relationship (SAR) can be explained on the basis of 
substitutions on both the aromatic rings less hindered substitution like methyl 
and ethyl on ortho and para position of rings increases the anticancer activity 
in all four cell lines, interestingly ortho triflouromethyl and indoline group 
decreases the anticancer activity and despite steric hindrance 4b, 4d, 5d, and 
5g shows promising activity because of electron donating tendency. Most of the 
compounds show promising anticancer activity with electron donating groups 
on the ring than electron withdrawing groups.
2.3  General experimental procedure for the synthesis of N-(substituted 
phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g)
2.3.1 Step-1: preparation of ethyl 3-(chlorosulfonyl)benzoate (2)
To a stirred solution of ethyl benzoate (10 g, 67 mmol) in DCM (25 mL). RM 
was cooled to 0°C and chloro sulfonic acid (9 g, 73 mmol) was added drop wise and 
stirred for 1 h at same temperature followed by stirring at room temperature for 1 h. 
After completion of reaction, evaporate reaction mixture under reduced pressure 
and obtained gummy material is washed with excess of hexane and it is crystalized 
from 20% ethyl acetate: hexane mixture to obtain white solid as ethyl 3-(chlorosul-
fonyl)benzoate (2) which is used further for sulfonamide coupling reaction. Yield 
54 g (81%).
2.3.2 Step-2: preparation of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g)
To a stirred solution of ethyl 3-(chlorosulfonyl)benzoate (2) (3 g, 10.1 mmol) in 
DCM (5 ml) was added pyridine (5 ml) the mixture was stirred at room tempera-
ture for 10 min. RM was cooled to 0°C and 2-methyl aniline (1.6 g, 15.16 mmol) was 
added drop wise followed by stirring at room temperature for 3 h. The reaction was 
monitored by TLC and LCMS, after completion of reaction poured reaction mass 
on cold 2N aqueous HCl (10 ml) and stirred RM it for 30 min. Precipitation formed 
in RM. Filtered the obtained solid and wash it with excess of water and cold diethyl 
ether (10 ml) and cold pentane (10 ml) to obtain ethyl 3-(N-(o-tolyl)sulfamoyl)
benzoate 2 as white solid. Yield 2.8 g (90%).
2.3.3 Step-3: preparation of 3-(N-(o-tolyl)sulfamoyl)benzoic acid (4a-g)
To a stirred solution of ethyl 3-(N-(o-tolyl)sulfamoyl)benzoate (3a-g) (2 g, 
5.40 mmol) in THF (10 ml) added water (2 ml), and lithium hydroxide (0.377 g, 
18.2 mmol) and stirred reaction mixture for 4 h. Progress reaction was monitored 
by TLC and LCMS. After the completion of reaction evaporate reaction mixture 
under reduced pressure to obtain gummy material. Added 10 ml of water in it and 
extracted it with diethyl ether (10 ml). Collected aqueous layer and adjust its pH to 
4 by using 6N aqueous HCl. Precipitation occurs stirred it for 30 min. Filtered the 
obtained solid and wash it with excess of water, cold diethyl ether (10 ml) and cold 
pentane (10 ml) to obtain desired 3-(N-(o-tolyl)sulfamoyl)benzoic acid 4a as white 
solids. Yield 1.6 g (90%).
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2.3.4  Step-4: N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide 
(5a-g)
The compound 3-(N-(o-tolyl)sulfamoyl)benzoic acid 4a-g (0.2 g, 0.65 mmol) 
was treated with EDCI (0.188 g, 0.98 mmol), DIPEA (0.34 ml, 1.96 mmol) in DCM 
(10 ml). Then added 2,4-dimentyl aniline (0.238 g, 1.96 mmol) and stirred RM at 
room temperature for 4 h. The reaction was monitored by TLC. Added 10 ml of 
cold water and stirred for 10 min, then extracted it with 10 ml of DCM. Collected 
organic layer wash it with 1N aqueous HCl and washed with brine (10 ml). To 
evaporate the organic layer to obtained the compound with 90% purity (5a-g). 
Purification done by washing with 5:95% of DCM: hexane. Obtained solid washed 
with cold diethyl ether (20 ml) and cold pentane (20 ml) to obtain compounds (5a-g).  
N-(2,4-dimethylphenyl)-3-(N-(o-tolyl)sulfamoyl)benzamide (5a): (0.240 g, 90%) 
as white solid, LC-MS m/z (%): 395 (M + H). 1H NMR (400 MHz, DMSO-d6) δ 
10.05 (s, 1H), 9.70 (s, 1H), 8.26 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 7.81 (d, J = 8 Hz, 
1H), 7.7 (d, J = 8 Hz, 1H), 7.18–7.13 (m, 2H), 7.1–7.08 (m, 3H), 7.01 (d, J = 8.4 Hz, 
1H), 6.95–6.92 (m, 1H), 2.28 (s, 3H), 2.15 (s, 3H), 2.02 (s, 3H). HPLC-98.25% 
RT-5.68 min. 13C NMR (CDCl3, 100 MHZ): 17.65, 17.79, 20.54, 126.09, 126.38, 126.40, 
126.43, 126.58, 129.23, 129.42, 130.82, 130.89, 131.38, 133.42, 133.62, 134.27, 134.65, 
135.40, 135.41, 135.45, 141.09, 163.93.
3. Conclusion
An effective method was developed which provided an easy access to a new 
series N-(substituted phenyl)-3-(indoline-1-carbonyl)benzenesulfonamide (5a-g) 
analogs. The mild reaction conditions, good to excellent yields, ease of workup 
and easily available substrates make the reactions attractive for the preparation of 
compounds. The compounds (4b, 4d, 5d, and 5g) show potent anticancer activity 
in all the four cell lines tested. The compounds are easy, simple and reproducible to 
synthesize in normal conditions and no additional conditions or expensive chemi-
cals are required for the reaction. The cell-lines with maximum IC50 values are the 
important in the study.
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Chapter 9
Synthesis and Biological 
Evaluation of Novel Phosphonyl 
Thiazolo Pyrazoles
Avula Srinivas
Abstract
A series of novel dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-
4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-phenyl-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate 11a–g were synthesized 
by the reaction of chalcone derivatives of (E)-5-benzylidene-2-((2S,3S)-3-((1-
(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-
3-phenylthiazolidin-4-one 10a–g with Bestmann-Ohira reagent. The chemical 
structures of newly synthesized compounds were elucidated by IR, NMR, MS, and 
elemental analysis. The compounds 11a–g were evaluated for their nematicidal 
activity against Dietylenchus myceliophagus and Caenorhabditis elegans, and com-
pounds 11b, 11c, 11g, and 11f showed appreciable nematicidal activity.
Keywords: phosponylpyrazoles, Bestmann-Ohira reagent, click reaction, 
Knoevenagel condensation, cyclisation, nematicidal activity
1. Introduction
1,2,3-Triazoles are one of the most important classes of heterocyclic organic 
compounds, which are reported to present in a plethora of biological activities 
for diverse therapeutic areas [1–12]. The 1,2,3-triazole motif is associated with 
diverse pharmacological activities such as antibacterial, antifungal, hypoglycemic, 
antihypertensive and analgesic properties [13–15]. Polysubstituted five-membered 
aza heterocyclic’s rank the most potent glycosidase inhibitors [16–19]. Further, this 
nucleus in combination with or in linking with various other classes of compounds 
such as amino acids, steroids, aromatic compounds, carbohydrates etc. became 
prominent in having various pharmacological properties [20]. 1,2,3-Triazole modi-
fied carbohydrates have became easily available after the discovery of the Cu(I) 
catalyzed azide-alkynes 1,3-dipolar cycloaddition reaction [21–25] and quickly 
became a prominent class of non-natural sugars. The chemistry and biology of 
triazole modified sugars is dominated by triazole glycosides [26]. Therefore, the 
synthesis and investigation of biological activity of 1,2,3-triazole glycosides is an 
important objective, which also received the considerable attention by the medici-
nal chemists.
Thiazoles are familiar group of heterocyclic compounds possessing a wide 
variety of biological activities and their utility as medicine is very much estab-
lished [27]. Thiazole nucleus is also an integral part of all the available penicillins 
Heterocycles - Synthesis and Biological Activities
116
thiophene-4-carboxamide synthesis and 
anti-proliferative activity study. Letters 
in Drug Design & Discovery. 2018. DOI: 
10.2174/1570180815666181004114125
[29] Pawar CD, Pansare DN,  
Shinde DB. Synthesis of new 
3-(substituted phenyl)-N-(2-hydroxy- 
2-(substituted phenyl)ethyl)- 
N-methylthiophene-2-sulfonamide 
derivatives as antiproliferative agents. 
European Journal of Chemistry. 
2018;9(1):13. DOI: 10.5155/
eurjchem.9.1.13-21.1669
[30] Pawar CD, Pansare DN, Shinde DB.  
Synthesis and antiproliferative activity 
of 3-(substituted)-4,5,6,7-tetrahydro-
6-(substituted)-1H-pyrazolo[3,4-c]
pyridine derivatives. European Journal 
of Chemistry. 2017;8(4):400. DOI: 
10.5155/eurjchem.8.4.400-409.1645
[31] Skehan P, Storeng R, Scudiero D, 
Monks A, McMohan J, Vistica D, et al. 
New colorimetric cytotoxicity assay 
for anticancer-drug screening. Journal 
of the National Cancer Institute. 
1990;82:1107
117
Chapter 9
Synthesis and Biological 
Evaluation of Novel Phosphonyl 
Thiazolo Pyrazoles
Avula Srinivas
Abstract
A series of novel dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-
4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-phenyl-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate 11a–g were synthesized 
by the reaction of chalcone derivatives of (E)-5-benzylidene-2-((2S,3S)-3-((1-
(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-
3-phenylthiazolidin-4-one 10a–g with Bestmann-Ohira reagent. The chemical 
structures of newly synthesized compounds were elucidated by IR, NMR, MS, and 
elemental analysis. The compounds 11a–g were evaluated for their nematicidal 
activity against Dietylenchus myceliophagus and Caenorhabditis elegans, and com-
pounds 11b, 11c, 11g, and 11f showed appreciable nematicidal activity.
Keywords: phosponylpyrazoles, Bestmann-Ohira reagent, click reaction, 
Knoevenagel condensation, cyclisation, nematicidal activity
1. Introduction
1,2,3-Triazoles are one of the most important classes of heterocyclic organic 
compounds, which are reported to present in a plethora of biological activities 
for diverse therapeutic areas [1–12]. The 1,2,3-triazole motif is associated with 
diverse pharmacological activities such as antibacterial, antifungal, hypoglycemic, 
antihypertensive and analgesic properties [13–15]. Polysubstituted five-membered 
aza heterocyclic’s rank the most potent glycosidase inhibitors [16–19]. Further, this 
nucleus in combination with or in linking with various other classes of compounds 
such as amino acids, steroids, aromatic compounds, carbohydrates etc. became 
prominent in having various pharmacological properties [20]. 1,2,3-Triazole modi-
fied carbohydrates have became easily available after the discovery of the Cu(I) 
catalyzed azide-alkynes 1,3-dipolar cycloaddition reaction [21–25] and quickly 
became a prominent class of non-natural sugars. The chemistry and biology of 
triazole modified sugars is dominated by triazole glycosides [26]. Therefore, the 
synthesis and investigation of biological activity of 1,2,3-triazole glycosides is an 
important objective, which also received the considerable attention by the medici-
nal chemists.
Thiazoles are familiar group of heterocyclic compounds possessing a wide 
variety of biological activities and their utility as medicine is very much estab-
lished [27]. Thiazole nucleus is also an integral part of all the available penicillins 
Heterocycles - Synthesis and Biological Activities
118
which have revolutionized the therapy of bacterial diseases [28]. The chemistry of 
thiazolidinone ring system is one of considerable interest as it is the core structure 
in various synthetic pharmaceuticals displaying a broad spectrum of biological 
activities [29]. The thiazolidinone nucleus also appears frequently in the structure 
of various natural products notably thiamine, compounds possessing cardiac and 
glycemic benefits such as troglitazone [30] and many metabolic products of fungi 
and primitive marine animals, including 2-(aminoallyl)-thiazole-4-carboxylic acids 
[31]. Numerous thiazolidinone derivatives have shown significant bio activities 
such as antidiarrhoeal [32], anticonvulsant [33], antimicrobial [34], antidiabetic 
[35], antihistaminic [36], anticancer [37], anti HIV [38], Ca2+ channel blocker 
[39], PAF antagonist [40], cardioprotective [41], antiischemic [42], COX inhibi-
tory [43], antiplatelet activating factor [44], non-peptide thrombin receptor 
antagonist [45], tumor necrosis factor-α-antagonist [46] and nematicidal activities. 
Organophosphorus compounds continue to attract much attention because of their 
various potent biological activities [47, 48] in particular, phosphonates are impor-
tant synthetic derivatives which can have often act as phosphate and carboxylic 
acid mimics, and interfere with enzymatic processes. Much of this activity has 
been attributed to the relatively inert nature of the C▬P bond [47, 48], which is not 
easily hydrolyzed as compared to the P▬O bond found in phosphates. The syn-
thesis and biological activities of important natural and nonnatural phosphonate 
derivatives, including phosphonated aza heterocyclics and nucleotides, have been 
reviewed [49–51]. In view of the importance of heterocyclics bearing a phosphonate 
group, new synthetic methods that would allow straightforward access to these 
versatile building blocks are needed [47, 48, 52]. Among the various bioactive 
heterocyclics the pyrazole moiety remains of great interest because of its wide 
applications in the pharmaceutical and agrochemical industry [53, 54]. In addition, 
pyrazoles also play a central role in coordination chemistry [55].
Nematodes are tiny worms, some of them are plant parasites, and can play an 
important role in the predisposition of the host plant to the invasion by secondary 
pathogens [56]. Plants attacked by nematodes show retarded growth and develop-
ment, as well as loss in the quality and quantity of the harvest. The nematicide 
use is slated for reduction due to environmental problems, and human and animal 
health concern. For example, effective nematicides such as dibromochloropropane 
(DBCD) and ethylene dibromide (EDB) have been withdrawn from the market due 
to their deleterious effects on human and the environment. Methyl bromide, the 
most effective and widely used fumigant for soil borne pests including nematodes, 
has already been banned.
The use of nonfumigant nematicides, based on organophosphates and carba-
mates, is expected to increase the withdrawal of methyl bromide, which will bring 
about new environmental concerns. In fact, the highly toxic aldicarb used to control 
insects and nematodes has been detected in ground water [57]. Therefore alterna-
tive nematode control methods or less toxic nematicides need to be developed [58]. 
One way of searching for such nematicidal compounds is to screen naturally occur-
ring compounds in plants. Several such compounds, e.g., alkaloids, phenols, ses-
quiterpenes, diterpenes, polyacetylenes, and thienyl derivatives have nematicidal 
activity [59]. For example, α-terthienyl is a highly effective nematicidal compound 
[60]. Other compounds with nematicidal activity have been isolated from plants, 
mainly from the family Asteraceae [59]. However, compounds of plant origin and 
their analogs have not been developed into commercial nematicides; hence there is a 
need to develop commercial synthesis.
Following the successful introduction of nematicidal agents, inspired by the 
biological profile of triazoles, thiazoles, Phosponylpyrazoles. In continuation of 
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our work on biological active molecules [61–69] it was thought to interest to accom-
modate all those moieties in single molecular frame work. In this article we wish to 
report the synthesis of a new class of hybrid heterocyclic’s 11a–g in good yields and 
their evaluated nematicidal activity.
2. Result and discussion
The key intermediate, 8 required for the synthesis of title compound was 
prepared according to the procedure outlined in Figure 1. Diacetyl-D-glucal (2) 
prepared from 3,4,6-tri-O-acetyl D-glucal by treating with triethyl silane and boron 
trifluoride diethyl etherate, de acylation of 2, with NaOMe in methanol at 0°C for 
1 hour gave 3 (77%), which on subsequent treatment with TBDMSCl in dichloro-
methane in presence of NEt3 for 12 hours afforded TBS ether 4 (80%), on treatment 
with propargyl bromide in toluene in presence of tetra butyl ammonium hydrogen 
sulfate produced di ether 5. After deprotection of TBS ether the propargyl ether 
converted into triazole 7 (82%) by using 1,3-dipolar cycloaddition with p-chloro 
phenyl azide was carried out at ambient temperature in the presence of CuSO4 
and sodium ascorbate in a mixture of 1:1 CH2Cl2-H2O. Oxidation of 7 with IBX in 
Figure 1. 
R= (a) C6H5; (b) 4-Cl-C6H5; (c) 4-NO2-C6H5; (d) 2-CH3-C6H5; (e) 4-CH3-C6H5; (f) 3-OH-C6H5;  
(g) 2-OH-C6H5.
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about new environmental concerns. In fact, the highly toxic aldicarb used to control 
insects and nematodes has been detected in ground water [57]. Therefore alterna-
tive nematode control methods or less toxic nematicides need to be developed [58]. 
One way of searching for such nematicidal compounds is to screen naturally occur-
ring compounds in plants. Several such compounds, e.g., alkaloids, phenols, ses-
quiterpenes, diterpenes, polyacetylenes, and thienyl derivatives have nematicidal 
activity [59]. For example, α-terthienyl is a highly effective nematicidal compound 
[60]. Other compounds with nematicidal activity have been isolated from plants, 
mainly from the family Asteraceae [59]. However, compounds of plant origin and 
their analogs have not been developed into commercial nematicides; hence there is a 
need to develop commercial synthesis.
Following the successful introduction of nematicidal agents, inspired by the 
biological profile of triazoles, thiazoles, Phosponylpyrazoles. In continuation of 
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our work on biological active molecules [61–69] it was thought to interest to accom-
modate all those moieties in single molecular frame work. In this article we wish to 
report the synthesis of a new class of hybrid heterocyclic’s 11a–g in good yields and 
their evaluated nematicidal activity.
2. Result and discussion
The key intermediate, 8 required for the synthesis of title compound was 
prepared according to the procedure outlined in Figure 1. Diacetyl-D-glucal (2) 
prepared from 3,4,6-tri-O-acetyl D-glucal by treating with triethyl silane and boron 
trifluoride diethyl etherate, de acylation of 2, with NaOMe in methanol at 0°C for 
1 hour gave 3 (77%), which on subsequent treatment with TBDMSCl in dichloro-
methane in presence of NEt3 for 12 hours afforded TBS ether 4 (80%), on treatment 
with propargyl bromide in toluene in presence of tetra butyl ammonium hydrogen 
sulfate produced di ether 5. After deprotection of TBS ether the propargyl ether 
converted into triazole 7 (82%) by using 1,3-dipolar cycloaddition with p-chloro 
phenyl azide was carried out at ambient temperature in the presence of CuSO4 
and sodium ascorbate in a mixture of 1:1 CH2Cl2-H2O. Oxidation of 7 with IBX in 
Figure 1. 
R= (a) C6H5; (b) 4-Cl-C6H5; (c) 4-NO2-C6H5; (d) 2-CH3-C6H5; (e) 4-CH3-C6H5; (f) 3-OH-C6H5;  
(g) 2-OH-C6H5.
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acetonitrile afforded compound 8. Subsequently one pot synthesis of triazole linked 
thiazolidinone glycosides was carried out by the condensation reaction between 8, 
primary aromatic amine and a thio glycolic acid in presence of ZnCl2 under micro-
wave irradiation (Figure 1). The reaction is completed in only 5–10 minutes and the 
compounds, isolated by conventional work-up, (9a–g) are obtained in satisfactory 
yields, Compound 9a–g was then reacted with p-fluoro benzaldehyde in presence 
of anhydrous NaOAc in glacial AcOH at reflux temperature gave chalcone deriva-
tives of triazole linked thiazolidinone glycosides 10a–g, on cyclocondensation 
under conventional and microwave irradiation with Bestmann-Ohira reagent in 
presence of anhydrous KOH gave compounds 11(a–g). The structures of synthe-
sized compounds were confirmed by IR, NMR, MS and elemental analysis. Further 
the compounds were subject to nematicidal activity testing.
3. Nematicidal activity
The compounds synthesized 10a-g in this study were also screened for their 
nematicidal activity against Dietylenchus myceliophagus and Caenorhabditis elegans 
by aqueous in vitro screening technique [70] at various concentrations. The 
nematicidal activity of each test compound was compared with the standard drug 
Levamisole. The results have been expressed in terms of LD50 i.e., median lethal dose 
at which 50% nematodes became immobile (dead). The screened data reveal that, 
compounds 11b, 11c, 11f and 11g are the most effective against Dietylenchus myce-
liophagus and Caenorhabditis elegans the other test compounds showed moderate 
activity. The LD50 values of the test compounds screened are presented in Table 1.
4. Experimental
Commercial grade reagents were used as supplied. Solvents except analytical 
reagent grade were dried and purified according to literature when necessary. 
Di-methyl 2-oxopropyl phosphonate was purchased from Aldrich for the synthesis 
o Bestmann-Ohira reagent. Reaction progress and purity of the compounds were 
checked by thin-layer chromatography (TLC) on pre-coated silica gel F254 plates 
from Merck and compounds visualized either by exposure to UV light or dipping in 
1% aqueous potassium permanganate solution. Silica gel chromatographic columns 
Compound LD50 value (ppm)
D. myceliophagus C. elegans
11a 740 860
11b 220 280
11c 320 270
11d 501 540
11e 960 900
11f 209 210
11g 310 360
Levamisole 160 180
Table 1. 
Nematicidal activity of 11(a–g).
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(60–120 mesh) were used for separations. Optical rotations were measured on a 
Perkin-Elmer 141 polarimeter by using a 2 ml cell with a path length of 1 dm with 
CHCl3 or CDCl3 as solvent. All melting points are uncorrected and measured using 
Fisher-Johns apparatus. IR spectra were recorded as KBr disks on a Perkin-Elmer 
FTIR spectrometer. Micro wave reactions are carried out in mini lab microwave 
catalytic reactor (ZZKD, WBFY-201). The 1HNMR and 13C NMR spectra were 
recorded on a Varian Gemini spectrometer (300 MHz for 1H and 75 MHz for 13C).  
Chemical shifts are reported as δ ppm against TMS as internal reference and 
coupling constants (J) are reported in Hz units. Mass spectra were recorded on a 
VG micro mass 7070H spectrometer. Elemental analysis (C, H, N) determined by a 
Perkin-Elmer 240 CHN elemental analyzer, were within ±0.4% of theoretical.
((2R,3S)-3-acetoxy-3,6-dihydro-2H-pyran-2-yl)methyl acetate (2): Tri-O-
acetyl-D-glucal (1) (3.0 g, 11.02 mmol) was dissolved in anhydrous dichlorometh-
ane (5 ml). The solution was cooled to 0°C, triethyl silane (1.53 g, 13.22 mmol) was 
added and the mixture was stirred for 5 minutes. Next boron tri fluoride diethyl 
etherate (690 μl of a 40 w% solution in diethyl ether, 11.02 mmol) was added drop 
wise and the reaction mixture was stirred for 90 minutes. The mixture was poured 
into a saturated solution of NaHCO3. The organic layer was washed with water, 
dried over Na2SO4 and concentrated under reduced pressure. Column chromatog-
raphy on silica gel (PE/EtOAc, 3:1) yielded the title compound (2.24 g, 10.42 mmol, 
95%) as a colorless syrup. [α]D20: +115.5 (c = 1.00, CHCl3).1H NMR (300 MHz, 
CDCl3): δ 5.87-5.84 (m, 2H, =CH),4.95 (t,1H, OCH),4.03-3.99 (m, 1H, CH),4.12-
4.09 (m,4H, OCH2), 2.20 (s, 6H, COCH3);13C NMR (75 MHz, CDCl3): δ170.2, 127.2, 
125.8, 73.6, 65.1, 64.0, 62.5, 21.1; MS: m/z (M++H) 215. Anal. Calcd for C10H14O5: C, 
56.07; H, 6.59; Found: C, 55.82; H, 6.35.
(2R,3S)-2-((tert-butyldimethylsilyloxy)methyl)-3,6-dihydro-2H-pyran-
3-ol (4): Diacetate 2 (17.22 mmol) was treated by a catalytic amount of sodium 
methoxide in methanol (100 ml) at room temperature. After evaporation of the 
solvent, the free hydroxyl unsaturated glycoside was obtained in quantitative yield 
and used without further purification. This diol was treated with 2.50 equiv. of TBD 
MSCl (3.14 g, 21.14 mmol), 2.6 equiv. of NEt3 (3.2 ml, 22.4 mmol), and 0.05 equiv. 
of imidazole (30 mg, 0.43 mmol) in CH2Cl2 (30 ml) at room temperature for ca. 
24 hours (until TLC analysis showed no more starting material). After addition of 
25 ml of water and extraction with 3–30 ml of CH2Cl2, the organic layer was dried. 
After evaporation of the solvent under reduced pressure, the residue was puri-
fied by column chromatography using petroleum ether/ethyl acetate as the eluent 
yielded the title compound (1.94 g, 10.42 mmol, 85%) as a colorless syrup. 1H NMR 
(300 MHz, CDCl3): δ 6.0–5.82 (m, 2H, 〓CH), 5.42 (d, J = 6.5 Hz, 1H, CH),4.50 
(brs, 1H, OH), 4.20–4.12(m,1H, CH), 3.91–3.80(m,4H, CH2), 0.98 (s, 9H, t-Bu), 
0.24 (s, 6H, CH3); 13C NMR (75 MHz, CDCl3): δ 127.5, 125.6, 84.6, 81.5, 73.6, 62.7, 
25.6, 18.1; MS: m/z (M++Na) 267. Anal. Calcd for C12H24O3Si: C, 58.97; H, 9.90; 
Found: C, 58.62; H, 9.75.
tert-butyldimethyl(((2R,3S)-3-(prop-2-ynyloxy)-3,6-dihydro-2H-pyran-2-yl)
methoxy)silane (5): To a solution of alcohol 4 (400 mg, 1.63 mmol, 1.0 equiv) in 
toluene (1.6 ml) was added a 35% aqueous solution of NaOH (1.6 ml), propargyl 
bromide (80% solution in toluene, 363 μl, 2.4 mmol, 1.5 equiv), and n-Bu4NHSO4 
(280 mg, 0.82 mmol, 0.5 equiv). After 6 hours of vigorous stirring at room tempera-
ture, Et2NH (1.6 ml) was added. The reaction mixture was stirred for 1 hour, poured 
into ice water, cautiously neutralized by addition of a 3 M solution of hydrochloric 
acid, and extracted with EtOAc. The combined organic extracts were washed with 
brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (hexane/EtOAc 
85:15) to afford propargyl ether as colorless oil (0.345 g, 75%). 1H NMR (300 MHz, 
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acetonitrile afforded compound 8. Subsequently one pot synthesis of triazole linked 
thiazolidinone glycosides was carried out by the condensation reaction between 8, 
primary aromatic amine and a thio glycolic acid in presence of ZnCl2 under micro-
wave irradiation (Figure 1). The reaction is completed in only 5–10 minutes and the 
compounds, isolated by conventional work-up, (9a–g) are obtained in satisfactory 
yields, Compound 9a–g was then reacted with p-fluoro benzaldehyde in presence 
of anhydrous NaOAc in glacial AcOH at reflux temperature gave chalcone deriva-
tives of triazole linked thiazolidinone glycosides 10a–g, on cyclocondensation 
under conventional and microwave irradiation with Bestmann-Ohira reagent in 
presence of anhydrous KOH gave compounds 11(a–g). The structures of synthe-
sized compounds were confirmed by IR, NMR, MS and elemental analysis. Further 
the compounds were subject to nematicidal activity testing.
3. Nematicidal activity
The compounds synthesized 10a-g in this study were also screened for their 
nematicidal activity against Dietylenchus myceliophagus and Caenorhabditis elegans 
by aqueous in vitro screening technique [70] at various concentrations. The 
nematicidal activity of each test compound was compared with the standard drug 
Levamisole. The results have been expressed in terms of LD50 i.e., median lethal dose 
at which 50% nematodes became immobile (dead). The screened data reveal that, 
compounds 11b, 11c, 11f and 11g are the most effective against Dietylenchus myce-
liophagus and Caenorhabditis elegans the other test compounds showed moderate 
activity. The LD50 values of the test compounds screened are presented in Table 1.
4. Experimental
Commercial grade reagents were used as supplied. Solvents except analytical 
reagent grade were dried and purified according to literature when necessary. 
Di-methyl 2-oxopropyl phosphonate was purchased from Aldrich for the synthesis 
o Bestmann-Ohira reagent. Reaction progress and purity of the compounds were 
checked by thin-layer chromatography (TLC) on pre-coated silica gel F254 plates 
from Merck and compounds visualized either by exposure to UV light or dipping in 
1% aqueous potassium permanganate solution. Silica gel chromatographic columns 
Compound LD50 value (ppm)
D. myceliophagus C. elegans
11a 740 860
11b 220 280
11c 320 270
11d 501 540
11e 960 900
11f 209 210
11g 310 360
Levamisole 160 180
Table 1. 
Nematicidal activity of 11(a–g).
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(60–120 mesh) were used for separations. Optical rotations were measured on a 
Perkin-Elmer 141 polarimeter by using a 2 ml cell with a path length of 1 dm with 
CHCl3 or CDCl3 as solvent. All melting points are uncorrected and measured using 
Fisher-Johns apparatus. IR spectra were recorded as KBr disks on a Perkin-Elmer 
FTIR spectrometer. Micro wave reactions are carried out in mini lab microwave 
catalytic reactor (ZZKD, WBFY-201). The 1HNMR and 13C NMR spectra were 
recorded on a Varian Gemini spectrometer (300 MHz for 1H and 75 MHz for 13C).  
Chemical shifts are reported as δ ppm against TMS as internal reference and 
coupling constants (J) are reported in Hz units. Mass spectra were recorded on a 
VG micro mass 7070H spectrometer. Elemental analysis (C, H, N) determined by a 
Perkin-Elmer 240 CHN elemental analyzer, were within ±0.4% of theoretical.
((2R,3S)-3-acetoxy-3,6-dihydro-2H-pyran-2-yl)methyl acetate (2): Tri-O-
acetyl-D-glucal (1) (3.0 g, 11.02 mmol) was dissolved in anhydrous dichlorometh-
ane (5 ml). The solution was cooled to 0°C, triethyl silane (1.53 g, 13.22 mmol) was 
added and the mixture was stirred for 5 minutes. Next boron tri fluoride diethyl 
etherate (690 μl of a 40 w% solution in diethyl ether, 11.02 mmol) was added drop 
wise and the reaction mixture was stirred for 90 minutes. The mixture was poured 
into a saturated solution of NaHCO3. The organic layer was washed with water, 
dried over Na2SO4 and concentrated under reduced pressure. Column chromatog-
raphy on silica gel (PE/EtOAc, 3:1) yielded the title compound (2.24 g, 10.42 mmol, 
95%) as a colorless syrup. [α]D20: +115.5 (c = 1.00, CHCl3).1H NMR (300 MHz, 
CDCl3): δ 5.87-5.84 (m, 2H, =CH),4.95 (t,1H, OCH),4.03-3.99 (m, 1H, CH),4.12-
4.09 (m,4H, OCH2), 2.20 (s, 6H, COCH3);13C NMR (75 MHz, CDCl3): δ170.2, 127.2, 
125.8, 73.6, 65.1, 64.0, 62.5, 21.1; MS: m/z (M++H) 215. Anal. Calcd for C10H14O5: C, 
56.07; H, 6.59; Found: C, 55.82; H, 6.35.
(2R,3S)-2-((tert-butyldimethylsilyloxy)methyl)-3,6-dihydro-2H-pyran-
3-ol (4): Diacetate 2 (17.22 mmol) was treated by a catalytic amount of sodium 
methoxide in methanol (100 ml) at room temperature. After evaporation of the 
solvent, the free hydroxyl unsaturated glycoside was obtained in quantitative yield 
and used without further purification. This diol was treated with 2.50 equiv. of TBD 
MSCl (3.14 g, 21.14 mmol), 2.6 equiv. of NEt3 (3.2 ml, 22.4 mmol), and 0.05 equiv. 
of imidazole (30 mg, 0.43 mmol) in CH2Cl2 (30 ml) at room temperature for ca. 
24 hours (until TLC analysis showed no more starting material). After addition of 
25 ml of water and extraction with 3–30 ml of CH2Cl2, the organic layer was dried. 
After evaporation of the solvent under reduced pressure, the residue was puri-
fied by column chromatography using petroleum ether/ethyl acetate as the eluent 
yielded the title compound (1.94 g, 10.42 mmol, 85%) as a colorless syrup. 1H NMR 
(300 MHz, CDCl3): δ 6.0–5.82 (m, 2H, 〓CH), 5.42 (d, J = 6.5 Hz, 1H, CH),4.50 
(brs, 1H, OH), 4.20–4.12(m,1H, CH), 3.91–3.80(m,4H, CH2), 0.98 (s, 9H, t-Bu), 
0.24 (s, 6H, CH3); 13C NMR (75 MHz, CDCl3): δ 127.5, 125.6, 84.6, 81.5, 73.6, 62.7, 
25.6, 18.1; MS: m/z (M++Na) 267. Anal. Calcd for C12H24O3Si: C, 58.97; H, 9.90; 
Found: C, 58.62; H, 9.75.
tert-butyldimethyl(((2R,3S)-3-(prop-2-ynyloxy)-3,6-dihydro-2H-pyran-2-yl)
methoxy)silane (5): To a solution of alcohol 4 (400 mg, 1.63 mmol, 1.0 equiv) in 
toluene (1.6 ml) was added a 35% aqueous solution of NaOH (1.6 ml), propargyl 
bromide (80% solution in toluene, 363 μl, 2.4 mmol, 1.5 equiv), and n-Bu4NHSO4 
(280 mg, 0.82 mmol, 0.5 equiv). After 6 hours of vigorous stirring at room tempera-
ture, Et2NH (1.6 ml) was added. The reaction mixture was stirred for 1 hour, poured 
into ice water, cautiously neutralized by addition of a 3 M solution of hydrochloric 
acid, and extracted with EtOAc. The combined organic extracts were washed with 
brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The 
crude material was purified by flash chromatography on silica gel (hexane/EtOAc 
85:15) to afford propargyl ether as colorless oil (0.345 g, 75%). 1H NMR (300 MHz, 
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CDCl3): δ 6.03–5.80 (m, 2H, 〓CH), 4.69 (t, J = 3.9 Hz 1H, CH), 3.68 (dd, J = 8.9 Hz, 
4.1 Hz, 1H, OCH), 3.99–3.89(m, 6H, CH2), 3.20 (s, 1H, CH), 0.96 (s, 9H, t-Bu), 0.23 
(s, 6H, CH3); 13C NMR (75 MHz, CDCl3): δ 127.2, 124.9, 78.0, 76.2, 74.2, 64.2, 63.2, 
58.5, 25.3, 18.5; MS: m/z (M++H) 283. Anal. Calcd for C15H26O3Si: C, 63.78; H, 9.28; 
Found: C, 63.62; H, 8.95.
((2R,3S)-3-(prop-2-ynyloxy)-3,6-dihydro-2H-pyran-2-yl)methanol (6): 
To a stirred solution of 5 (0.325 g) in Tetra hydro furan catalytic amount of TBAF 
was added and stirred the reaction mixture at room temperature for 15 minutes, 
extracted the product with Ethyl acetate (20 ml). The combined organic extracts 
were washed with brine, dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude material was purified by flash chromatography on silica 
gel (60–120 mesh, hexane/EtOAc 70, 0) to afford alcohol as yellow oil (0.285 g, 85%) 
1H NMR (300 MHzCDCl3) 5.95–5.75 (m, 2H, 〓CH), 4.65(d, J = 3.9 Hz, 1H, CH), 4.52 
(brs, 1H, OH), 4.09–4.11 (m, 4H, OCH2), 3.64 (dd, J = 4.1 Hz, 8.9 Hz, 1H, OCH), 
3.76 (d, J = 6.8 Hz, 2H, OCH2), 3.28 (s, 1H, CH): 13C NMR (75 MHz, CDCl3): δ 127.2, 
125.6, 78.3, 76.1, 74.1, 64.2, 61.4, 58.0; MS: m/z (M++H) 169. Anal. Calcd for C9H12O3: 
C, 64.27; H, 7.10; Found: C, 64.02; H, 6.95.
((2R,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)methanol (7): To a solution containing alkyne 6 (0.250 g, 
0.778 mmol), p-chloro phenyl azide (0.130 g, 0.849 mmol) in dichloromethane 
(10 ml) and water (10 ml) were added CuSO4.5H2O (0.110 g) and sodium ascorbate 
(0.114 g). The resulting suspension was stirred at room temperature for 6 hours. 
After this time, the mixture was diluted with 5 ml dichloromethane and 5 ml water. 
The organic phase was separated, dried with sodium sulfate and concentrated at 
reduced pressure the crude product was purified by column chromatography on 
silica gel (60–120 mesh, hexane/EtOAc 65:35) to afford 7 (0.290 g, 75%) as a white 
powder. Mp: 149–1510°C. 1HNMR (300 MHz, CDCl3): δ8.05 (s, 1H, Ar-H), 7.56 (d, 
J = 9.2 Hz, 2H, Ar-H),7.45 (d, J = 8.9 Hz, 2H, Ar-H), 5.85–5.79 (m, 2H, 〓CH), 4.59 (s, 
2H, OCH2), 4.50 (brs, 1H, OH), 3.88–3.99 (m, 4H, OCH2), 3.8–3.75 (m, 2H, OCH): 
13CNMR (75 MHz, CDCl3): δ140.9, 134.5, 134.1, 128.4, 127.5, 125.4, 122.1, 11.5, 78.6, 
68.5, 65.7, 64.2, 62.4: MS: m/z (M++H) 322. Anal. Calcd for C15H16ClN3O3: C, 55.90; H, 
5.01, N, 13.06; Found: C, 55.65, H, 4.95. N, 12.86.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-phenylthiazolidin-4-one 9(a-g): To a solution 
of alcohol 7 (0.120 g, 0.465 mmol) in CH2Cl2 (5 ml), catalytic amount of IBX was 
added at 0°C and stirred at room temperature for 30 minutes. The reaction mixture 
was filtered and washed with CH2Cl2 (2 × 10 ml). It was dried (Na2SO4) and evapo-
rated to give aldehyde 7 (0.110 g) in quantitative yield as a yellow liquid, which was 
used as such for the next reaction.
To a stirred mixture of 8 (0.110 g, 0.373 mmol), aromatic amine (0.373 mmol) 
and anhydrous thioglycolic acid (0.140 g, 0.211 mmol) in dry toluene (5 ml), 
ZnCl2 (0.100 g, 0.751 mmol) was added after 2 minutes and irradiated in micro-
wave bath reactor at 280 W for 4–7 minutes at 110°C. After cooling, the filtrate 
was concentrated to dryness under reduced pressure and the residue was taken-up 
in ethyl acetate. The ethyl acetate layer was washed with 5% sodium bicarbon-
ate solution and finally with brine. The organic layer was dried over Na2SO4 and 
evaporated to dryness at reduced pressure. The crude product thus obtained was 
purified by column chromatography on silica gel (60–120 mesh) with hexane-
ethyl acetate as eluent.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)
methoxy)-3,6-dihydro-2H-pyran-2-yl)-3-phenylthiazolidin-4-one (9a): mp: 
157–159°C. Yield—75%. 1HNMR (300 MHz, CDCl3): δ8.04 (s, 1H, Ar-H), 7.50 
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(d, J = 9.2 Hz, 2H, Ar-H), 7.40 (d, J = 8.9 Hz, 2H, Ar-H), 7.10–6.20 (m, 5H, Ar-H), 
5.80–5.71 (m, 2H, 〓CH), 4.90 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 
4.09–3.94 (m, 2XCH), 3.79 (d, J = 6.6 Hz, 2H, OCH2), 3.72 (s, 2H, CH2): 13CNMR 
(75 MHz, CDCl3): δ170.4, 144.1, 141.8, 134.1, 128.2, 125.6, 122.4, 119.4, 85.6, 72.6, 
66.4, 64.0, 51.4, 33.9: MS: m/z (M++H) 469. Anal. Calcd for C23H21ClN4O3S: C, 58.91; 
H, 4.51, N, 11.95; Found: C, 58. 68, H, 4.35. N, 11.66.
(R)-3-(4-chlorophenyl)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)thiazolidin-4-one (9b): mp: 
226–228°C Yield—69%. 1HNMR (300 MHz, CDCl3): 8.05 (s, 1H, Ar-H), 7.54 (d, 
J = 9.4 Hz, 4H, Ar-H), 7.42 (d, J = 8.6 Hz, 4H, Ar-H), 5.84–5.75 (m, 2H, 〓CH), 4.94 
(d, J = 5.2 Hz, CH-S), 4.50 (s, 2H, OCH2), 4.06–3.96 (m, 2H, 2XCH), 3.80 (t, 2H, 
OCH2), 3.72 (s, 2H, CH2): 13CNMR (75 MHz, CDCl3): δ 170.5, 144.2, 139.2, 134.2, 
129.2, 125.5, 122.2, 119.4, 85.4, 72.8, 65.4, 63.4, 51.2, 34.1: MS: m/z (M++Na) 525. 
Anal. Calcd for C23H20Cl2N4O3S: C, 54.88; H, 4.00, N, 11.13; Found: C, 54.58, H, 
3.75. N, 10.86.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-(4-nitrophenyl)thiazolidin-4-one (9c): mp: 
211–213°C, Yield—71%. 1HNMR (300 MHz, CDCl3): δ8.26 (d, J = 8.7 Hz, 2H, Ar-H), 
8.03 (s, 1H, Ar-H), 7.61 (d, J = 9.4 Hz, 2H, Ar-H), 7.46 (d, J = 8.5 Hz, 2H, Ar-H), 6.84 
(d, J = 9.8 Hz, 2H, Ar-H), 5.86–5.79 (m, 2H, 〓CH), 4.96 (d, J = 5.2 Hz, CH-S), 4.55 
(s, 2H, OCH2), 4.05–3.95 (m, 2H, 2XCH), 3.85 (d, J = 6.9 Hz, 2H, OCH2), 3.82 (s, 2H, 
CH2): 13CNMR (75 MHz, CDCl3): δ171.5, 144.0, 141.8, 134.2, 128.5, 125.4, 119.5, 85.4, 
72.4, 65.9, 63.6, 51.5, 34.6: MS: m/z (M++H) 514. Anal. Calcd for C23H20ClN5O5S:  
C, 53.75; H, 3.92, N, 13.63; Found: C, 53.58, H, 3.75. N, 13.39.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)-3-o-tolylthiazolidin-4-one (9d): mp: 191–193°C, Yield—65%. 
1HNMR (300 MHz, CDCl3): δ8.08 (s, 1H, Ar-H), 7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.49 (d, 
J = 8.7 Hz, 2H, Ar-H), 7.45–7.39 (m, 4H, Ar-H), 5.76 (m, 2H, 〓CH), 4.93 (d, J = 5.2 Hz, 
1H, CHS), 4.60 (s, 2H, OCH2), 4.05–3.96 (m, 2H, CH), 3.90 (t, 2H, OCH2), 3.81  
(s, 2H, CH2), 2.1 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.5, 144.2, 138.2, 134.2, 
130.7, 128.6, 125.6, 122.0, 119.5, 116.5, 85.4, 72.6, 65.8, 63.4, 52.0, 32.3, 17.5: MS: m/z 
(M++H) 483. Anal. Calcd for C24H23ClN4O3S: C, 59.68; H, 4.80, N, 11.60; Found: C, 
59.48, H, 4.55. N, 11.49.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-p-tolylthiazolidin-4-one (9e): mp: 195–198°C 
Yield—79%. 1HNMR (300 MHz, CDCl3): δ8.05 (s, 1H, Ar-H), 7.51 (d, J = 9.2 Hz, 
2H, Ar-H), 7.45 (d, J = 8.7 Hz, 2H, Ar-H), 7.25 (d, J = 8.2 Hz, 2H, Ar-H), 6.84  
(d, J = 9.4 Hz, 2H, Ar-H), 5.72–5.68 (m, 2H, 〓CH), 4.95 (s, 1H, CHS), 4.59 (s, 2H, 
OCH2), 4.04–3.99 (m, 2H, CH), 3.98 (t, 2H, OCH2), 3.90 (s, 2H, CH2), 2.32  
(s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.5, 144.2, 138.6, 136.2, 14.1, 133.2, 
129.4, 127.5, 122.5, 119.5, 85.4, 72.0, 66.4, 63.5, 51.5, 34.0, 21.4: MS: m/z (M++H) 483. 
Anal. Calcd for C24H23ClN4O3S: C, 59.68; H, 4.80, N, 11.60; Found: C, 59.58, H, 4.65. 
N, 11.43.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-(3-hydroxyphenyl)thiazolidin-4-one (9f): mp: 
218–219°C, Yield—85%. 1H-NMR (300 MHz, CDCl3): δ9.40 (brs, 1H, Ph-OH), 8.08 
(s, 1H, Ar-H), 7.58 (d, J = 9.3 Hz, 2H, Ar-H), 7.49 (d, J = 8.6 Hz, 2H, Ar-H), 6.83–6.76 
(m, 4H, Ar-H), 5.72–5.68 (m, 2H, 〓CH), 4.94 (d, J = 5.2 Hz, 1H, CHS), 4.64 (s, 
2H, OCH2), 4.12 (t, 2H, OCH2), 4.01–3.94 (m, 2H, CH), 3.92 (s, 2H, CH2): 13CNMR 
(75 MHz, CDCl3): δ 170.5, 158.2, 143.8, 134.5, 130.4, 128.6, 125.6, 122.4, 119.5, 
114.8, 106.5, 85.4, 72.5, 66.4, 63.4, 51.5, 34.1: MS: m/z (M++Na) 507. Anal. Calcd for 
C23H21ClN4O4S: C, 59.96; H, 4.36, N, 11.55; Found: C, 59.28, H, 4.65. N, 11.43.
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CDCl3): δ 6.03–5.80 (m, 2H, 〓CH), 4.69 (t, J = 3.9 Hz 1H, CH), 3.68 (dd, J = 8.9 Hz, 
4.1 Hz, 1H, OCH), 3.99–3.89(m, 6H, CH2), 3.20 (s, 1H, CH), 0.96 (s, 9H, t-Bu), 0.23 
(s, 6H, CH3); 13C NMR (75 MHz, CDCl3): δ 127.2, 124.9, 78.0, 76.2, 74.2, 64.2, 63.2, 
58.5, 25.3, 18.5; MS: m/z (M++H) 283. Anal. Calcd for C15H26O3Si: C, 63.78; H, 9.28; 
Found: C, 63.62; H, 8.95.
((2R,3S)-3-(prop-2-ynyloxy)-3,6-dihydro-2H-pyran-2-yl)methanol (6): 
To a stirred solution of 5 (0.325 g) in Tetra hydro furan catalytic amount of TBAF 
was added and stirred the reaction mixture at room temperature for 15 minutes, 
extracted the product with Ethyl acetate (20 ml). The combined organic extracts 
were washed with brine, dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude material was purified by flash chromatography on silica 
gel (60–120 mesh, hexane/EtOAc 70, 0) to afford alcohol as yellow oil (0.285 g, 85%) 
1H NMR (300 MHzCDCl3) 5.95–5.75 (m, 2H, 〓CH), 4.65(d, J = 3.9 Hz, 1H, CH), 4.52 
(brs, 1H, OH), 4.09–4.11 (m, 4H, OCH2), 3.64 (dd, J = 4.1 Hz, 8.9 Hz, 1H, OCH), 
3.76 (d, J = 6.8 Hz, 2H, OCH2), 3.28 (s, 1H, CH): 13C NMR (75 MHz, CDCl3): δ 127.2, 
125.6, 78.3, 76.1, 74.1, 64.2, 61.4, 58.0; MS: m/z (M++H) 169. Anal. Calcd for C9H12O3: 
C, 64.27; H, 7.10; Found: C, 64.02; H, 6.95.
((2R,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)methanol (7): To a solution containing alkyne 6 (0.250 g, 
0.778 mmol), p-chloro phenyl azide (0.130 g, 0.849 mmol) in dichloromethane 
(10 ml) and water (10 ml) were added CuSO4.5H2O (0.110 g) and sodium ascorbate 
(0.114 g). The resulting suspension was stirred at room temperature for 6 hours. 
After this time, the mixture was diluted with 5 ml dichloromethane and 5 ml water. 
The organic phase was separated, dried with sodium sulfate and concentrated at 
reduced pressure the crude product was purified by column chromatography on 
silica gel (60–120 mesh, hexane/EtOAc 65:35) to afford 7 (0.290 g, 75%) as a white 
powder. Mp: 149–1510°C. 1HNMR (300 MHz, CDCl3): δ8.05 (s, 1H, Ar-H), 7.56 (d, 
J = 9.2 Hz, 2H, Ar-H),7.45 (d, J = 8.9 Hz, 2H, Ar-H), 5.85–5.79 (m, 2H, 〓CH), 4.59 (s, 
2H, OCH2), 4.50 (brs, 1H, OH), 3.88–3.99 (m, 4H, OCH2), 3.8–3.75 (m, 2H, OCH): 
13CNMR (75 MHz, CDCl3): δ140.9, 134.5, 134.1, 128.4, 127.5, 125.4, 122.1, 11.5, 78.6, 
68.5, 65.7, 64.2, 62.4: MS: m/z (M++H) 322. Anal. Calcd for C15H16ClN3O3: C, 55.90; H, 
5.01, N, 13.06; Found: C, 55.65, H, 4.95. N, 12.86.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-phenylthiazolidin-4-one 9(a-g): To a solution 
of alcohol 7 (0.120 g, 0.465 mmol) in CH2Cl2 (5 ml), catalytic amount of IBX was 
added at 0°C and stirred at room temperature for 30 minutes. The reaction mixture 
was filtered and washed with CH2Cl2 (2 × 10 ml). It was dried (Na2SO4) and evapo-
rated to give aldehyde 7 (0.110 g) in quantitative yield as a yellow liquid, which was 
used as such for the next reaction.
To a stirred mixture of 8 (0.110 g, 0.373 mmol), aromatic amine (0.373 mmol) 
and anhydrous thioglycolic acid (0.140 g, 0.211 mmol) in dry toluene (5 ml), 
ZnCl2 (0.100 g, 0.751 mmol) was added after 2 minutes and irradiated in micro-
wave bath reactor at 280 W for 4–7 minutes at 110°C. After cooling, the filtrate 
was concentrated to dryness under reduced pressure and the residue was taken-up 
in ethyl acetate. The ethyl acetate layer was washed with 5% sodium bicarbon-
ate solution and finally with brine. The organic layer was dried over Na2SO4 and 
evaporated to dryness at reduced pressure. The crude product thus obtained was 
purified by column chromatography on silica gel (60–120 mesh) with hexane-
ethyl acetate as eluent.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)
methoxy)-3,6-dihydro-2H-pyran-2-yl)-3-phenylthiazolidin-4-one (9a): mp: 
157–159°C. Yield—75%. 1HNMR (300 MHz, CDCl3): δ8.04 (s, 1H, Ar-H), 7.50 
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(d, J = 9.2 Hz, 2H, Ar-H), 7.40 (d, J = 8.9 Hz, 2H, Ar-H), 7.10–6.20 (m, 5H, Ar-H), 
5.80–5.71 (m, 2H, 〓CH), 4.90 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 
4.09–3.94 (m, 2XCH), 3.79 (d, J = 6.6 Hz, 2H, OCH2), 3.72 (s, 2H, CH2): 13CNMR 
(75 MHz, CDCl3): δ170.4, 144.1, 141.8, 134.1, 128.2, 125.6, 122.4, 119.4, 85.6, 72.6, 
66.4, 64.0, 51.4, 33.9: MS: m/z (M++H) 469. Anal. Calcd for C23H21ClN4O3S: C, 58.91; 
H, 4.51, N, 11.95; Found: C, 58. 68, H, 4.35. N, 11.66.
(R)-3-(4-chlorophenyl)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)thiazolidin-4-one (9b): mp: 
226–228°C Yield—69%. 1HNMR (300 MHz, CDCl3): 8.05 (s, 1H, Ar-H), 7.54 (d, 
J = 9.4 Hz, 4H, Ar-H), 7.42 (d, J = 8.6 Hz, 4H, Ar-H), 5.84–5.75 (m, 2H, 〓CH), 4.94 
(d, J = 5.2 Hz, CH-S), 4.50 (s, 2H, OCH2), 4.06–3.96 (m, 2H, 2XCH), 3.80 (t, 2H, 
OCH2), 3.72 (s, 2H, CH2): 13CNMR (75 MHz, CDCl3): δ 170.5, 144.2, 139.2, 134.2, 
129.2, 125.5, 122.2, 119.4, 85.4, 72.8, 65.4, 63.4, 51.2, 34.1: MS: m/z (M++Na) 525. 
Anal. Calcd for C23H20Cl2N4O3S: C, 54.88; H, 4.00, N, 11.13; Found: C, 54.58, H, 
3.75. N, 10.86.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-(4-nitrophenyl)thiazolidin-4-one (9c): mp: 
211–213°C, Yield—71%. 1HNMR (300 MHz, CDCl3): δ8.26 (d, J = 8.7 Hz, 2H, Ar-H), 
8.03 (s, 1H, Ar-H), 7.61 (d, J = 9.4 Hz, 2H, Ar-H), 7.46 (d, J = 8.5 Hz, 2H, Ar-H), 6.84 
(d, J = 9.8 Hz, 2H, Ar-H), 5.86–5.79 (m, 2H, 〓CH), 4.96 (d, J = 5.2 Hz, CH-S), 4.55 
(s, 2H, OCH2), 4.05–3.95 (m, 2H, 2XCH), 3.85 (d, J = 6.9 Hz, 2H, OCH2), 3.82 (s, 2H, 
CH2): 13CNMR (75 MHz, CDCl3): δ171.5, 144.0, 141.8, 134.2, 128.5, 125.4, 119.5, 85.4, 
72.4, 65.9, 63.6, 51.5, 34.6: MS: m/z (M++H) 514. Anal. Calcd for C23H20ClN5O5S:  
C, 53.75; H, 3.92, N, 13.63; Found: C, 53.58, H, 3.75. N, 13.39.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)-3-o-tolylthiazolidin-4-one (9d): mp: 191–193°C, Yield—65%. 
1HNMR (300 MHz, CDCl3): δ8.08 (s, 1H, Ar-H), 7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.49 (d, 
J = 8.7 Hz, 2H, Ar-H), 7.45–7.39 (m, 4H, Ar-H), 5.76 (m, 2H, 〓CH), 4.93 (d, J = 5.2 Hz, 
1H, CHS), 4.60 (s, 2H, OCH2), 4.05–3.96 (m, 2H, CH), 3.90 (t, 2H, OCH2), 3.81  
(s, 2H, CH2), 2.1 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.5, 144.2, 138.2, 134.2, 
130.7, 128.6, 125.6, 122.0, 119.5, 116.5, 85.4, 72.6, 65.8, 63.4, 52.0, 32.3, 17.5: MS: m/z 
(M++H) 483. Anal. Calcd for C24H23ClN4O3S: C, 59.68; H, 4.80, N, 11.60; Found: C, 
59.48, H, 4.55. N, 11.49.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-p-tolylthiazolidin-4-one (9e): mp: 195–198°C 
Yield—79%. 1HNMR (300 MHz, CDCl3): δ8.05 (s, 1H, Ar-H), 7.51 (d, J = 9.2 Hz, 
2H, Ar-H), 7.45 (d, J = 8.7 Hz, 2H, Ar-H), 7.25 (d, J = 8.2 Hz, 2H, Ar-H), 6.84  
(d, J = 9.4 Hz, 2H, Ar-H), 5.72–5.68 (m, 2H, 〓CH), 4.95 (s, 1H, CHS), 4.59 (s, 2H, 
OCH2), 4.04–3.99 (m, 2H, CH), 3.98 (t, 2H, OCH2), 3.90 (s, 2H, CH2), 2.32  
(s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.5, 144.2, 138.6, 136.2, 14.1, 133.2, 
129.4, 127.5, 122.5, 119.5, 85.4, 72.0, 66.4, 63.5, 51.5, 34.0, 21.4: MS: m/z (M++H) 483. 
Anal. Calcd for C24H23ClN4O3S: C, 59.68; H, 4.80, N, 11.60; Found: C, 59.58, H, 4.65. 
N, 11.43.
(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-3-(3-hydroxyphenyl)thiazolidin-4-one (9f): mp: 
218–219°C, Yield—85%. 1H-NMR (300 MHz, CDCl3): δ9.40 (brs, 1H, Ph-OH), 8.08 
(s, 1H, Ar-H), 7.58 (d, J = 9.3 Hz, 2H, Ar-H), 7.49 (d, J = 8.6 Hz, 2H, Ar-H), 6.83–6.76 
(m, 4H, Ar-H), 5.72–5.68 (m, 2H, 〓CH), 4.94 (d, J = 5.2 Hz, 1H, CHS), 4.64 (s, 
2H, OCH2), 4.12 (t, 2H, OCH2), 4.01–3.94 (m, 2H, CH), 3.92 (s, 2H, CH2): 13CNMR 
(75 MHz, CDCl3): δ 170.5, 158.2, 143.8, 134.5, 130.4, 128.6, 125.6, 122.4, 119.5, 
114.8, 106.5, 85.4, 72.5, 66.4, 63.4, 51.5, 34.1: MS: m/z (M++Na) 507. Anal. Calcd for 
C23H21ClN4O4S: C, 59.96; H, 4.36, N, 11.55; Found: C, 59.28, H, 4.65. N, 11.43.
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(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)-3-(4-hydroxyphenyl)thiazolidin-4-one (9g): mp: 273–275°C, 
Yield—82%. 1H-NMR (300 MHz, CDCl3): δ9.42 (brs, 1H, Ph-OH), 8.05 (s, 1H, Ar-H), 
7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H), 7.32 (d, J = 8.6 Hz, 2H, Ar- 
H), 7.02 (d, J = 8.8 Hz, 2H, Ar-H), 5.89–5.80 (m, 2H, 〓CH), 4.96 (d, J = 5.4 Hz,  
1H, CHS), 4.66 (s, 2H, OCH2), 4.09 (d, J = 2H, OCH2), 4.04–3.98 (m, 2H, CH), 3.94 
(s, 2H, CH2): 13CNMR (75 MHz, CDCl3): δ170.9, 154.1, 144.4, 134.9, 134.8, 128.8, 127.2, 
125.6, 123.2, 119.4, 116.4, 85.4, 72.6, 66.5, 64.0, 51.6, 34.5: MS: m/z (M++H) 485. Anal. 
Calcd for C23H21ClN4O4S: C, 59.96; H, 4.36, N, 11.55; Found: C, 59.38, H, 4.75. N, 11.33.
General procedure for the synthesis of (10a-g): A mixture of compound 9a 
(0.01 mol), p-fluoro benzaldehyde (0.02 mol) and sodium acetate (0.01 mol) in 
anhydrous glacial acetic acid (20 ml), was refluxed for 3 hours. The reaction mix-
ture was concentrated and then poured into ice cold water, the solid thus separated, 
was filtered, washed with water and crystallized from glacial acetic acid. To afford 
pure 10a as yellow solid.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-phenylthiazolidin-4-one 
(10a): mp: 235–237°C, Yield—85%. 1HNMR (300 MHz, CDCl3): δ8.07 (s, 1H, 
Ar-H), 7.80 (s, 1H, CH〓C), 7.72 (d, J = 9.6 Hz, 2H, Ar-H), 7.40 (d, J = 9.2 Hz, 2H, 
Ar-H), 7.45 (d, J = 8.9 Hz, 2H, Ar-H), 7.19 (d, J = 8.2 Hz, 2H, Ar-H), 7.02–6.80  
(m, 5H, Ar-H), 5.80–5.74 (m, 2H, 〓CH), 4.90 (d, J = 5.2 Hz, 1H, CH▬S), 4.52 (s, 
2H, OCH2), 4.09–3.94 (m, 2H, 2XCH), 3.79 (d, J = 6.6 Hz, 2H, OCH2): 13CNMR 
(75 MHz, CDCl3): δ170.4, 162.1, 144.1, 141.8, 139.8, 134.1, 130.4, 128.2, 125.6, 124.6, 
122.4, 119.4, 115.5, 85.6, 72.6, 66.4, 64.0, 51: MS: m/z (M++H) 575. Anal. Calcd for 
C30H24ClFN4O3S: C, 62.66; H, 4.21, N, 9.74; Found: C, 62. 48, H, 4.15. N, 9.56.
(R,Z)-3-(4-chlorophenyl)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)
thiazolidin-4-one (10b): mp: 216–218°C. Yield—72%. 1HNMR (300 MHz, CDCl3): 
8.09 (s, 1H, Ar-H), 7.75 (s, 1H, CH〓C), 7.62 (d, J = 9.5 Hz, 2H, Ar-H), 7.52 (d, 
J = 9.4 Hz, 4H, Ar-H), 7.40 (d, J = 8.6 Hz, 4H, Ar-H), 7.19 (d, J = 8.1 Hz, 2H, Ar-H), 
5.84–5.75 (m, 2H, 〓CH), 4.94 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 4.06–
3.94 (m, 2H, 2XCH), 3.80 (t, 2H, OCH2): 13CNMR (75 MHz, CDCl3): δ170.5, 162.1, 
144.2, 139.2, 134.2, 130.4, 129.2, 125.5, 124.1, 122.2, 119.4, 85.4, 72.8, 65.4, 63.4, 51.2: 
MS:m/z(M++Na)632. Anal. Calcd for C30H23Cl2 FN4O3S: C, 59.12; H, 3.80, N, 9.19; 
Found: C, 59.01, H, 3.45. N, 8.96.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(4-nitrophenyl)
thiazolidin-4-one (10c): mp: 221–223°C Yield—75%. 1HNMR (300 MHz, CDCl3): 
δ8.29 (d, J = 8.7 Hz, 2H, Ar-H), 8.09 (s, 1H, Ar-H), 7.69 (d, J = 9.1 Hz, 2H, Ar-H), 7.65 
(s, 1H, CH〓C), 7.61 (d, J = 9.4 Hz, 2H, Ar-H), 7.46 (d, J = 8.5 Hz, 2H, Ar-H), 7.18 (d, 
J = 8.3 Hz, 2H, Ar-H), 6.84 (d, J = 9.8 Hz, 2H, Ar-H), 5.86–5.79 (m, 2H, 〓CH), 4.96 
(d, J = 5.2 Hz, CH-S), 4.55 (s, 2H, OCH2), 4.05–3.95 (m, 2H, 2XCH), 3.85 (d, J = 6.9 Hz, 
2H, OCH2): 13CNMR (75 MHz, CDCl3): δ171.5, 162.1, 144.0, 141.8, 134.2, 130.4, 
128.5, 125.4, 119.5, 115.4, 85.4, 72.4, 65.9, 63.6, 51.5: MS: m/z (M++H) 620. Calcd for 
C30H23ClFN5O5S: C, 58.11; H, 3.74, N, 11.29; Found: C, 57.98, H, 3.55. N, 11.09.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-o-tolylthiazolidin-
4-one (10d): mp: 201–203°C, Yield—85%. 1HNMR (300 MHz, CDCl3): δ8.08 (s, 
1H, Ar-H), 7.69 (d, J = 8.5 Hz, 2H, Ar-H), 7.62 (s, 1H, CH〓C), 7.56 (d, J = 9.2 Hz, 
2H, Ar-H), 7.49 (d, J = 8.7 Hz, 2H, Ar-H), 7.45–7.39 (m, 4H, Ar-H), 7.10  
(d, J = 9.1 Hz, 2H, Ar-H), 5.76 (m, 2H, 〓CH), 4.93 (d, J = 5.2 Hz, 1H, CHS), 4.60  
(s, 2H, OCH2), 4.05–3.96 (m, 2H, CH), 3.90 (t, 2H, OCH2), 2.1 (s, 3H, CH3): 
13CNMR (75 MHz, CDCl3): δ170.8, 162.9, 144.6, 137.2, 133.2, 130.6, 130.4, 128.2, 
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125.9, 122.7, 119.2, 116.2, 115.4, 84.4, 72.1, 65.3, 63.1, 52.5, 32.0, 17.5: MS: m/z 
(M++H) 589. Anal. Calcd for C31H26ClFN4O3S: C, 63.21; H, 4.45, N, 9.51; Found: C, 
62.75, H, 4.25. N, 9.29.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-p-tolylthiazolidin-4-one 
(10e): mp: 205–215°C, Yield—66%. 1HNMR (300 MHz, CDCl3): δ8.02  
(s, 1H, Ar-H), 7.69 (s, 1H, CH〓C), 7.65 (d, J = 9.1 Hz, 2H, Ar-H), 7.54 (d, J = 9.2 Hz, 
2H, Ar-H), 7.42 (d, J = 8.7 Hz, 2H, Ar-H), 7.35 (d, J = 8.2 Hz, 2H, Ar-H), 7.18 (d, 
J = 8.8 Hz, 2H, Ar-H), 6.80 (d, J = 9.4 Hz, 2H, Ar-H), 5.70–5.69 (m, 2H, 〓CH), 4.94 
(s, 1H, CHS), 4.55 (s, 2H, OCH2), 4.04–3.98 (m, 2H, CH), 3.96 (t, 2H, OCH2), 2.32 
(s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.1, 162.5, 144.1, 139.5, 137.6, 135.2, 
133.2, 130.4, 129.1, 127.5, 124.1, 122.5, 119.5, 115.3, 85.1, 72.5, 66.1, 63.2, 51.2, 21.6: 
MS: m/z (M++H) 589. Anal. Calcd for C31H26ClFN4O3S: C, 63.21; H, 4.45, N, 9.51; 
Found: C, 62.98, H, 4.25. N, 9.33.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-
dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(3-hydroxyphenyl)thiazolidin-
4-one (10f): mp: 218–219°C, Yield—82%. 1H-NMR (300 MHz, CDCl3): δ9.42 (brs, 1H, 
Ph-OH), 8.08 (s, 1H, Ar-H), 7.71 (d, J = 9.7 Hz, 2H, Ar-H), 7.65 (s, 1H, CH〓C), 7.59 
(d, J = 9.3 Hz, 2H, Ar-H), 7.44 (d, J = 8.6 Hz, 2H, Ar-H), 7.15 (d, J = 8.4 Hz, 2H, Ar 
-H), 6.80–6.78 (m, 4H, Ar-H), 5.70–5.68 (m, 2H, 〓CH), 4.92 (d, J = 5.2 Hz, 1H, CHS), 
4.64 (s, 2H, OCH2), 4.10 (t, 2H, OCH2), 4.01–3.98 (m, 2H, CH): 13CNMR (75  
MHz, CDCl3): δ170.5, 162.1, 158.2, 143.8, 139.8, 134.5, 130.8, 128.6, 125.6, 124.1, 122.4, 
119.5, 115.7, 114.8, 106.5, 85.4, 72.5, 66.4, 63.4, 51.5: MS: m/z (M++H) 591. Anal. Calcd 
for C30H24ClFN4O4S: C, 60.96; H, 4.09, N, 9.48; Found: C, 60.58, H, 3.85. N, 9.13.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(4-hydroxyphenyl)
thiazolidin-4-one (10g): mp: 283–285°C, Yield—62%. 1H-NMR (300 MHz,CDCl3): 
δ9.42 (brs, 1H, Ph-OH), 8.05 (s, 1H, Ar-H), 7.85 (d, J = 9.3 Hz, 2H, Ar-H), 7.65 (s, 
1H, CH〓C), 7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H), 7.32  
(d, J = 8.6 Hz, 2H, Ar-H), 7.19 (d, J = 8.3 Hz, 2H, ArH), 7.02 (d, J = 8.8 Hz, 2H, 
Ar-H), 5.89–5.80 (m, 2H, 〓CH), 4.96 (d, J = 5.4 Hz, 1H, CHS), 4.66 (s, 2H, 
OCH2), 4.09 (d, J = 2H, OCH2), 4.04–3.98 (m, 2H, CH), 13CNMR (75 MHz, CDCl3): 
δ170.9, 162.5, 154.1, 144.4, 139.8, 134.9, 134.8, 130.4, 128.8, 127.2, 125.6, 123.2, 
119.4, 116.4, 115.9, 85.4, 72.6, 66.5, 64.0, 51.6: MS: m/z (M++H) 591. Anal. Calcd for 
C30H24ClFN4O4S: C, 60.96; H, 4.09, N, 9.48; Found: C, 60.58, H, 3.95. N, 9.23.
General procedure for the synthesis of Pyrazole phosphonates (11a-g): To a 
stirred mixture of 10a (1 mmol), and Bestmann-Ohira Reagent (2.5 mmol) in dry EtOH 
(10 ml) was added KOH (2.5 mmol) at room temperature, after 2 minutes and irradi-
ated in microwave bath reactor at 500 W for 4–7 minutes at 50°C. The crude product 
thus obtained was purified by column chromatography on silica gel (60–120 mesh) 
with hexane-ethyl acetate as eluent. Under conventional method the reaction mixture 
in EtOH (10 ml) was stirred at room temperature for the appropriate time (Table 2).
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-phenyl-6-thia-1,2,8-
triazaspiro[4.4]non-2-en-3-ylphosphonate (11a): 245–247°C, Yield—75%. 1HNMR 
(300 MHz, CDCl3): δ13.06 (brs, 1H, 〓NH), 8.03 (s, 1H, Ar-H), 7.70 (d, J = 9.6 Hz, 
2H, Ar-H), 7.30 (d, J = 9.2 Hz, 2H, Ar-H), 7.45 (d, J = 8.9 Hz, 2H, Ar-H), 7.19 (d, 
J = 8.2 Hz, 2H, Ar-H), 6.95–6.70 (m, 5H, Ar-H), 5.80–5.74 (m, 2H, 〓CH), 4.80  
(d, J = 5.2 Hz, 1H, CH-S), 4.42 (s, 2H, OCH2), 4.09–3.94 (m, 2H, 2XCH), 3.78  
(s, 6H, OCH3), 3.69 (d, J = 6.6 Hz, 2H, OCH2), 3.52 (s, 1H, CH): 13CNMR (75 MHz, 
CDCl3): δ170.1, 160.1, 155.2, 144.1, 141.6, 136.2, 134.1, 129.2, 127.5, 125.6, 122.1, 
119.1, 115.8, 86.6, 72.9, 63.8, 53.8, 44.5, 34.9: MS: m/z (M++H) 725. Anal. Calcd for 
C33H31ClFN6O6PS: C, 54.66; H, 4.31, N, 11.59; Found: C, 54.48, H, 4.05. N, 11.36.
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(R)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-di-
hydro-2H-pyran-2-yl)-3-(4-hydroxyphenyl)thiazolidin-4-one (9g): mp: 273–275°C, 
Yield—82%. 1H-NMR (300 MHz, CDCl3): δ9.42 (brs, 1H, Ph-OH), 8.05 (s, 1H, Ar-H), 
7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H), 7.32 (d, J = 8.6 Hz, 2H, Ar- 
H), 7.02 (d, J = 8.8 Hz, 2H, Ar-H), 5.89–5.80 (m, 2H, 〓CH), 4.96 (d, J = 5.4 Hz,  
1H, CHS), 4.66 (s, 2H, OCH2), 4.09 (d, J = 2H, OCH2), 4.04–3.98 (m, 2H, CH), 3.94 
(s, 2H, CH2): 13CNMR (75 MHz, CDCl3): δ170.9, 154.1, 144.4, 134.9, 134.8, 128.8, 127.2, 
125.6, 123.2, 119.4, 116.4, 85.4, 72.6, 66.5, 64.0, 51.6, 34.5: MS: m/z (M++H) 485. Anal. 
Calcd for C23H21ClN4O4S: C, 59.96; H, 4.36, N, 11.55; Found: C, 59.38, H, 4.75. N, 11.33.
General procedure for the synthesis of (10a-g): A mixture of compound 9a 
(0.01 mol), p-fluoro benzaldehyde (0.02 mol) and sodium acetate (0.01 mol) in 
anhydrous glacial acetic acid (20 ml), was refluxed for 3 hours. The reaction mix-
ture was concentrated and then poured into ice cold water, the solid thus separated, 
was filtered, washed with water and crystallized from glacial acetic acid. To afford 
pure 10a as yellow solid.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-phenylthiazolidin-4-one 
(10a): mp: 235–237°C, Yield—85%. 1HNMR (300 MHz, CDCl3): δ8.07 (s, 1H, 
Ar-H), 7.80 (s, 1H, CH〓C), 7.72 (d, J = 9.6 Hz, 2H, Ar-H), 7.40 (d, J = 9.2 Hz, 2H, 
Ar-H), 7.45 (d, J = 8.9 Hz, 2H, Ar-H), 7.19 (d, J = 8.2 Hz, 2H, Ar-H), 7.02–6.80  
(m, 5H, Ar-H), 5.80–5.74 (m, 2H, 〓CH), 4.90 (d, J = 5.2 Hz, 1H, CH▬S), 4.52 (s, 
2H, OCH2), 4.09–3.94 (m, 2H, 2XCH), 3.79 (d, J = 6.6 Hz, 2H, OCH2): 13CNMR 
(75 MHz, CDCl3): δ170.4, 162.1, 144.1, 141.8, 139.8, 134.1, 130.4, 128.2, 125.6, 124.6, 
122.4, 119.4, 115.5, 85.6, 72.6, 66.4, 64.0, 51: MS: m/z (M++H) 575. Anal. Calcd for 
C30H24ClFN4O3S: C, 62.66; H, 4.21, N, 9.74; Found: C, 62. 48, H, 4.15. N, 9.56.
(R,Z)-3-(4-chlorophenyl)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)
thiazolidin-4-one (10b): mp: 216–218°C. Yield—72%. 1HNMR (300 MHz, CDCl3): 
8.09 (s, 1H, Ar-H), 7.75 (s, 1H, CH〓C), 7.62 (d, J = 9.5 Hz, 2H, Ar-H), 7.52 (d, 
J = 9.4 Hz, 4H, Ar-H), 7.40 (d, J = 8.6 Hz, 4H, Ar-H), 7.19 (d, J = 8.1 Hz, 2H, Ar-H), 
5.84–5.75 (m, 2H, 〓CH), 4.94 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 4.06–
3.94 (m, 2H, 2XCH), 3.80 (t, 2H, OCH2): 13CNMR (75 MHz, CDCl3): δ170.5, 162.1, 
144.2, 139.2, 134.2, 130.4, 129.2, 125.5, 124.1, 122.2, 119.4, 85.4, 72.8, 65.4, 63.4, 51.2: 
MS:m/z(M++Na)632. Anal. Calcd for C30H23Cl2 FN4O3S: C, 59.12; H, 3.80, N, 9.19; 
Found: C, 59.01, H, 3.45. N, 8.96.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(4-nitrophenyl)
thiazolidin-4-one (10c): mp: 221–223°C Yield—75%. 1HNMR (300 MHz, CDCl3): 
δ8.29 (d, J = 8.7 Hz, 2H, Ar-H), 8.09 (s, 1H, Ar-H), 7.69 (d, J = 9.1 Hz, 2H, Ar-H), 7.65 
(s, 1H, CH〓C), 7.61 (d, J = 9.4 Hz, 2H, Ar-H), 7.46 (d, J = 8.5 Hz, 2H, Ar-H), 7.18 (d, 
J = 8.3 Hz, 2H, Ar-H), 6.84 (d, J = 9.8 Hz, 2H, Ar-H), 5.86–5.79 (m, 2H, 〓CH), 4.96 
(d, J = 5.2 Hz, CH-S), 4.55 (s, 2H, OCH2), 4.05–3.95 (m, 2H, 2XCH), 3.85 (d, J = 6.9 Hz, 
2H, OCH2): 13CNMR (75 MHz, CDCl3): δ171.5, 162.1, 144.0, 141.8, 134.2, 130.4, 
128.5, 125.4, 119.5, 115.4, 85.4, 72.4, 65.9, 63.6, 51.5: MS: m/z (M++H) 620. Calcd for 
C30H23ClFN5O5S: C, 58.11; H, 3.74, N, 11.29; Found: C, 57.98, H, 3.55. N, 11.09.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-o-tolylthiazolidin-
4-one (10d): mp: 201–203°C, Yield—85%. 1HNMR (300 MHz, CDCl3): δ8.08 (s, 
1H, Ar-H), 7.69 (d, J = 8.5 Hz, 2H, Ar-H), 7.62 (s, 1H, CH〓C), 7.56 (d, J = 9.2 Hz, 
2H, Ar-H), 7.49 (d, J = 8.7 Hz, 2H, Ar-H), 7.45–7.39 (m, 4H, Ar-H), 7.10  
(d, J = 9.1 Hz, 2H, Ar-H), 5.76 (m, 2H, 〓CH), 4.93 (d, J = 5.2 Hz, 1H, CHS), 4.60  
(s, 2H, OCH2), 4.05–3.96 (m, 2H, CH), 3.90 (t, 2H, OCH2), 2.1 (s, 3H, CH3): 
13CNMR (75 MHz, CDCl3): δ170.8, 162.9, 144.6, 137.2, 133.2, 130.6, 130.4, 128.2, 
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125.9, 122.7, 119.2, 116.2, 115.4, 84.4, 72.1, 65.3, 63.1, 52.5, 32.0, 17.5: MS: m/z 
(M++H) 589. Anal. Calcd for C31H26ClFN4O3S: C, 63.21; H, 4.45, N, 9.51; Found: C, 
62.75, H, 4.25. N, 9.29.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-p-tolylthiazolidin-4-one 
(10e): mp: 205–215°C, Yield—66%. 1HNMR (300 MHz, CDCl3): δ8.02  
(s, 1H, Ar-H), 7.69 (s, 1H, CH〓C), 7.65 (d, J = 9.1 Hz, 2H, Ar-H), 7.54 (d, J = 9.2 Hz, 
2H, Ar-H), 7.42 (d, J = 8.7 Hz, 2H, Ar-H), 7.35 (d, J = 8.2 Hz, 2H, Ar-H), 7.18 (d, 
J = 8.8 Hz, 2H, Ar-H), 6.80 (d, J = 9.4 Hz, 2H, Ar-H), 5.70–5.69 (m, 2H, 〓CH), 4.94 
(s, 1H, CHS), 4.55 (s, 2H, OCH2), 4.04–3.98 (m, 2H, CH), 3.96 (t, 2H, OCH2), 2.32 
(s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.1, 162.5, 144.1, 139.5, 137.6, 135.2, 
133.2, 130.4, 129.1, 127.5, 124.1, 122.5, 119.5, 115.3, 85.1, 72.5, 66.1, 63.2, 51.2, 21.6: 
MS: m/z (M++H) 589. Anal. Calcd for C31H26ClFN4O3S: C, 63.21; H, 4.45, N, 9.51; 
Found: C, 62.98, H, 4.25. N, 9.33.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-
dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(3-hydroxyphenyl)thiazolidin-
4-one (10f): mp: 218–219°C, Yield—82%. 1H-NMR (300 MHz, CDCl3): δ9.42 (brs, 1H, 
Ph-OH), 8.08 (s, 1H, Ar-H), 7.71 (d, J = 9.7 Hz, 2H, Ar-H), 7.65 (s, 1H, CH〓C), 7.59 
(d, J = 9.3 Hz, 2H, Ar-H), 7.44 (d, J = 8.6 Hz, 2H, Ar-H), 7.15 (d, J = 8.4 Hz, 2H, Ar 
-H), 6.80–6.78 (m, 4H, Ar-H), 5.70–5.68 (m, 2H, 〓CH), 4.92 (d, J = 5.2 Hz, 1H, CHS), 
4.64 (s, 2H, OCH2), 4.10 (t, 2H, OCH2), 4.01–3.98 (m, 2H, CH): 13CNMR (75  
MHz, CDCl3): δ170.5, 162.1, 158.2, 143.8, 139.8, 134.5, 130.8, 128.6, 125.6, 124.1, 122.4, 
119.5, 115.7, 114.8, 106.5, 85.4, 72.5, 66.4, 63.4, 51.5: MS: m/z (M++H) 591. Anal. Calcd 
for C30H24ClFN4O4S: C, 60.96; H, 4.09, N, 9.48; Found: C, 60.58, H, 3.85. N, 9.13.
(R,Z)-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-5-(4-fluorobenzylidene)-3-(4-hydroxyphenyl)
thiazolidin-4-one (10g): mp: 283–285°C, Yield—62%. 1H-NMR (300 MHz,CDCl3): 
δ9.42 (brs, 1H, Ph-OH), 8.05 (s, 1H, Ar-H), 7.85 (d, J = 9.3 Hz, 2H, Ar-H), 7.65 (s, 
1H, CH〓C), 7.56 (d, J = 9.2 Hz, 2H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H), 7.32  
(d, J = 8.6 Hz, 2H, Ar-H), 7.19 (d, J = 8.3 Hz, 2H, ArH), 7.02 (d, J = 8.8 Hz, 2H, 
Ar-H), 5.89–5.80 (m, 2H, 〓CH), 4.96 (d, J = 5.4 Hz, 1H, CHS), 4.66 (s, 2H, 
OCH2), 4.09 (d, J = 2H, OCH2), 4.04–3.98 (m, 2H, CH), 13CNMR (75 MHz, CDCl3): 
δ170.9, 162.5, 154.1, 144.4, 139.8, 134.9, 134.8, 130.4, 128.8, 127.2, 125.6, 123.2, 
119.4, 116.4, 115.9, 85.4, 72.6, 66.5, 64.0, 51.6: MS: m/z (M++H) 591. Anal. Calcd for 
C30H24ClFN4O4S: C, 60.96; H, 4.09, N, 9.48; Found: C, 60.58, H, 3.95. N, 9.23.
General procedure for the synthesis of Pyrazole phosphonates (11a-g): To a 
stirred mixture of 10a (1 mmol), and Bestmann-Ohira Reagent (2.5 mmol) in dry EtOH 
(10 ml) was added KOH (2.5 mmol) at room temperature, after 2 minutes and irradi-
ated in microwave bath reactor at 500 W for 4–7 minutes at 50°C. The crude product 
thus obtained was purified by column chromatography on silica gel (60–120 mesh) 
with hexane-ethyl acetate as eluent. Under conventional method the reaction mixture 
in EtOH (10 ml) was stirred at room temperature for the appropriate time (Table 2).
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-phenyl-6-thia-1,2,8-
triazaspiro[4.4]non-2-en-3-ylphosphonate (11a): 245–247°C, Yield—75%. 1HNMR 
(300 MHz, CDCl3): δ13.06 (brs, 1H, 〓NH), 8.03 (s, 1H, Ar-H), 7.70 (d, J = 9.6 Hz, 
2H, Ar-H), 7.30 (d, J = 9.2 Hz, 2H, Ar-H), 7.45 (d, J = 8.9 Hz, 2H, Ar-H), 7.19 (d, 
J = 8.2 Hz, 2H, Ar-H), 6.95–6.70 (m, 5H, Ar-H), 5.80–5.74 (m, 2H, 〓CH), 4.80  
(d, J = 5.2 Hz, 1H, CH-S), 4.42 (s, 2H, OCH2), 4.09–3.94 (m, 2H, 2XCH), 3.78  
(s, 6H, OCH3), 3.69 (d, J = 6.6 Hz, 2H, OCH2), 3.52 (s, 1H, CH): 13CNMR (75 MHz, 
CDCl3): δ170.1, 160.1, 155.2, 144.1, 141.6, 136.2, 134.1, 129.2, 127.5, 125.6, 122.1, 
119.1, 115.8, 86.6, 72.9, 63.8, 53.8, 44.5, 34.9: MS: m/z (M++H) 725. Anal. Calcd for 
C33H31ClFN6O6PS: C, 54.66; H, 4.31, N, 11.59; Found: C, 54.48, H, 4.05. N, 11.36.
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Dimethyl8-(4-chlorophenyl)-7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11b): mp: 206–208°C, 
Yield—82%. 1HNMR (300 MHz, CDCl3): δ13.11 (brs, 1H, ▬NH), 8.19  
(s, 1H, Ar-H), 7.60 (d, J = 9.5 Hz, 2H, Ar-H), 7.54 (d, J = 9.4 Hz, 4H, Ar-H), 7.30 
(d, J = 8.6 Hz, 4H, Ar-H), 7.22 (d, J = 8.1 Hz, 2H, Ar-H), 5.80–5.78 (m, 2H, 〓CH), 
4.92 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 4.06–3.94 (m, 2H, 2XCH), 3.80 
(t, 2H, OCH2), 3.68 (s, 6H, OCH3), 3.54 (s, 1H, CH): 13CNMR (75 MHz, CDCl3): 
δ170.9, 162.1, 155.4, 144.2, 139.8, 134.6, 129.5, 125.8, 124.1, 122.0, 119.2, 115.4, 
86.1, 72.5, 64.4, 53.5, 44.8, 34.9: MS: m/z (M++Na) 781. Anal. Calcd for C33H30Cl2 
FN6O6PS: C, 52.18; H, 3.98, N, 11.06; Found: C, 51.91, H, 3.65. N, 10.86.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(4-nitrophenyl)-9-oxo-6-thia-
1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11c): mp: 231–233°C, Yield—82%. 
1HNMR (300 MHz, CDCl3): δ13.06 (brs, 1H, ▬NH), 8.23 (d, J = 8.7 Hz, 2H, Ar-H), 
8.06 (s, 1H, Ar-H), 7.65 (d, J = 9.1 Hz, 2H, Ar-H), 7.51 (d, J = 9.4 Hz, 2H, Ar-H), 7.41 
(d, J = 8.5 Hz, 2H, Ar-H), 7.10 (d, J = 8.3 Hz, 2H, Ar-H), 6.64 (d, J = 9.8 Hz, 2H, Ar-H), 
5.76–5.59 (m, 2H, 〓CH), 4.86 (d, J = 5.2 Hz, 1H, CH-S), 4.35 (s, 2H, OCH2), 4.01–3.93 
(m, 2H, 2XCH), 3.72 (s, 6H, OCH3), 3.65 (d, J = 6.9 Hz, 2H, OCH2), 3.45 (s, 1H, CH), 
13CNMR (75 MHz, CDCl3): δ171.1, 162.1, 150.0, 147.8, 144.0, 136.8, 131.4, 128.8, 127.2, 
122.0, 119.5, 115.4, 86.4, 72.4, 65.9, 63.9, 53.5, 44.5, 34.8: MS: m/z (M++H) 780. Calcd 
for C33H30ClFN7O8PS: C, 51.47; H, 3.93, N, 12.73; Found: C, 51.18, H, 3.55. N, 12.49.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-o-tolyl-6-thia-1,2,8-tri-
azaspiro[4.4]non-2-en-3-ylphosphonate (11d): mp: 221–223°C, Yield—75%. 1HNMR 
(300 MHz, CDCl3): δ13.10 (brs, 1H, ▬NH), 8.02 (s, 1H, Ar-H), 7.59 (d, J = 8.5 Hz, 2H, 
Ar-H), 7.59 (d, J = 9.2 Hz, 2H, Ar-H), 7.44 (d, J = 8.7 Hz, 2H, Ar-H), 7.42–7.40  
(m, 4H, Ar-H), 7.12 (d, J = 9.1 Hz, 2H, Ar-H), 5.76 (m, 2H, 〓CH), 4.92 (d, J = 5.2 Hz, 
1H, CHS), 4.62 (s, 2H, OCH2), 4.09–3.99 (m, 2H, CH), 3.74 (s, 6H, OCH3), 3.62  
(s, 1H, CH), 3.80 (t, 2H, OCH2), 2.12 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.4, 
160.1, 155.1, 144.4, 138.6, 136.2, 134.3, 130.7, 128.6, 127.2, 122.0, 119.2, 116.9, 115.4, 86.1, 
72.8, 63.8, 53.5, 44.9, 34.8, 17.9: MS: m/z (M++H) 739. Anal. Calcd for C34H33ClFN6O6S: 
C, 55.25; H, 4.50, N, 11.37; Found: C, 55.01, H, 4.25. N, 11.09.
Compound R Mol. formula Reaction time Yield %
A 
(hours)
B 
(minutes)
A B
11a C6H5 C33H31ClFN6O6PS 3.5 6 62 89
11b 4-Cl-C6H4 C33H30Cl2FN6O6PS 2.5 4 60 85
11c 4-NO2-C6H4 C33H30ClFN7O8PS 2.0 5 61 84
11d 2-CH3-C6H4 C34H33ClFN6O6PS 3.0 6 65 86
11e 4-CH3-C6H4 C34H33ClFN6O6PS 3.2 4 69 85
11f 3-OH-C6H4 C35H31ClFN6O7PS 2.0 5 72 89
11g 4-OH-C6H4 C35H35ClFN6O7PS 3.0 4 71 82
A: conventional method; B: microwave irradiation method.
Table 2. 
Synthesis of phosphonyl pyrazoles 11(a–g).
127
Synthesis and Biological Evaluation of Novel Phosphonyl Thiazolo Pyrazoles
DOI: http://dx.doi.org/10.5772/intechopen.86977
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-p-tolyl-6-thia-1,2,8-
triazaspiro[4.4]non-2-en-3-ylphosphonate (11e): mp: 209–211°C, Yield—76%. 
1HNMR (300 MHz, CDCl3): δ13.01 (brs, 1H, ▬NH), 8.07 (s, 1H, Ar-H), 7.62  
(d, J = 9.1 Hz, 2H, Ar-H), 7.50 (d, J = 9.2 Hz, 2H, Ar-H), 7.40 (d, J = 8.7 Hz, 2H, 
Ar-H), 7.32 (d, J = 8.2 Hz, 2H, Ar-H), 7.18 (d, J = 8.8 Hz, 2H, Ar-H), 6.70  
(d, J = 9.4 Hz, 2H, Ar-H), 5.60–5.59 (m, 2H, 〓CH), 4.90 (s, 1H, CHS), 4.45 (s, 2H, 
OCH2), 4.01–3.99 (m, 2H, CH), 3.94 (t, 2H, OCH2), 3.75 (s, 6H, OCH3), 3.62  
(s, 1H, CH), 2.30 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.9, 160.1, 155.0, 
144.1, 138.7, 136.8, 133.4, 130.4, 129.1, 127.2, 122.0, 119.1, 115.3, 86.1, 72.9, 68.1, 63.9, 
53.5, 44.5, 34.8, 21.6: MS: m/z (M++H) 739. Anal. Calcd for C31H26ClFN4O3S:  
C, 55.25; H, 4.50, N, 11.37; Found: C, 54.98, H, 4.25. N, 11.03.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(3-hydroxyphenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11f ): mp: 228–229°C, 
Yield—88%. 1H-NMR (300 MHz, CDCl3): δ13.09 (brs, 1H, ▬NH), 9.40  
(brs, 1H, Ph-OH), 8.04 (s, 1H, Ar-H), 7.61 (d, J = 9.7 Hz, 2H, Ar-H), 7.52  
(d, J = 9.3 Hz, 2H, Ar-H), 7.42 (d, J = 8.6 Hz, 2H, Ar-H), 7.13 (d, J = 8.4 Hz, 2H, 
Ar-H), 6.70–6.68 (m, 4H, Ar-H), 5.73–5.70 (m, 2H, =CH), 4.82 (d, J = 5.2 Hz, 1H, 
CHS), 4.54 (s, 2H, OCH2), 4.14 (t, 2H, OCH2), 4.0–3.97 (m, 2H, CH), 3.70  
(s, 6H, OCH3), 3.57 (s, 1H, CH): 13CNMR (75 MHz, CDCl3): δ170.2, 156.1, 155.2, 
144.8, 136.8, 129.6, 128.2, 127.5, 122.4, 119.4, 115.4, 106.5, 86.4, 72.5, 66.4, 63.4, 53.5, 
44.9, 34.3: MS: m/z (M++H) 741. Anal. Calcd for C33H31ClFN6O7PS: C, 53.48;  
H, 4.22, N, 11.34; Found: C, 53.18, H, 4.01. N, 11.13.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(4-hydroxyphenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11g): mp: 293–295°C, 
Yield—69%. 1H-NMR (300 MHz, CDCl3): δ12.85 (brs, 1H, ▬NH), 9.32  
(brs, 1H, Ph-OH), 8.02 (s, 1H, Ar-H), 7.65 (d, J = 9.3 Hz, 2H, Ar-H), 7.59  
(d, J = 9.2 Hz, 2H, Ar-H), 7.49 (d, J = 8.4 Hz, 2H, Ar-H), 7.30 (d, J = 8.6 Hz, 2H, Ar-H), 
7.16 (d, J = 8.3 Hz, 2H, ArH), 7.0 (d, J = 8.8 Hz, 2H, Ar-H), 5.89–5.82 (m, 2H, 〓CH), 
4.96 (d, J = 5.4 Hz, 1H, CHS), 4.56 (s, 2H, OCH2), 4.07 (d, J = 2H, OCH2), 4.02–3.99 
(m, 2H, CH), 3.82 (s, 6H, OCH3), 3.62 (s, 1H, CH), 13CNMR (75 MHz, CDCl3): 
δ172.9, 160.5, 154.3, 144.6, 136.2, 134.9, 134.3, 130.4, 129.8, 127.2, 125.6, 123.2, 119.8, 
116.1, 86.4, 73.6, 66.5, 64.0, 53.6, 44.8, 34.9: MS: m/z (M++Na) 763. Anal. Calcd for 
C33H31ClFN6O7PS: C, 53.48; H, 4.22, N, 11.34; Found: C, 53.18, H, 3.99. N, 11.13.
5. Conclusion
In conclusion, a series of a new class of hybrid heterocyclic’s 11a–g has been 
synthesized. The nematicidal activity of these compounds was evaluated against 
Dietylenchus myceliophagus and Caenorhabditis elegans. Among synthesized com-
pounds 11b, 11c, 11f and 11g are the most effective against Dietylenchus myceliopha-
gus and Caenorhabditis elegans the other test compounds showed moderate activity.
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Dimethyl8-(4-chlorophenyl)-7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11b): mp: 206–208°C, 
Yield—82%. 1HNMR (300 MHz, CDCl3): δ13.11 (brs, 1H, ▬NH), 8.19  
(s, 1H, Ar-H), 7.60 (d, J = 9.5 Hz, 2H, Ar-H), 7.54 (d, J = 9.4 Hz, 4H, Ar-H), 7.30 
(d, J = 8.6 Hz, 4H, Ar-H), 7.22 (d, J = 8.1 Hz, 2H, Ar-H), 5.80–5.78 (m, 2H, 〓CH), 
4.92 (d, J = 5.2 Hz, 1H, CH-S), 4.52 (s, 2H, OCH2), 4.06–3.94 (m, 2H, 2XCH), 3.80 
(t, 2H, OCH2), 3.68 (s, 6H, OCH3), 3.54 (s, 1H, CH): 13CNMR (75 MHz, CDCl3): 
δ170.9, 162.1, 155.4, 144.2, 139.8, 134.6, 129.5, 125.8, 124.1, 122.0, 119.2, 115.4, 
86.1, 72.5, 64.4, 53.5, 44.8, 34.9: MS: m/z (M++Na) 781. Anal. Calcd for C33H30Cl2 
FN6O6PS: C, 52.18; H, 3.98, N, 11.06; Found: C, 51.91, H, 3.65. N, 10.86.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(4-nitrophenyl)-9-oxo-6-thia-
1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11c): mp: 231–233°C, Yield—82%. 
1HNMR (300 MHz, CDCl3): δ13.06 (brs, 1H, ▬NH), 8.23 (d, J = 8.7 Hz, 2H, Ar-H), 
8.06 (s, 1H, Ar-H), 7.65 (d, J = 9.1 Hz, 2H, Ar-H), 7.51 (d, J = 9.4 Hz, 2H, Ar-H), 7.41 
(d, J = 8.5 Hz, 2H, Ar-H), 7.10 (d, J = 8.3 Hz, 2H, Ar-H), 6.64 (d, J = 9.8 Hz, 2H, Ar-H), 
5.76–5.59 (m, 2H, 〓CH), 4.86 (d, J = 5.2 Hz, 1H, CH-S), 4.35 (s, 2H, OCH2), 4.01–3.93 
(m, 2H, 2XCH), 3.72 (s, 6H, OCH3), 3.65 (d, J = 6.9 Hz, 2H, OCH2), 3.45 (s, 1H, CH), 
13CNMR (75 MHz, CDCl3): δ171.1, 162.1, 150.0, 147.8, 144.0, 136.8, 131.4, 128.8, 127.2, 
122.0, 119.5, 115.4, 86.4, 72.4, 65.9, 63.9, 53.5, 44.5, 34.8: MS: m/z (M++H) 780. Calcd 
for C33H30ClFN7O8PS: C, 51.47; H, 3.93, N, 12.73; Found: C, 51.18, H, 3.55. N, 12.49.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-o-tolyl-6-thia-1,2,8-tri-
azaspiro[4.4]non-2-en-3-ylphosphonate (11d): mp: 221–223°C, Yield—75%. 1HNMR 
(300 MHz, CDCl3): δ13.10 (brs, 1H, ▬NH), 8.02 (s, 1H, Ar-H), 7.59 (d, J = 8.5 Hz, 2H, 
Ar-H), 7.59 (d, J = 9.2 Hz, 2H, Ar-H), 7.44 (d, J = 8.7 Hz, 2H, Ar-H), 7.42–7.40  
(m, 4H, Ar-H), 7.12 (d, J = 9.1 Hz, 2H, Ar-H), 5.76 (m, 2H, 〓CH), 4.92 (d, J = 5.2 Hz, 
1H, CHS), 4.62 (s, 2H, OCH2), 4.09–3.99 (m, 2H, CH), 3.74 (s, 6H, OCH3), 3.62  
(s, 1H, CH), 3.80 (t, 2H, OCH2), 2.12 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.4, 
160.1, 155.1, 144.4, 138.6, 136.2, 134.3, 130.7, 128.6, 127.2, 122.0, 119.2, 116.9, 115.4, 86.1, 
72.8, 63.8, 53.5, 44.9, 34.8, 17.9: MS: m/z (M++H) 739. Anal. Calcd for C34H33ClFN6O6S: 
C, 55.25; H, 4.50, N, 11.37; Found: C, 55.01, H, 4.25. N, 11.09.
Compound R Mol. formula Reaction time Yield %
A 
(hours)
B 
(minutes)
A B
11a C6H5 C33H31ClFN6O6PS 3.5 6 62 89
11b 4-Cl-C6H4 C33H30Cl2FN6O6PS 2.5 4 60 85
11c 4-NO2-C6H4 C33H30ClFN7O8PS 2.0 5 61 84
11d 2-CH3-C6H4 C34H33ClFN6O6PS 3.0 6 65 86
11e 4-CH3-C6H4 C34H33ClFN6O6PS 3.2 4 69 85
11f 3-OH-C6H4 C35H31ClFN6O7PS 2.0 5 72 89
11g 4-OH-C6H4 C35H35ClFN6O7PS 3.0 4 71 82
A: conventional method; B: microwave irradiation method.
Table 2. 
Synthesis of phosphonyl pyrazoles 11(a–g).
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Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-9-oxo-8-p-tolyl-6-thia-1,2,8-
triazaspiro[4.4]non-2-en-3-ylphosphonate (11e): mp: 209–211°C, Yield—76%. 
1HNMR (300 MHz, CDCl3): δ13.01 (brs, 1H, ▬NH), 8.07 (s, 1H, Ar-H), 7.62  
(d, J = 9.1 Hz, 2H, Ar-H), 7.50 (d, J = 9.2 Hz, 2H, Ar-H), 7.40 (d, J = 8.7 Hz, 2H, 
Ar-H), 7.32 (d, J = 8.2 Hz, 2H, Ar-H), 7.18 (d, J = 8.8 Hz, 2H, Ar-H), 6.70  
(d, J = 9.4 Hz, 2H, Ar-H), 5.60–5.59 (m, 2H, 〓CH), 4.90 (s, 1H, CHS), 4.45 (s, 2H, 
OCH2), 4.01–3.99 (m, 2H, CH), 3.94 (t, 2H, OCH2), 3.75 (s, 6H, OCH3), 3.62  
(s, 1H, CH), 2.30 (s, 3H, CH3): 13CNMR (75 MHz, CDCl3): δ170.9, 160.1, 155.0, 
144.1, 138.7, 136.8, 133.4, 130.4, 129.1, 127.2, 122.0, 119.1, 115.3, 86.1, 72.9, 68.1, 63.9, 
53.5, 44.5, 34.8, 21.6: MS: m/z (M++H) 739. Anal. Calcd for C31H26ClFN4O3S:  
C, 55.25; H, 4.50, N, 11.37; Found: C, 54.98, H, 4.25. N, 11.03.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(3-hydroxyphenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11f ): mp: 228–229°C, 
Yield—88%. 1H-NMR (300 MHz, CDCl3): δ13.09 (brs, 1H, ▬NH), 9.40  
(brs, 1H, Ph-OH), 8.04 (s, 1H, Ar-H), 7.61 (d, J = 9.7 Hz, 2H, Ar-H), 7.52  
(d, J = 9.3 Hz, 2H, Ar-H), 7.42 (d, J = 8.6 Hz, 2H, Ar-H), 7.13 (d, J = 8.4 Hz, 2H, 
Ar-H), 6.70–6.68 (m, 4H, Ar-H), 5.73–5.70 (m, 2H, =CH), 4.82 (d, J = 5.2 Hz, 1H, 
CHS), 4.54 (s, 2H, OCH2), 4.14 (t, 2H, OCH2), 4.0–3.97 (m, 2H, CH), 3.70  
(s, 6H, OCH3), 3.57 (s, 1H, CH): 13CNMR (75 MHz, CDCl3): δ170.2, 156.1, 155.2, 
144.8, 136.8, 129.6, 128.2, 127.5, 122.4, 119.4, 115.4, 106.5, 86.4, 72.5, 66.4, 63.4, 53.5, 
44.9, 34.3: MS: m/z (M++H) 741. Anal. Calcd for C33H31ClFN6O7PS: C, 53.48;  
H, 4.22, N, 11.34; Found: C, 53.18, H, 4.01. N, 11.13.
Dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-
3,6-dihydro-2H-pyran-2-yl)-4-(4-fluorophenyl)-8-(4-hydroxyphenyl)-9-oxo-
6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate (11g): mp: 293–295°C, 
Yield—69%. 1H-NMR (300 MHz, CDCl3): δ12.85 (brs, 1H, ▬NH), 9.32  
(brs, 1H, Ph-OH), 8.02 (s, 1H, Ar-H), 7.65 (d, J = 9.3 Hz, 2H, Ar-H), 7.59  
(d, J = 9.2 Hz, 2H, Ar-H), 7.49 (d, J = 8.4 Hz, 2H, Ar-H), 7.30 (d, J = 8.6 Hz, 2H, Ar-H), 
7.16 (d, J = 8.3 Hz, 2H, ArH), 7.0 (d, J = 8.8 Hz, 2H, Ar-H), 5.89–5.82 (m, 2H, 〓CH), 
4.96 (d, J = 5.4 Hz, 1H, CHS), 4.56 (s, 2H, OCH2), 4.07 (d, J = 2H, OCH2), 4.02–3.99 
(m, 2H, CH), 3.82 (s, 6H, OCH3), 3.62 (s, 1H, CH), 13CNMR (75 MHz, CDCl3): 
δ172.9, 160.5, 154.3, 144.6, 136.2, 134.9, 134.3, 130.4, 129.8, 127.2, 125.6, 123.2, 119.8, 
116.1, 86.4, 73.6, 66.5, 64.0, 53.6, 44.8, 34.9: MS: m/z (M++Na) 763. Anal. Calcd for 
C33H31ClFN6O7PS: C, 53.48; H, 4.22, N, 11.34; Found: C, 53.18, H, 3.99. N, 11.13.
5. Conclusion
In conclusion, a series of a new class of hybrid heterocyclic’s 11a–g has been 
synthesized. The nematicidal activity of these compounds was evaluated against 
Dietylenchus myceliophagus and Caenorhabditis elegans. Among synthesized com-
pounds 11b, 11c, 11f and 11g are the most effective against Dietylenchus myceliopha-
gus and Caenorhabditis elegans the other test compounds showed moderate activity.
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Among heterocyclic compounds, quinoline is a privileged scaffold that appears 
as an important construction motif for the development of new drugs. Quinoline 
nucleus is endowed with a variety of therapeutic activities, and new quinolone 
derivatives are known to be biologically active compounds possessing several 
pharmacological activities. Many new therapeutic agents have been developed 
by using quinoline nucleus. Hence, quinoline and its derivatives form an impor-
tant class of heterocyclic compounds for the new drug development. Numerous 
synthetic routes have been developed for the synthesis of quinoline and its deriva-
tives due to its wide range of biological and pharmacological activities. The article 
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1. Introduction
Quinoline 1 or 1-azanaphthalene or benzo[b]pyridine is an aromatic nitrogen-
containing heterocyclic compound having a molecular formula of C9H7N, and the 
molecular weight is 129.16. Being a weak tertiary base, it forms salts with acids and 
exhibits reactions similar to benzene and pyridine. It participates in both electro-
philic and nucleophilic substitution reactions.
Quinoline moiety commonly exists in various natural compounds (Cinchona 
alkaloids), and pharmacological studies have shown that the quinolone ring 
system is present in many compounds exhibiting a broad range of biological 
activities. Quinoline has been found to have antibacterial, antifungal, antimalar-
ial, anthelmintic, anticonvulsant, cardiotonic, anti-inflammatory, and analgesic 
activities.
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2. Synthesis
In the literature, a number of established protocols have been reported for the 
synthesis of quinoline ring, which can be altered to produce a number of differently 
substituted quinolines. The quinoline ring has been generally synthesized by vari-
ous conventional named reactions such as Skraup, Doebner-Von Miller, Pfitzinger, 
Friedlander, Conrad-Limpach, and Combes synthesis (Figure 1) [1].
Apart from the conventional methods, a vast number of synthetic routes have 
been developed for the synthesis of quinoline and quinoline derivatives. Chen et al. 
reported the synthesis of 2,4-disubstituted quinolines, 2 by the condensation of 
2-iodoanilines with alkynyl aryl ketones using nickel catalyst [2].
2,4-Disubstituted quinolones, 3 have been obtained by the cyclization of 
2-aminoaryl ketones with phenylacetylenes. This reaction takes place in ionic liquid 
medium ([hmim]PF6) in the presence of zinc trifluoromethanesulfonate catalyst 
[3]. Lekhok et al. synthesized the same product in the presence of catalytic amount 
of indium(III) trifluoromethanesulfonate (In(CF3SO3)3) under microwave and 
solvent-free conditions [4].
Figure 1. 
Conventional methods of synthesis of various substituted quinolines.
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2,4-Diphenyl-2-methyl-1,2-dihydroquinoline, 4 has been prepared by the 
condensation followed by cyclization of aniline and acetophenone. The reaction 
proceeds with the help of a zeolite catalyst, E4a [5].
2,3,4-Trisubstituted quinolones, 5 have been synthesized by Friedlander annula-
tion of 2-amino substituted aromatic ketones and reactive methylene group con-
taining carbonyl compounds in the presence of ethyl ammonium nitrate (EAN) [6].
By stirring 2-aminoaryl ketones and various α-methylene ketones in the pres-
ence of dodecylphosphonic acid (DPA) catalyst in water or solvent-free conditions, 
poly-substituted quinolones, 6 have been synthesized [7].
2-Aminobenzyl alcohol reacts with ketones or alcohols in the presence of a base, 
and benzophenone resulted in the formation of poly-substituted quinolones, 7 [8]. 
Here, benzophenone acts as a hydride scavenger.
Horn et al. reported the synthesis of quinolines, 8 from α, β-unsaturated ketones 
and o-aminophenylboronic acid derivatives [9]. This method is the modification of 
the conventional Skraup-Doebner-Von Miller synthesis and that the reaction 
proceeded under basic conditions.
3,4-Dihydroquinolin-2-ones, 9 have been synthesized by treating 2-iodoanilines 
and various acrylates using azobisisobutyronitrile (AIBN) in the presence of 
tributyltin hydride [10].
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Wang et al. developed a method for the synthesis of 2-phenylquinoline-4-car-
boxylic acids, 10 by the treatment of pyruvic acid with substituted aniline and 
benzaldehyde in the presence of rare-earth metal catalysts in water under reflux 
condition [11].
Kouznetsov et al. synthesized phenyl-substituted quinolones, 11 by reacting 
ethyl vinyl ether or ethyl vinyl sulfide with N-arylaldimine in the presence of Lewis 
acidic catalysts such as boron trifluoride etherate (BF3.OEt2) to obtain 2,4-substi-
tuted tetrahydroquinolines. The tetrahydroquinolines were aromatized to 2-phenyl-
substituted quinolines under vacuum distillation in the presence of p-TSOH [12].
Wang et al. reported the synthesis of 2-phenyl-4-alkoxy quinolines, 12 by 
cyclocondensation of 2-(2-trimethylsilyl)ethynyl) aniline with aromatic aldehydes 
in the presence of sulfuric acid as catalyst in methanol solvent [13].
Two molecules of o-haloacetophenones condensed with urea or primary amines 
yielded certain halogen-substituted quinolones, 13. The halogen-substituted 
quinolines were formed through the cleavage of C(sp2)–halogen and α-C(sp3)–H 
bonds and the formation of new bonds in a selective manner [14].
A one-pot reaction of 2-aminoaryl ketones with certain arylacetylenes results in 
the formation of 2,4-disubstituted quinolones, 14. The reaction was performed in a 
green synthetic route using potassium dodecatugstocobaltate trihydrate 
(K5CoW12O40.3H2O) as a recyclable and eco-friendly catalyst under microwave and 
solvent-free conditions [15].
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Kowsari et al. synthesized certain quinolones, 15 by reacting isatin with aryl 
methyl ketones in the presence of basic ionic liquids in water [16]. The reaction was 
conducted under ultrasound green synthetic conditions. The main advantages of 
this procedure are (i) a green method, (ii) milder and shorter reaction time, and 
(iii) higher yields and selectivity without a transition metal catalyst.
1,4-Diazabicyclo[2.2.2]octane (DABCO) promoted structurally diverse 
2- alkoxy- and 2-aryloxy-3-substituted quinolones, 16 that have been synthesized by 
treating o-alkynylaryl isocyanides with alcohols and phenols [17]. DABCO initiates 
the reaction as a nucleophile and facilitates the formation of the product as a leaving 
group being replaced by oxygen nucleophiles.
Benzimidoyl chlorides when treated with 1-(1-(allyloxy)prop-2-ynyl)benzene 
(1,6-enynes) yielded diverse quinoline derivatives, 17 via a domino palladium-
catalyzed Sonogashira coupling and followed by cyclization [18].
Diversified quinolones, 18 have been synthesized by the intramolecular cyclocon-
densation of 1-azido-2-(2-propynyl)benzenes using electrophilic reagents (I2, Br2, 
ICl, NBS, NIS, and HNTf2) in nitromethane at 0°C to room temperature. The reaction 
also proceeds in the presence of AuCl3/AgNTf2 catalysts in THF at 100°C [19].
3. Biological activity
3.1 Antimalarial
Quinolines are known for their excellent antimalarial properties. Raynes et al. 
developed bisquinolines, 19, 20 that exhibit antimalarial activity against chloro-
quine-resistant and chloroquine-sensitive parasites [20]. Derivatives of ferrochloro-
quine, 21 were also found to possess antimalarial activity [21]. In these derivatives, 
the carbon skeleton of chloroquine is replaced by ferrocene group. Modapa et al. 
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reported that the synthesis of ureido-4-quinolinamides, 22 showed antimalarial 
activity at MIC 0.25 mg/mL against chloroquine-sensitive Plasmodium falciparum 
strain [22]. Several 7-chloroquinolinyl thioureas, 23, 24 have been synthesized by 
Mahajan et al. that possess excellent antimalarial properties [23]. Kovi et al. synthe-
sized a chloroquinolyl derivative, 25 that has an excellent antimalarial activity even 
at very low concentrations [24]. Acharya et al. reported the synthesis and potent 
antimalarial activity of certain pyridine-quinoline hybrid conjugates, 26, 27 against 
chloroquine susceptible P. falciparum strain [25]. Shiraki et al. produced some 
5-aryl-8-aminoquinolines, 28 with good antimalarial activity and had mild hemo-
lytic activity than tafenoquine [26]. Singh et al. developed several antimalarial 
4-anilinoquinolines, 29 which showed good antimalarial activity against chloro-
quine-sensitive P. falciparum strains [27]. Novel hybrid conjugates of N-(7-
chloroquinolin-4-yl) piperazine-1-carbothioamide and 1,3,5-triazine derivatives, 
30 have been synthesized by Bhat et al. These hybrid conjugates possess consider-
able antimalarial activity against both wild and mutant parasites on changing the 
pattern of substitution [28]. McNulty et al. developed 4-arylquinoline-2-carboxyl-
ate derivatives, 31 which show antiprotozoal activity against the pathogenic parasite 
Toxoplasma gondii [29].
3.2 Anti-inflammatory activity
A quinoline derivative, 32 with strong anti-inflammatory activity was syn-
thesized by Baba et al. in adjuvant arthritis rat model [30]. Chen et al. developed 
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2-(furan-2-yl)-4-phenoxy-quinoline derivatives, 33, 34 that inhibit the lysozyme 
and β-glucuronidase release [2]. Few quinoline derivatives, 35, 36 have been 
synthesized and evaluated by Gilbert et al. for treating osteoarthritis and that are 
amino-acetamide inhibitors of aggrecanase-2 [31].
3.3 Analgesic activity
4-Substituted-7-trifluoromethylquinolines 37, 38 have been developed by Abadi 
et al., and these derivatives were found to possess excellent analgesic activity with 
nitric oxide releasing characteristics [32]. Gomtsyan et al. synthesized an analgesic 
active derivative, 39. The activity is due to its antagonism at vanilloid receptors [33]. 
Some quinoline derivatives, 40 were synthesized by Manera et al. that show 
analgesic activity and are selective agonists at cannabinoid CB2 receptors [34].
3.4 Antibacterial
Ma et al. reported the synthesis and antibacterial evaluation of phenoxy-, 
phenylthio-, and benzyloxy-substituted quinolones, 41 [35]. A few 8-substituted 
quinoline carboxylic acids, 42 were synthesized by Sanchez et al. that showed 
antibacterial activity [36]. Upadhayaya et al. developed 3-benzyl-6-bromo-2-me-
thoxy quinoline derivatives, 43, and these derivatives are active against 
Mycobacterium tuberculosis H37Rv strain [37]. A few analogues of 7-chloro quino-
lones, 44 were synthesized by De Souza et al., and these derivatives were found to 
be effective against multidrug-resistant tuberculosis [38]. Lilienkampf et al. 
synthesized quinoline-based compounds containing an isoxazole unit and side 
chain, 45 that was active against Mycobacterium tuberculosis [39]. The novel hybrid 
Heterocycles - Synthesis and Biological Activities
138
reported that the synthesis of ureido-4-quinolinamides, 22 showed antimalarial 
activity at MIC 0.25 mg/mL against chloroquine-sensitive Plasmodium falciparum 
strain [22]. Several 7-chloroquinolinyl thioureas, 23, 24 have been synthesized by 
Mahajan et al. that possess excellent antimalarial properties [23]. Kovi et al. synthe-
sized a chloroquinolyl derivative, 25 that has an excellent antimalarial activity even 
at very low concentrations [24]. Acharya et al. reported the synthesis and potent 
antimalarial activity of certain pyridine-quinoline hybrid conjugates, 26, 27 against 
chloroquine susceptible P. falciparum strain [25]. Shiraki et al. produced some 
5-aryl-8-aminoquinolines, 28 with good antimalarial activity and had mild hemo-
lytic activity than tafenoquine [26]. Singh et al. developed several antimalarial 
4-anilinoquinolines, 29 which showed good antimalarial activity against chloro-
quine-sensitive P. falciparum strains [27]. Novel hybrid conjugates of N-(7-
chloroquinolin-4-yl) piperazine-1-carbothioamide and 1,3,5-triazine derivatives, 
30 have been synthesized by Bhat et al. These hybrid conjugates possess consider-
able antimalarial activity against both wild and mutant parasites on changing the 
pattern of substitution [28]. McNulty et al. developed 4-arylquinoline-2-carboxyl-
ate derivatives, 31 which show antiprotozoal activity against the pathogenic parasite 
Toxoplasma gondii [29].
3.2 Anti-inflammatory activity
A quinoline derivative, 32 with strong anti-inflammatory activity was syn-
thesized by Baba et al. in adjuvant arthritis rat model [30]. Chen et al. developed 
139
Quinoline Heterocycles: Synthesis and Bioactivity
DOI: http://dx.doi.org/10.5772/intechopen.81239
2-(furan-2-yl)-4-phenoxy-quinoline derivatives, 33, 34 that inhibit the lysozyme 
and β-glucuronidase release [2]. Few quinoline derivatives, 35, 36 have been 
synthesized and evaluated by Gilbert et al. for treating osteoarthritis and that are 
amino-acetamide inhibitors of aggrecanase-2 [31].
3.3 Analgesic activity
4-Substituted-7-trifluoromethylquinolines 37, 38 have been developed by Abadi 
et al., and these derivatives were found to possess excellent analgesic activity with 
nitric oxide releasing characteristics [32]. Gomtsyan et al. synthesized an analgesic 
active derivative, 39. The activity is due to its antagonism at vanilloid receptors [33]. 
Some quinoline derivatives, 40 were synthesized by Manera et al. that show 
analgesic activity and are selective agonists at cannabinoid CB2 receptors [34].
3.4 Antibacterial
Ma et al. reported the synthesis and antibacterial evaluation of phenoxy-, 
phenylthio-, and benzyloxy-substituted quinolones, 41 [35]. A few 8-substituted 
quinoline carboxylic acids, 42 were synthesized by Sanchez et al. that showed 
antibacterial activity [36]. Upadhayaya et al. developed 3-benzyl-6-bromo-2-me-
thoxy quinoline derivatives, 43, and these derivatives are active against 
Mycobacterium tuberculosis H37Rv strain [37]. A few analogues of 7-chloro quino-
lones, 44 were synthesized by De Souza et al., and these derivatives were found to 
be effective against multidrug-resistant tuberculosis [38]. Lilienkampf et al. 
synthesized quinoline-based compounds containing an isoxazole unit and side 
chain, 45 that was active against Mycobacterium tuberculosis [39]. The novel hybrid 
Heterocycles - Synthesis and Biological Activities
140
conjugates of N-(7-chloroquinolin-4-yl) piperazine-1-carbothioamide and 1,3,5-tri-
azine derivatives, 30 synthesized by Bhat et al. also showed excellent antibacterial 
activity against several Gram-positive and Gram-negative microorganisms [40].
3.5 Antitumor
Some amido-anilinoquinolines, 46 were synthesized by Scott et al. that act as 
antitumor agents by inhibiting CSF-1R kinase [41]. Certain derivatives of 
4-hydroxyquinolines, 47 were synthesized by Mai et al. that showed histone 
acetyltransferase (HAT) inhibitory activity [42]. A few 3-cyanoquinolines, 48 were 
developed by Miller et al. as inhibitors of growth factor receptors (IGF-1R) for 
treating cancer [43]. 4-Anilinoquinolines, 49 were synthesized by Assefa et al. 
which were found to contain tyrosine kinase inhibitors [44]. Quinoline carboxylic 
acids, 50 have been synthesized by Chen et al. that act as antitumor compounds by 
inhibiting insulin-like growth factors [45]. A few c-Met kinase inhibitory quino-
lones, 51 were developed by Wang et al. with IC50 < 1 nM. These derivatives were 
found to show the inhibition of c-Met phosphorylation in c-Met-dependent cell 
lines [46]. Marganakop et al. developed few 6,7,8-substituted thiosemicarbazones 
of 2-chloro-3-formyl-quinoline derivatives, 52 which exhibit excellent anticancer 
activities [47]. Recently, some quinoline derivatives, 53 were synthesized as novel 
Raf kinase inhibitors with potent and selective antitumor activities. These deriva-
tives were synthesized by modifying the structure of sorafenib [48].
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3.6 Antifungal
Certain tetrahydroquinolines, 54 were synthesized by Gholap et al. which were 
found to possess good antifungal activity against Candida albicans, Fusarium oxys-
porum, and Mucor fungi [49]. Kharkar et al. synthesized few quinoline derivatives, 
55 that show good antifungal properties [50]. Kumar et al. developed few non-azole 
antimycotic agents having secondary amine attached 2-chloroquinolines, 56 and 
evaluated their antifungal activity against Penicillium citrinum, Aspergillus niger, 
Monascus purpureus, and A. flavus sp. [51].
3.7 Antiviral
Several mono- and poly-substituted quinolones, 57–59 synthesized by Fakhfakh 
et al. were found to exhibit activity against HIV-1 [52]. Ghosh et al. synthesized 
anilidoquinoline derivatives, 60 which were found to possess an excellent antiviral 
activity against Japanese encephalitis virus [53]. A few quinoline derivatives, 61 
possessing the behavior as HIV-1 Tat-TAR interaction inhibitors were synthesized 
by Chen et al. [45]. Massari et al. synthesized few desfluoroquinolones, 62 for 
treating HIV infection [54].
3.8 Anthelmintic
Substituted 2,4-arylquinolines, 63–66 have been synthesized by Rossiter et al. 
which possess good anthelmintic activity against levamisole-, ivermectin-, and 
thiabendazole-resistant strains of H. contortus [55].
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3.9 Antiprotozoal
2-Propyl quinoline and 2-(3-methyloxiran-2-yl)quinoline alkaloids 67, 68 
isolated from G. longiflora plant were found to show antileishmanial activity 
against Leishmania spp. [56]. Alkenyl and alkynyl quinolones, 69, 70 reported by 
Fakhfakh et al. were found to have antiprotozoal activity against cutaneous 
leishmaniasis, African trypanosomiasis, Chagas disease, and visceral leishmaniasis 
[52]. Ma et al. developed a few quinolones, 71 that showed activity against 
Trypanosoma cruzi [35].
3.10 Cardiovascular activity
Srimal et al. demonstrated the hypotensive activity of centhaquin, 72, and it was 
found to show the property of reducing the blood pressure in cat in a dose-depen-
dent manner [57]. Quinoline-4-carboxylic acids, 73 have been synthesized by Lloyd 
et al. that are angiotensin II receptor antagonists and thereby act as hypotensive 
agents [58]. Certain biarylether amide quinolones, 74 have been developed by 
Bernotas et al. which act as liver X receptor agonists and are useful in the situation 
of dyslipidemia [59]. Phenyl acetic acid-based quinolones, 75 have been developed 
by Hu et al. which act as agonists at liver X receptors and found to have good 
binding affinity for LXRb and LXRa receptors [60]. A few 4-thiophenyl quinolones, 
76 have been developed by Cai et al. that are HMG-CoA reductase inhibitors and 
useful as hypocholesterolemic agents [61]. Tetrahydroquinolines, 77 which inhibit 
the cholesteryl ester transfer protein have been synthesized by Rano et al. [62]. 
Certain tetrahydroquinolinamines, 78 have been developed by Ramos et al. which 
are found to inhibit platelet aggregation [63].
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3.11 Reproductive system
Tetrahydroquinolines, 79 have been synthesized by Wallace et al. that are selec-
tive estrogen receptor modulators [64]. Bi et al. developed few quinolones, 80 which 
are potent PDE5 inhibitors thus are useful in the treating erectile dysfunction [65].
3.12 Miscellaneous
Quinolines and quinoline derivatives possess a number of miscellaneous biologi-
cal activities also. Evans et al. synthesized few quinolones, 81 that are leukotriene 
synthesis inhibitors [66]. 1,2,3,4-Tetrahydroquinoline-2,2,4-trione oximes, 82 are 
developed by Cai et al. that act as antagonists of NDMA in glycine receptors and 
also found to be used as agents against neurodegenerative diseases (e.g., Alzheimer’s 
disease) [61]. Lunniss et al. developed few selective PDE4 inhibitor quinolones 83, 
84 which are useful in chronic obstructive pulmonary disorder [67]. Bachiller et al. 
have developed few tacrine–8-hydroxyquinoline hybrids, 85 that show activity 
against Alzheimer’s [68]. Tetrahydroquinoline-6-yloxy propanes, 86 have been 
developed by Shakya et al. which show the β-3 agonists [69]. Few aminoalkoxy-
quinolines, 87 which act as somatostatin receptor subtype-2 agonists have been 
developed by Wolkenberg et al. which are useful in proliferative diabetic retinopa-
thy and also found utility in exudative age-related macular degeneration [70].
4. Conclusion
Since quinoline and its derivatives are known for their wide spectrum of phar-
macological activities, a number of synthetic methods have been developed from 
time to time for their synthesis by conventional, homogeneous, and heterogeneous 
acid-catalyzed methods; rare-earth-catalyzed, transition metal-catalyzed, radical-
catalyzed, microwave-assisted, ultrasound-promoted, or solvent-free conditions, 
and many more. This book chapter will be very useful to the researcher working in 
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Abstract
Pharmaceutics and therapeutics industries enforced chemists to seek/discover
antibacterial novel heterocycles owing specific bioactivity and innate characteristics
significance. This chapter summarized potent antibacterial profile of 5-oxo-
imidazolines in the new millennium as an antibacterial against Gram-positive and
Gram-negative bacteria viz. B. thuringiensis, S. aureus, E. coli, and E. aerogenes is
presented in this chapter. 5-(H/Br benzofuran-2-yl)-1-phenyl 1H-pyrazole-3-
carbohydrazides are condensed with 4-(arylidene)-2 phenyloxazol-5(4H)-one in
acetic acid at elevated temperature to yield product 5-(H/Br benzofuran-2-yl)-N-
(4-arylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-1-phenyl-1H-pyrazole-3-
carboxamides. Different substrates like 4-(arylidene)-2-phenyloxazol-5(4H)-one
allowed to react with benzaldehyde hippuric acid to yield 5-oxo-imidazolines/
5-oxo-4,5-dihydroimidazole. All synthesized 5-oxo-imidazolines were characterized
via elemental analysis and FT-IR, 1H-NMR and mass spectra techniques. All
5-oxo-imidazolines assayed in vitro for inherent antimicrobial activity at different
concentration against stated bacterial strains and compared with standard chloram-
phenicol. 5-Oxo-imidazolines (3a and 3c) with 125 μg/mL concentration showed
excellent antibacterial profile against Gram-positive bacteria, B. thuringiensis, while
other derivatives at different concentrations showed moderate antibacterial activity
against Gram-positive bacteria, S. aureus and B. thuringiensis. Gram-negative bacte-
ria like E. coli and E. aerogenes are tested at higher concentration (1000, 500, and
125 μg/mL) and found good-to-moderate antibacterial activity. Tested products
found non-active against E. aerogenes for 125, 61, and 31 μg/mL concentration also
inactive at conc. 31 μg/mL against E. coli.
Keywords: antibacterial, Gram positive/negative, B. thuringiensis, S. aureus, E. coli,
E. aerogenes, 5-oxo-imidazoline, azlactones, medicinal
1. Introduction
Imidazole is a planer five-member ring with molecular formula C3N2H4,
containing three carbon atoms and two nitrogen atoms in 1 and 3 skeletal positions
as depicted in Figure 1. This is an aromatic heterocyclic ring that’s classified as a
diazole family owing non-adjacent nitrogens in its skeleton.
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containing three carbon atoms and two nitrogen atoms in 1 and 3 skeletal positions
as depicted in Figure 1. This is an aromatic heterocyclic ring that’s classified as a
diazole family owing non-adjacent nitrogens in its skeleton.
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Assorted naturally occurring alkaloids own this imidazole moiety as vital bio-
logical building blocks viz; histidine and related hormone histamine. Various
synthetic drugs are based on imidazole rings like antifungal, antibiotics:
nitroimidazole and sedative: midazolam etc. Oxo-imidazoline derivatives are keto-
dihydroimidazoles too, known as imidazolinone a five member ring system having
2-nitrogen situated at 1 and 3-positions and ─C═O at various positions like 2, 4 and
5 of ring. Three possible isomers of imidazolinone observed based on position of
C═O substituent at skeleton namely: 2-oxo-imidazoline (2), 4-oxo-imidazoline (3)
and 5-oxo-imidazoline (4).
5-Oxo-4,5-dihydroimidazole derivative is called as 5-oxo-imidazoline, unsatu-
rated system, in fact nitrogen analogues of azlactone/oxazolone can be converted
into amino acids [1, 2] and also employed active pharmaceutical ingredient/API
component in drugs [3]. 5-Oxo-imidazoline holds biological as well as chemical
aspects for a long time; among the various heterocycles, it is preferred due to its
wide antimicrobial profile. Certain imidazolines are useful intermediates in synthe-
sis of many natural products as well as common building blocks in many biologi-
cally active moieties [4].
Figure 1.
Certain potent antibacterial profile of 5-oxo-imidazolines in the new millennium [5–16].
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Biological importance of 5-oxo-imidazoline: Literature survey indicated that
the synthetic drugs/molecules incorporated with 5-oxo-imidazoline found to owe
assorted biological/clinical significance and wide range of pharmacological activities
as mention below:
Solankee et al. [17] synthesized some 5-imidazolinones (5) and evaluated as
anticancer agent.
Mistry et al. [18] have synthesized imidazolinone (6) and studied antibacterial,
antifungal activities.
Kathrotiya et al. [19] and co-workers reported a series of some new quinoline
based imidazole-5-one derivatives (7) and evaluated them as antibacterial and
antifungal agent.
Desai et al. [20] also reported the synthesis of 5-oxo-imidazole amides derivatives
including quinoline unit (8) and assessed their antibacterial and antifungal agent.
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Mohammad and coworkers [21] have prepared some new imidazolinones and
investigated their antimicrobial activities. Khan et al. [22] have also reported
antibacterial and fungicidal activity of 5-oxo-imidazolines. Herbicidal activity of
imidazolinone derivatives have been reported by Andreani et al. [23]. Moreover
Zhou et al. [24] and Pai et al. [25] have reported anticancer active analogues of
5-oxo-imidazolines. Imidazolinone derivatives which possess antifungal activities
have been reported by Shah et al. [26]. Some new 5-oxo-imidazolines as antimicro-
bial agents have been investigated by Patel et al. [27]. Rao [28] have prepared
substituted imidazolone derivatives and reported their pharmaceutical use as
inhibitors of p38 MAP Kinase and ERK-2 inhibitors. Xue et al. [29] have
synthesized and evaluated imidazole-2-one derivatives as potential antitumor
agents. Parekh and co-workers [30] have synthesized 5-oxo-imidazolines as novel
bioactive compounds derived from benzimidazole. Kanjaria and co-workers [31]
have described imidazolinones as potential antimicrobial agents. Joshi et al. [3]
have synthesized imidazolinones as potent anticonvulsant agents. Acharya et al.
[32] tested the imidazolinone (9) having quinolone nucleus for their antibacterial
activity toward Gram-positive and Gram-negative bacteria and antifungal activity
toward Aspergillus niger at a concentration of 40 μg, they found active against
microorganism.
In view of potent antimicrobial and other pharmacological activities
exhibited by 5-oxo-imidazolines, a variety of novel imidazolone analogs (3a-g)
were synthesized by the condensation of different substituted oxazolines (2a-g)
with hetero-aromatic amines (1a-b). All the synthesized compounds were
screened for in vitro activities against a panel of Gram-positive and Gram-negative
bacteria.
2. Materials and method
Melting points of all synthesized compounds were recorded in open capillary
tube and are uncorrected. IR was recorded on a Shimadzu IR Spectrophotometer in
KBr pellets. 1H-NMR recorded on a Bruker AM 400 model (400 MHz) using
tetramethylsilane (TMS) as an internal reference and DMSO-d6 as solvent. Chem-
ical shifts are given in parts per million (ppm). Positive-ion electrospray ionization
(ESI) mass spectra were obtained with a Waters MicromassQ–TOF Micro, Mass
Spectrophotometer. Elemental analysis was done on Vario EL III Elemental
Analyzer, all compounds showed satisfactory elemental analysis. Reactions were
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monitored by E. Merck TLC aluminum sheet silica gel 60F254 and seen spot in UV
light and iodine chamber.
3. Experimental
(I) Synthesis of benzoyl glycine [33]: A solution of glycine (0.33 mol) in
10% NaOH (250 mL) of was prepared and benzoyl chloride (45 mL,
0.385 mol) was added to the above solution in portions. The mixture
was shaken vigorously after each addition until all the chlorides have been
reacted. The mixture was cooled by adding few grams of crushed ice and
was acidified by adding conc. HCl slowly with constant stirring. The
resulting crystalline precipitate of benzoyl glycine was filtered and
washed with cold water and dried. The solid was treated with hot CCl4
in order to remove benzoic acid. The dried product was recrystallized
with boiling water.
(II) Synthesis of 4-(arylidene)-2-phenyloxazol-5(4H)-ones [33] (2a-g):
Benzoyl glycine (0.0476 mmol), aryl aldehydes (0.0476 mol), acetic
anhydride (14 mL, 0.146 mmol) and anhydrous sodium acetate
(0.0476 mmol) were placed in a 250 mL conical flask. It was heated
on electric hot plate with constant shaking until the mixture liquefies
completely. Then it was refluxed for 2 h on water bath. Then
ethanol (10 mL) was added and mixture was allowed to stand
overnight. The crystalline precipitate was filtered, washed with ice-cold
alcohol and boiling water. The product was dried and recrystallized using
benzene.
(III) Preparation of 5-(5-H/Br benzofuran-2-yl)-1-phenyl-1H-pyrazole
carbohydrazide (1a-b): Synthesis of (5-(5-H/Br benzofuran-2-yl)-1-
phenyl-1H-pyrazole-3-carbohydrazides (1a-b) were prepared in laboratory
in quantitative yield according to reference method [34].
(IV) General procedure for the synthesis of 5-(5-H/Br benzofuran-2-yl)-N-
(4-arylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-1-phenyl-1H-
pyrazole-3 carboxamide (3a-g): To a mixture of 4-benzylidene-2-
phenyloxazol-5(4H)-one, 2a (0.002 mol) and 5-(benzofuran-2-yl)-1-
phenyl-1H-pyrazole-3-carbohydrazide 1a (0.002 mol), acetic acid (20 mL)
were added and the contents were refluxed for 9 h. Resulting mass was
poured onto crushed ice, filtered and the product was recrystallized from
ethanol to give 3a.
Similarly, other 5-(bromobenzofuran-2-yl)-N-(4-arylidene-5-oxo-2-phenyl-4,5-
dihydro imidazole-1-yl)-1-phenyl-1H-pyrazole-3-carboxamide 3b-g were synthe-
sized from 1b and 2b-g by extending the same procedure followed for 3a.
• Reaction scheme:
See Figures 2 and 3.
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• Reaction scheme:
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4. Results and discussion
4.1 Spectral, elemental and physical data of synthesized compounds
5-(Benzofuran-2-yl)-N-(4-benzylidene-5-oxo-2-phenyl-4,5-
dihydroimidazol-1-yl)-1-phenyl-1H-pyrazole-3-carboxamide (3a): Yellow crys-
talline solid; mp. 200–204°C; yield, 90%.
IR (KBr, v max in cm1): 3197 (NH), 3062 (ArH), 1793, 1719 (C═O imidazole),
1597, 1525, 1496, 1448, (C═C), 1207, 1292, 1028 (C─O─C), 1164 (C─N─C stretch),
1640 (C═O in amide group), 1525 (C═N), 1110 (C─N).
1H-NMR (DMSO-d6): δ (ppm) 6.53 (s, 1H, C4 of pyrazole ring), 11.65 (s, 1H,
NH of amide group), 7.22–8.37 (m, 21H, ArH + benzofuran ring).
MS: m/z550 [M+H]+, 551 [M+2]+, 572 [M+Na]+, 573 [(M+H)+Na]+.
Elemental analysis: Calcd: for C34H23N5O3; calculated: C, 74.30; H, 4.22; N,
12.74; found: C, 74.16; H, 4.05; N, 12.37.
Figure 3.
3D representation of 5-(benzofuran-2-yl)-N-(4-benzylidene-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-1-
phenyl-1H-pyrazole-3-carboxamide (compound 3a).
Figure 2.
Reaction scheme for 5-oxo-imidazoline derivatives.
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4-(4-Methoxybenzylidene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-5-
(5-bromo benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carboxamide (3b): Yellow
crystalline solid; recrystallization solvent, Ethanol; mp. 132–135°C; yield, 78%; IR
(KBr, v max in cm1): 3315 (NH), 3063 (ArH), 1779, 1720 (C═O imidazole), 1502,
1438 (C═C), 1257, 998 (C─O─C), 1159 (C─N─C stretch), 1649 (C═O in amide
group), 1595 (C═N), 1106 (C─N). Elemental anal. calcd: for C35H24BrN5O4; calcu-
lated: N, 10.64; found: N, 10.03.
4-(2-Chlorobenzylidene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-5-(5-
bromobenzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carboxamide (3c): Yellow
crystalline solid; re-crystallization solvent, ethanol; mp. 155–158°C; yield, 82%; IR
(KBr, v max in cm1): 3417 (NH), 1786, 1715 (C═O imidazole), 1501, 1433 (C═C),
1243, 1060 (C─O─C), 1155 (C─N─C stretch), 1643 (C═O in amide group), 1595
(C═N), 1106 (C─N). Elemental anal. calcd: for C34H21BrClN5O3; calculated: N,
10.56; found: N, 10.11.
5-(5-Bromobenzofuran-2-yl)-N-(4-(naphthalen-1-ylmethylene)-5-oxo-2-
phenyl-4,5-dihydroimidazol-1-yl)-1-phenyl-1H-pyrazole-3-carboxamide (3d):
Yellow crystalline solid; recrystallization solvent, ethanol; mp. 136–138°C; yield,
76%; IR (KBr, v max in cm1): 3378 (NH), 3005 (ArH), 1778, (C═O imidazole),
1489, 1431 (C═C), 1236, 1069 (C─O─C), 1151 (C─N─C stretch), 1689 (C═O in
amide group), 1593 (C═N), 1151 (C─N). Elemental anal. calcd: for C38H24BrN5O3;
calculated: N, 10.32; found: N, 10.40.
4-(4-(Benzyloxy)benzylidene)-5-oxo-2-phenyl-4,5-dihydroimidazol-1-yl)-
5-(5 bromobenzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carboxamide (3e):Yellow
crystalline solid; recrystallization solvent, ethanol; mp. 155–157°C; yield, 80%; IR
(KBr, v max in cm1): 3432 (NH), 3062, 2986 (ArH), 1786, 1716 (C═O imidazole),
1501, 1438 (C═C), 1249, 998 (C─O─C), 1160 (C─N─C stretch), 1642 (C═O in
amide group), 1595 (C═N), 1110 (C─N). Elemental anal. calcd: for C41H28BrN5O4;
calculated: N, 9.53; found: N, 9.07.
5-(5-Bromobenzofuran-2-yl)-N-(5-oxo-2-phenyl-4-((E)-3-phenylal-
lylidene)-4,5-dihydroimidazol-1-yl)-1-phenyl-1H-pyrazole-3-carboxamide
(3f): Yellow crystalline solid; recrystallization solvent, ethanol; mp. 158–160°C;
yield, 84%; IR (KBr, v max in cm1): 3342 (NH), 3034 (ArH), 1783 (C═O imidaz-
ole), 1493, 1439 (C═C), 1237, 1068 (C─O─C), 1158 (C─N─C stretch), 1627 (C═O
in amide group), 1597 (C═N), 1105 (C─N). Elemental anal. calcd: for
C36H24BrN5O3; calculated: N, 10.70; found: N, 10.25.
5-(5-Bromobenzofuran-2-yl)-N-(4-(furan-2-ylmethylene)-5-oxo-2-phenyl-
4,5-dihydroimidazol-1-yl)-1-phenyl-1H-pyrazole-3-carboxamide(3g): Yellow
crystalline solid; recrystallization solvent, ethanol; mp. 148–150°C; yield, 83%; IR
(KBr, v max in cm1): 3431 (NH), 3062(ArH), 1783 (C═O imidazole), 1496, 1450
(C═C), 1231, 1008 (C─O─C), 1153 (C─N─C stretch), 1641 (C═O in amide group),
1525 (C═N in imidazole), 1079 (C─N). Elemental anal. calcd: for C32H20BrN5O4;
calculated: N, 11.32; found: N, 10.96.
4.2 Common examination of the product
The newly synthesized compounds are soluble in following solvents which are
listed in table also identification of newly synthesized compounds has been further
confirmed by Lassaigne’s test for nitrogen, all compound gives positive test. Table 1
represents the structure of all derivatives along with solubility solvent and
Lassaigne’s test.
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4.3 Physico-chemical characterization
The synthesis of the novel compounds 3a-g is described in the reaction schemes.
Purity of the compounds was monitored by TLC technique. The structures of the
newly synthesized compounds were confirmed using chemical transformation
reaction, physical data, elemental analysis and different spectroscopic techniques
such as IR, 1H NMR and mass. The synthesis of the starting compound, 5-(5-H/Br
benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbohydrazides (1a-b) and 4-
(arylidene)-2-phenyloxazol-5(4H)-ones (2a-g) achieved in quantitative yields
according to the reference method. The reaction of 1a-b with 2a-g (4-(arylidene)-
2-phenyloxazol-5(4H)-ones) in acetic acid solvent yields compounds 3a-g.
IR spectrum of this 3a showed absorption bands at 3197 cm1 due to ─NH
stretching, disappearance of absorption band due to ─NH2 stretching and two
absorption bands at 1719 and 1640 cm1 for two carbonyl groups of imidazoline and
aryl amide respectively indicated that 4-(arylidene)-2-phenyloxazol-5(4H)-ones
has condensed with 5-(5-H/Br benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-
carbohydrazides to form 3a. In addition, 1H NMR spectrum of 3a showed singlet at
δ 10.65 ppm for ─NH group and disappearance of signal due to ─NH2 group in the
synthesized compound 3a which is expected in carbohydrazide 1a and also
exhibited multiplet at δ 7.22–8.37 ppm due to 21 aromatic protons is in consistent
with aromatic protons of 3a. The % of elements in 3a was C 74.16, H 4.05 and N
12.37, while its mass spectrum shows molecular ion peaks at m/z 550 [M+H]+, 551
[M+2]+, 572 [M+Na]+, 573 [(M+H)+Na].+ which is in good agreement with the
proposed structure and molecular formula C34H23N5O3.
Similarly other imidazolinones (3b-g) were also identified on the basis of chem-
ical transformation reaction, physical data, IR and elemental detection. IR spectra of
each compound showed characteristics absorption bands for ─NH stretching and
disappearance of absorption band due to ─NH2 stretching, also showed
corresponding band for carbonyl group. Elemental analysis was carried for nitrogen
and sulfur of all compounds is found to be in good agreement with the calculated
values.
4.4 Antimicrobial activity/profile
Antimicrobial activity means activity of any agent or drug against microbial
organism. Microbial organism includes bacteria, viruses, fungi and protozoa. On the
basis of their activity against specific microbial organism they termed as like
antibacterial (against bacteria) that means they are capable to inhibit the growth of
bacteria or to kill the bacteria. Other term is antifungal (against fungi), antiviral
(against virus), antiprotozoal (against protozoa). Heterocyclic entities possess dif-
ferent antimicrobial activity. Activity changes by changing structural unit. It is very
interesting thing to check out antimicrobial activity of newly synthesized com-
pound. We carried out antibacterial activity of the novel compound (Figure 4).
4.5 Potent antibacterial/inhibition profile of 5-oxo-imidazolines (at different
concentration) by agar disc-diffusion method
Test solutions were prepared with known weight of compound in DMSO and
half diluted suitably to give the resultant concentration of 31–1000 μg/mL [35].
Whatman No. 1 sterile filter paper discs (6 mm) were impregnated with solution
and allowed to dry at room temperature. In-vitro antibacterial activity was deter-
mined by using Mueller Hinton Agar obtained from Himedia Ltd., Mumbai. Petri
plates were prepared by pouring 10 mL of Mueller Hinton Agar for bacteria
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containing microbial culture was allowed to solidify. The discs were then applied
and the plates were incubated at 37°C for 24 h (bacteria) and the inhibition zone
was measured as diameter in four directions and expressed as mean. The results
were compared using chloramphenicol as a standard antibacterial agent. The
results of antibacterial activity (i.e. zone of inhibition in mm) are given in the
Tables 2 and 3.
4.6 Inhibition profile zone for Gram-positive bacterial strains of tested
compound-3a-g
The synthesized compounds 3a-g were screened for their in vitro antimicrobial
activity using agar disc-diffusion method against two Gram-positive bacterial
Figure 4.
Antibacterial drug mechanism in cell wall of microbe. Source: Google image.
Zone of inhibition (mm)
Gram-positive bacteria
B. thuringiensis S. aureus
Compd. code Conc. (μg/mL) Conc. (μg/mL)
1000 500 250 125 63 31 1000 500 250 125 63 31
3a 15 14 12 18 12 10 14 12 16 12 18 15
3b 16 15 11 16 9 9 16 11 11 8 12 —
3c 14 15 12 17 11 8 16 14 16 11 14 13
3d 16 13 12 14 8 — 13 12 14 10 12 11
3e 13 11 13 12 11 — 14 13 13 10 11 10
3f 14 14 11 10 10 8 13 12 10 — 9 —
3 g 17 16 13 11 12 10 15 15 14 17 9 7
Std. drug 22 20 21 16 15 16 26 30 27 21 18 20
Standard drug: chloramphenicol.
Bold value indicates activity of tested compound is equal or high than standard drug.
Table 2.
Antibacterial activity of 3a-g.
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Std. drug 22 20 21 16 15 16 26 30 27 21 18 20
Standard drug: chloramphenicol.
Bold value indicates activity of tested compound is equal or high than standard drug.
Table 2.
Antibacterial activity of 3a-g.
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strains such as B. thuringiensis, S. aureus. Chloramphenicol was used as standard
drug for bacteria. According to antibacterial data obtained the test compounds 3a–c
at 125 μg/mL conc. showed excellent activity i.e. equal or higher than the standard
drug and other derivatives viz. 3d–g at 125 μg/mL conc. showed good inhibitory
activity against B. thuringiensis. At conc. 1000, 500, and 250 μg/mL imidazolinone
derivatives 3a-g showed good to moderate activity against B. thuringiensis, whereas
3d and 3e are found to be inactive at 31 μg/mL against Gram-positive bacteria,
B. thuringiensis. In case of S. aureus 3a exhibit with excellent activity at 63 μg/mL
conc. While at 1000, 500, 250 μg/mL concentrations 3a-g possesses good to
moderate activity. Whereas 3b & 3f are found to be inactive at 31 μg/mL also 3f
found to be inactive at 125 μg/mL against S. aureus. Obtained results of in-vitro
antimicrobial activities of 3a-h are summarized in Table 2.
162
Heterocycles - Synthesis and Biological Activities
4.7 Inhibition profile zone for Gram-negative bacterial strains of tested
compound-3a-g
The synthesized compounds 3a-g were screened for their in vitro antimicrobial
activity using agar disc-diffusion method against two Gram-negative bacterial
strains such as E. coli, E. aerogenes. Chloramphenicol was used as standard drug for
bacteria. According to antibacterial data obtained the test compounds 3a-g pos-
sesses good to moderate activity at higher concentrations, i.e. 1000, 500, 250 and
125 μg/mL against Gram-negative bacteria E. coli. At conc. 63 μg/mL 3a-g showed
good activity while 3b & 3e found to be inactive against E. coli. At conc. 31 μg/mL
3d, 3f & 3g showed moderate activity whereas 3a, 3b, 3c & 3e found to be inactive
against E. coli. In case of E. aerogenes, tested compounds showed moderate activity
at higher concentrations while poor activity at lower concentrations. At conc.
125 μg/mL 3a, 3d, 3e and at 63 μg/mL 3a, 3b, 3d, 3e, 3f found to be inactive. All the
compounds were inactive at a concentration of 31 μg/mL against E. aerogenes.
Obtained results of in-vitro antimicrobial activities of synthesized 5-oxo-
imidazolines (3a-g) are summarized in Table 3.
Zone of inhibition (mm)
Gram-negative bacteria
E. coli E. aerogenes
Compd. code Conc. (μg/mL) Conc. (μg/mL)
1000 500 250 125 63 31 1000 500 250 125 63 31
3a 14 10 12 15 12 — 10 12 10 — — —
3b 11 11 9 12 — — 12 11 13 8 — —
3c 18 14 11 13 8 — 13 13 12 10 8 —
3d 13 12 10 12 10 8 10 9 10 — — —
3e 15 12 8 10 — — 9 10 11 — — —
3f 14 10 12 13 9 9 11 12 8 9 — —
3 g 15 13 12 14 10 8 12 10 9 7 8 —
Std. drug 24 20 18 17 17 21 16 16 17 16 15 15
Standard drug: chloramphenicol.
Bold value indicates activity of tested compound is equal or high than standard drug.
Table 3.
Antibacterial activity of 5-oxo-imidazoline compounds (3a-g).
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4.8 Mechanism of inhibition/prohibition
Gram-negative bacteria habitually owe low susceptibility as outer membrane of
their cell wall not gets blocked/penetrated by drugs easily and factors like amount of
peptidoglycan, receptors, and lipids availability, nature of cross-linking, autolytic
enzymes activity greatly influence the bio-activity, permeation, and incorporation
of the antibacterial drugs. 5-Oxo-imidazoles showed their specificity for polysac-
charides, thats present in the outer membrane of many Gram-negative bacteria and
so acted selectively toxic for series of B. thuringiensis, S. aureus bacteria. Mechanis-
tically, once alliance with lipopolysaccharide substrate in outer membrane of
B. thuringiensis, S. aureus bacteria, synthesized imidazolinone: potent antibacterial
agent changes their membrane structure, thus enhances permeability and
disruption of osmotic balance that ultimately results higher physiological effects.
Figure 5.
Inhibition profile zone for four different bacterial strains of tested compound-3a (at different concentration).
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Also, alteration like discharge of molecules from interior of B. thuringiensis, S. aureus
bacterial cell inhibits respiration and increased water uptake may leads to cell death.
Gram-positive bacteria own too thick cell wall and deny easy access of 5-oxo-
imidazoles via their bacterial cell membrane, thus less effective on E. coli and E.
aerogenes series of bacteria. The inhibition profile zone for four different bacterial
strains of tested compound-3a (at different concentration) 5-oxo-imidazoline com-
pounds are shown in Figure 5.
5. Conclusion
Assorted antibacterial agents own certain limitations viz.; resistance/potency,
vast types and numbers own different structures besides slightly dissimilar pattern
of activity which made it necessary to discover/explore the existing class and func-
tions of almost all the antibacterial agents. Thus, futuristic pathogenic bacterial
infections/diseases can be easily cured via promising antibacterial chemotherapeu-
tic agents derive from 5-oxo-Imidazole skeleton. Pursued chapter described
antibacterial resistance of 5-oxo-imidazoles mostly against Gram-positive series like
B. thuringiensis, S. aureus. 5-Oxo-imidazoles can act onto simple one-celled bacterial
organism that could kill, inhibit, or at least slower down their growth and ultimately
can inhibit concern diseases/infections. This chapter focused on helping futuristic
researchers, clinicians, and academicians involved in synthesizing and
corresponding biological screening of innate activity of certain novel imidazolinone
heterocycles. These synthesized 5-oxo-imidazoles restrain potent antibacterial
activity may own prospective different therapeutic behavior if developed as
advanced drug moiety. Therefore, chapter focus on the basis of chemical structure
of 5-oxo-imidazoles. Gram-positive and Gram-negative bacteria showed varied
response/susceptibility toward 5-oxo-imidazoles.
Targeted 5-oxo-imidazolines (3a-g) a class of imidazolinones are successfully
synthesized in good yields and purity checked by physical, analytical and spectral
data. Antibacterial screening of 5-oxo-imidazolines (3a-g) exhibited a potent bac-
tericidal. Thus, 5-oxo-imidazolines could be powerfully stimulates major advances
in remarkable significant chemotherapeutics in medicine, biology and pharmacy.
Overall these imidazolinones disturb macromolecules like cytoplasmic membrane
covering cytoplasm which acts selective barrier to control internal composition of
cell. 5-Oxo-imidazoles in particular interrupted such functional roles of cytoplasmic
membrane and ionic outflow that resulted cell destruction/death. Synthesized
potent bioactive 5-oxo-imidazoles may open new possibilities in the successful
treatment of several diseases due to promising antibacterial profile. So, ample scope
exists in further research of imidazolinones especially innate selectivity of 5-oxo-
imidazoles needs to carry out their chemotherapy as potent antibacterial aims to
target cell membrane of range of Gram-negative bacteria as to derive novel drugs of
new millennium.
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Chapter 12
Azoles as Potent Antimicrobial
Agents
Rohit Singh and Swastika Ganguly
Abstract
Imidazole analogs have proved to be a very good source of medicinal agents.
The various activities associated with these moieties include antibacterial, antifun-
gal, anthelmintic, Anti HIV activity, anticancer, antihypertensive, analgesic,
anti-inflammatory, anticonvulsant, sedative and other pharmacological activities.
Keywords: imidazole, antibacterial, antifungal and antiviral
1. Introduction
Azoles are basically five member heterocyclic compounds containing one or
more different hetero atom out of which at least one must be nitrogen and other
heterocyclic may be nitrogen or other than nitrogen like sulfur or oxygen.
Some of the common five member azoles which consist the nitrogen hetero atom
only are as follows as imidazole (1), pyrazole (2), 1,2,3-triazole (3), 1,2,4-triazole
(4), tetrazole (5) and pentazole (6).
Some of the five member azoles which consist sulfur and oxygen as hetero atom
along with nitrogen atom such as thiazole (7), isothiazole (8), 1,2,3-thiadiazole (9),
1,2,4-thiadiazole (10), 1,2,5-thiadiazole (11), 1,3,4-thiadiazole (12), oxazole (13),
isoxazole (14), 1,2,3-oxadiazole (15), 1,2,4-oxadiazole (16), 1,2,5-oxadiazole (17)
and 1,3,4-oxadiazole (18).
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Some of the heterocyclic azoles are fused with benzene ring to form bicyclic
azole derivatives such as benzimidazole (19), benzotriazole (20), benzothiazole
(21) and benzoxazole (22).
Among above mentioned class of azoles a brief review is presented focused on
imidazoles and benzotriazoles as given below.
2. Imidazole analogs and their significance
In various oxidation states (23 and 24) imidazole has shown a number of inter-
esting biological activities, like antiviral [1, 2], antibacterial [3] antifungal [4, 5],
antiprotozoal [6, 7], antihypertensive [8, 9], antihistaminic [10], alpha-adrenergic
agonist [11], alpha adrenergic blocking [12] and other activities [13, 14].
2.1 Antiprotozoals
Nitroimidazoles (25) with antitrichomonas activity were reported in year 1961
and then in 1966. Metronidazole (26) was among these compounds, it exhibited
broad antiprotozoal activity and has found wide use in treating trichomoniasis orally.
Structural variation of Metronidazole (26), mainly to improve trichomonacidal
activity led to the discovery of Tinidazole (27), Nimorazole (28), and Panidazole
(29). Tinadazole (27) is most potent towards Entamoeba histolytica, in vitro, cecal
amoebiasis and hepatic amoebiasis in experimental animals [6–8].
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Giraldi et al. [15] in year 1967, synthesized a series of 1-aminoalkyl and 1-
aminoalkyl-2-methyl-5(4)-nitro-4(5)-styrylimidazoles (30–37) and these com-
pounds were tested to check the potency of synthesized compounds against various
non-pathogenic bacteria and fungi.
In vitro activity against Trichomonas vaginalis of the compounds was found to
be very potential, moderate against Entamoeba histolytica and least active against
Candida albicans. It was found that those 5-nitroimidazoles in which the fourth
position is free showed higher activity against Trichomonas vaginalis, whereas
substituents at imidazole follow the order pyrrolidine > piperidine > diethylamine
> morpholine.
In the year 1969, Lancini et al. [16] synthesized a various number of 1,5-disub-
stituted 2-nitro imidazoles (38–44) through diazotization reaction or Gattermann
reaction.
All the synthesized compounds showed moderate In vitro activity against
Trichomonas vaginalis.
Miller et al. [17] in the year 1970, synthesized a novel series of 2-methyl-5-
nitroimidazoles (45–49) and evaluated their antiprotozoal activity. This series bore
an aliphatic side chain incorporated with electronegative group. In vitro and In vivo
evaluations were carried out against Trichomonas foetus and Trichomonas vaginalis as
well as against Entamoeba histolytica.
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All the synthesized compounds showed mild activity against Entamoeba
histolytica when compared to standard Tinidazole (27).
Nair et al. [18] in the year 1982, performed an acrylation of 1-methyl-5-
nitroimidazole (50–58) with aroyl chlorides to form 2-aroyl-1-methyl-5-
nitroimidazole through Beckmann rearrangement and yielded corresponding
oximes and anilides as Beckmann product.
Walsh et al. [19] in the year 1986, synthesized a library of 5-nitroimidazole
derivatives (59–65) which had ability to cause mutagenicity and these were also
evaluated for their antitrichomonal activity.
Compounds 64 and 65 showed very less mutagenicity in comparison to standard
drug ronidazole.
Foroumadi et al. [20] in the year 2005, synthesized a series of 2-(1-methyl-5-nitro
imidazol-2-yl)-5-(1-piperazinyl, 1-piperidinyl and 1-morpholinyl)-1,3,4-thiadiazoles
and estimated the antileishmanicidal activity for the synthesized compounds (77–83).
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All compounds exhibited better activity against Leishmania major (IC50
< 1.744 μM).
Bhandari et al. [21] in the year 2010, synthesized a series of various substituted
alkyl/aryl imidazoles (73–91) and estimated their activity against Leishmania
donovani as antileishmanial agents.
Most of the synthesized compounds exhibited very significant activity up to
84–91% inhibition at the concentration of 10 μg/ml while some compounds showed
high IC50 values ranging from 0.47–4.85 μg/ml against amastigotes.
Hernandez-Nunez et al. [22] in the year 2009, reported synthesis of novel
imidazole derivatives (103–117). These compounds were biologically examined
against various parasites namely Giardia intestinalis,Trichomonas vaginalis and
Entamoeba histolytica.
Compounds (100–106) exhibited two fold better activity in comparison to
benzimidazole analogs against Trichomonas vaginalis and Giardia intestinalis and
found to be more active analogs against Entamoeba histolytica.
2.2 Antibacterial and antifungal agents
During the last 30 years, antifungal azoles [23] such as clotrimazole (107),
miconazole (108), ketoconazole (109), butoconazole (110), econazole (111),
cloconazole (112), fenticonazole (113), oxiconazole (114) and sulcoconazole (115)
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have been introduced. In all these compounds N-1 atom of imidazole is linked to
other aromatic rings. The other antimycotic azoles have a five membered ring with
three nitrogen atoms.
The antifungal azoles inhibit the cytochrome P-450 which catalyzes the 14-α-
demethylation of lanosterol to ergosterol [15]. The azole drugs are relatively of
broad spectrum antifungal activity but there may be differences among the indi-
vidual compounds.
Castelli et al. [24] in the year 1997, synthesized two new compounds belonging to
5-nitroimidazole family: sulphuridazole and sulphonidazole derivatives (116–119)
and compared their minimum inhibitory concentrations with metronidazole (26).
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Sulphonidazole (116–117) showed better activity than sulphuridazole (118–119)
against all the bacterial and fungal strains.
Demirayak et al. [25] in the year 1999, synthesized a novel series of some
pyrrole-nitroimidazole clubbed hybrid derivatives (120–125) and evaluated their
antifungal activity.
Compounds 120–124 showed excellent activity against Staphylococcus aureus
at the dose of 8 mg/ml while all the synthesized compounds exhibited excellent
activity against fungal strain Candida albicans.
Kolavi et al. [26] in the year 2006, synthesized a library of some imidazo
thiadiazole derivatives (126–161) and evaluated their antibacterial activity.
177
Azoles as Potent Antimicrobial Agents
DOI: http://dx.doi.org/10.5772/intechopen.88547
have been introduced. In all these compounds N-1 atom of imidazole is linked to
other aromatic rings. The other antimycotic azoles have a five membered ring with
three nitrogen atoms.
The antifungal azoles inhibit the cytochrome P-450 which catalyzes the 14-α-
demethylation of lanosterol to ergosterol [15]. The azole drugs are relatively of
broad spectrum antifungal activity but there may be differences among the indi-
vidual compounds.
Castelli et al. [24] in the year 1997, synthesized two new compounds belonging to
5-nitroimidazole family: sulphuridazole and sulphonidazole derivatives (116–119)
and compared their minimum inhibitory concentrations with metronidazole (26).
176
Heterocycles - Synthesis and Biological Activities
Sulphonidazole (116–117) showed better activity than sulphuridazole (118–119)
against all the bacterial and fungal strains.
Demirayak et al. [25] in the year 1999, synthesized a novel series of some
pyrrole-nitroimidazole clubbed hybrid derivatives (120–125) and evaluated their
antifungal activity.
Compounds 120–124 showed excellent activity against Staphylococcus aureus
at the dose of 8 mg/ml while all the synthesized compounds exhibited excellent
activity against fungal strain Candida albicans.
Kolavi et al. [26] in the year 2006, synthesized a library of some imidazo
thiadiazole derivatives (126–161) and evaluated their antibacterial activity.
177
Azoles as Potent Antimicrobial Agents
DOI: http://dx.doi.org/10.5772/intechopen.88547
The antibacterial screening revealed that compounds 134 and 140 showed
significant activity against Escherichia coli. Compounds 126 and 127 showed
good inhibition of Escherichia coli at a concentration of 100 μg/ml.
The antifungal screening revealed that the compounds 132, 134, 142, 159
and 161, displayed good antifungal activity against Penicillium wortmannii and
Aspergillus niger.
Banfi et al. [27] in the year 2006 synthesized and evaluated new imidazoles
(162–166) and (167–171) for antifungal and antimycobacterial activity.
The results showed that the compounds 166 and 171 showed very good activity,
while rest of the derivatives exhibited weak antifungal activity against Candida
species.
Mamolo et al. [28] in the year 2007, reported the synthesis of novel bis-
imidazole derivatives (172–175) and screened their antimycobacterial and
antifungal activity.
Maximum compounds exhibited weak activity towards Mycobacterium tubercu-
losis and Candida species. Compound 175 was considered to be a significant anti-
fungal agent against Candida species.
Ganguly et al. [29] in the year 2009, synthesized a few compounds of the type
(176–183) and these were evaluated for antibacterial, antifungal and anti-HIV activity.
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Compound (176) exhibited good activity against Staphylococcus aureus whereas
compound (178) showed moderate activity towards Escherichia coli. However, all
the compounds were less active than standard drug ciprofloxacin (184). Com-
pounds (174) and (179) exhibited significant antifungal activities against Candida
albicans comparable to the standard drug fluconazole (185). None of the com-
pounds had appreciable anti-HIV activity.
Sharma et al. [30] in the year 2009, synthesized a series of novel 2-substituted
benzimidazoles (186–189) and imidazoles (190–193) from long chain alkenoic acids
and these were evaluated as antibacterial agents.
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Compounds (190) and (193) were found to be most active against Escherichia
coli and Bacillus subtilis. Whereas the imidazoles (186–189) exhibited moderate
activity against the tested bacterial strains when compared to chloramphenicol
(194) as standard.
Wu-Li-Ji et al. [31] in the year 2010, reported the synthesis of 2-benzyl
thioimidazoles and 2-benzylthio sulfonyl-1H-imidazoles (195–208) and were
evaluated for antibacterial, antifungal and antioxidant activity.
All newly reported derivatives exhibited excellent antibacterial activity towards
Proteus vulgaris and Klebsiella pneumonia while exhibiting excellent antifungal
activity towards Penicillium chrysogenum.
Ganguly et al. [32] in the year 2010, synthesized some novel 2-methyl-5-
nitroimidazole analogs (209–211). These were evaluated for antibacterial,
antifungal and antidiarrheal activities.
Compounds 209–211 showed significant anti-diarrheal activity at a dose of
60 mg/kg body wt. while compound 209 exhibited significant antibacterial activity
against Staphylococcus aureus.
Ganguly et al. [33] in the year 2011, reported some novel imidazole analogs of
the type (261–274) and evaluated their antibacterial and anti-HIV activity.
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Compounds 212, 215 and 220 exhibited moderate activity as antibacterials,
however compounds 212, 213 and 215 showed weak anti-HIV activity as compared
to the standard efavirenz (226).
Ganguly et al. [34] in the year 2011 synthesized a few compounds of type
(226–232) these were evaluated for antibacterial, antifungal and anti-HIV activity.
Compounds 228 exhibited 44% inhibitory activity against HIV-1 RT.
Pathan and Rahatgoankar [35] in the year 2011, synthesized a series of
substituted 4,5-diphenyl imidazolyl-pyrimidine hybrids (233–239).
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Compound 236 was found to be most active against Staphylococcus aureus among
all tested compounds.
Zhang and Zhou [36] in the year 2011 reported the synthesis of naphthalimide
derived azoles (240–248) as novel anti-microbial agents and evaluated their
efficiency in vitro against bacteria and fungi.
It was found that compounds 246–248 with different alkyl linkers were synthe-
sized selectively and gave antibacterial profiles, especially compounds 246 and 247
showed prominent activity against Pseudomonas aeruginosa being eight fold more
efficient than chloromycin.
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Vijesh et al. [37] in the year 2011, synthesized a dual series containing imidazole-
pyrazole combined derivatives (249–262).
Among the tested compounds, compound 253 emerged as highly active against
Trychophyton rubrum compared to standard fluconazole.
Zhu et al. [38] in year 2012 reported the design and synthesized oxadiazole
derivatives (263–264) and evaluated their antibacterial activity.
Compound 312 with MIC of 1.56–3.13 μg/ml and compound 313 with MIC of
1.56–6.25 μg/ml were the most potent inhibitors of FabH against Escherichia coli.
Desai et al. [39] in year 2012 synthesized a series of imidazole analogs (265–269)
and reported their activity towards bacterial and fungal species.
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Compounds (265–269) were evaluated against Gram-positive bacteria mainly
Staphylococcus aureus, Staphylococcus pyogenes and Gram-negative bacteria mainly
Escherichia coli, Pseudomonas aeruginosa and fungi.
2.3. Antiviral agents
The first report onN-Amino imidazoles as antiHIVagents andparticularly asNNRTIs
came upwith the discovery of Capravirine (S-1153) (270) in the year 2000 [1]. This also
retained activity against HIV-1 strains carrying K103Nmutation in RT structure.
After this, anti-viral active N-amino imidazole (271) derivatives were reported
by Lagoja et al. [2] in the year 2003, which exhibited considerable antiviral activity.
Methylation or benzoylation on sulfur groupmay demolish the anti HIV activity of
compound, whereas compounds bearing alkyl/aryl substituents at para position to
imidazole ring affected the antiHIV activity. Smaller the substituent higher the activity.
Silvestri et al. [40] in the year 2002 synthesized a novel series of 1-{2-
(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles (272) and evaluated their
antiHIV activity.
Substitution at meta position to the phenyl ring exhibited better anti-HIV activ-
ity while substituents like fluoro, chloro or methyl substituent enhances the activity
than its prototype.
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It was observed that substitution at meta position facilitates better activity rather
than substitution at ortho and para position. Fluorine at meta position exhibited
maximum potency among all derivatives.
De Martino et al. [40] replaced one phenyl ring of 1-[2-diarylmethoxy] ethyl)
2-methyl-5-nitroimidazoles (DAMNIs) with heterocyclic rings, such as 2-thienyl
(273) or 3-pyridinyl ring (274), leading to novel DAMNIs with increased activity.
N-Alkylation of imidazole, 2-methyl imidazole and 2-methyl-4-nitroimidazole
has been carried to achieve effective antiHIV agents.
Xu et al. [41] in the year 2008 synthesized some novel derivatives of N-
arylindoles (275–282) and evaluated as HIV integrase inhibitors for first time.
Among all synthesized compounds, 276, 279 and 282 exhibited very significant
anti HIV-1 integrase inhibitory activity. Especially, compound 277 showed highest
activity with EC50 value 7.88 μg/ml and therapeutic index 24.61.
Serrao et al. [42] in the year 2013, reported a novel series of 5-carbonyl-1H-
imidazole-4-carboxamides (283–299) capable of inhibiting HIV-1 integrase–
LEDGF/p75 interaction.
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All the synthesized compounds showed almost equivalent activity as their MTT/
MT-4 (CC50 and EC50) values were same.
Huang et al. [43] in the year 2017, synthesized a series of diarylpyrimidines
(300–310) and indolylarylsulphones (311–321) hybrids and showed their activity
against HIV1-IIIB strain.
Compound 311 exhibited favorable selectivity index (SI = 80) which was the
maximum above all synthesized compounds and determined by MTT method.
3. Conclusion
Compounds containing azole derivatives, exhibit a wide variety of activities
such as antibacterial, antifungal, anthelmintic, antiprotozoal, antiviral, anticancer,
antihistaminic, antiulcer, antipsychotic and various other biological activities.
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